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1.1 Antibody Array Technologies 
 
 
Protein array applications have wide fields including protein-protein interaction, protein-RNA 
interaction, protein-DNA interaction, phosphorylation, dephosphorylation, proteolytic cleavage 










Figure 1.1: Protein microarrays and their applications. Ligands, such as proteins, peptides, 
antibodies, antigens, allergens, and small molecules, are immobilized in high density on 
modified surfaces to form functional and analytical protein microarrays. These protein 
microarrays can also be used for various kinds of biochemical analysis(Zhu  et al. 2003). 
 
 
The number of antibodies, which are specific for proteins and protein modifications, including 
phosphorylation, is growing at a tremendous speed and it is very likely that good antibodies can 
be obtained for most proteins and their modifications in the future. To carry out research in a 
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timely manner it will be required that suitable antibodies combined on micro arrays are used for 
initial protein expression screening, very similar to the use of gene expression profiling today 
(Haab et al. 2001; Madoz-Gurpide et al. 2001).  
 
Antibody microarrays hold potential promise for the high-throughput profiling of a smaller 
number of proteins (Figure 1.1). Briefly, antibodies (or other affinity reagents directed against 
defined proteins) are spotted onto a surface such as a glass slide; a complex mixture, such as a 
cell lysate or serum, is passed over the surface to allow the antigens present to bind to their 
cognate antibodies (or targeted reagents). The bound antigen is detected either by using lysates 
containing fluorescently tagged or radioactively labelled proteins, or by using a secondary 
antibodies against each antigen of interest. Low-density antibody arrays have been constructed 
that measure the levels of several proteins in blood and sera. In high-density arrays constructed 
recently, Sreekumar et al. spotted 146 distinct antibodies on glass to monitor the changes in 
quantity of a number of antigens expressed in LoVo colon carcinoma cells (Zhu et al. 2003).  
 
One important issue for antibody array is the matrix or surface used for immobilization. The 
golden standard in this respect are porous membranes like nitrocellulose or nylon, which are 
used for a very long time in classical assays and have a very high capacity for protein binding. 
For application in micro array technology a combination of glass slides and nitrocellulose 
membranes is commercially available (Schleicher & Schuell) and is used for protein array 
applications (Knezevic et al. 2001). With a similar idea this group before had developed an 
activated agarose coating for slides that has a very good binding capacity for antibodies and 
ensures reliable and highly sensitive detection of protein antigens (Afanassiev et al. 2000). 
These and other microscope glass slide based technologies require an optimized regime for 
handling, incubation and washing and a dedicated set up of incubation chambers. 
 
Current methods of detecting protein activity by array require the use of fluorescence and 
radioisotopes. To date, no protocol for antibody arrays has been setup as standard. Many 
problems need to be addressed such as storage of antibody, protein purification, incubation and 
binding to arrays. This work tries to analyse and compare the results under different conditions 
in details. 
 
This experiment has developed parameters, thresholds, and testing conditions of a novel silver 
staining system. Antibodies were selected with high specificity for phosphorylated proteins and 
these antibodies were combined on the micro arrays in the ArrayTube™ platform. Nano-gold 
particles-mediated silver staining is a suitable technology for the detection of proteomics bound 
to an antibody array; Quantification is possible using an on-line measurement of the silver 
precipitation step. The onset of precipitation and the speed of signal accumulation of the silver 
staining of the process enables quantification whereas end point signals only provide qualitative 
results; Combination of selective purification, e.g. cytoplasmic extract vs. nuclear extract with 
the antibody array technology, allows to phosphorylated proteins to defined cellular 
compartments.  
 
In this study, first setting up the Cy3 and Cy5 staining in SDS-PAGE for the detection of 
labelling efficiency. Array technologies were developed into four stages from Cy3 and Cy5 
staining of Big Glass Arrayslide, Cy3 and Cy5 staining of Mini-Arrayslide, silver staining of Mini-
Arrayslide to silver staining of Arraytube including biotinylation of cellular proteins, incubation of 
protein extracts and silver staining of which has developed parameters, thresholds, and testing 
conditions of a novel silver staining system for quantitative detection of phosphorylation and 
localization for function on chip using biotinylation of cellular proteins. Silver staining of antibody 
microarrays allow for high-throughput identification of protein Phosphorylation. This method is 
sensitive, specific, reproducible, fast and cheap, presenting obvious advantages and may find 
wider uses in high-throughput protein screenings, pinciple shown as in Fig. 1.2.  
 
 
                                                                                                                    




Figure 1.2: Nano-gold silver staining principle, including biotin-labeling protein, blocking Array-tube 




1.2   Protein Phosphorylation, Localization and Function 
 
With the post-genome era proteomics study for direct analysis of a group of protein become 
more and more important (James et al. 1997). Identification of the type of modification and its 
location often provide crucial information for understanding the function or regulation of a given 
protein in biological pathways(Zhu et al. 2003).  
 
Phosphorylation is one of the most important protein modifications by which many different 
cellular responses and biological processes are regulated.  
 
Protein localization data provide valuable information in elucidating eukaryotic protein function 
(Zhu et al. 2003). Protein trafficking between nucleus and cytoplasm fundamentally important to 
cell regulation. As such, the nuclear import and export are pivotal in orchestrating the activities 
of the key regulators of the cell cycle  (Zhou et al. 2003 ), such as:  
 
 
Smad nuclear translocation is a required component of the activin A-induced cell death process 
in liver cells (Chen et al.  2000).  
 
ERK-1 and –2 nuclear translocation triggers cell proliferation in vitro models from (Tarnawski et 
al. 1998). ERK activation plays an active role in mediating cisplatin-induced apoptosis of HeLa 
cells and functions upstream of caspase activation(cyto) to initiate the apoptotic signal(Wang et 
al. 2000). Lorenzini et al (2002) verified in senescent cells that no ERK are able to 
phosphorylate efficiently their nuclear targets.  
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JNK cytoplasmic localization as inhibitor of proliferation from Dickens, et al. (1997) verifying that 
a murine cytoplasmic protein that binds specifically to JNK [the JNK interacting protein-1 (JIP-1)] 
and caused cytoplasmic retention of JNK and inhibition of JNK-regulated gene expression. 
  
MKK7-JNK/SAPK and MKK6-p38 pathways to cytoplasmic apoptotic activation induced by Fas 
(Toyoshima, F. et al. 1997). p38 MAPK induced cytoplasmic domain-dependent cellular 
migration (differentiation) of alpha 2 integrin subunit (Klekotka  et al. 2001). 
 
Phospho-Tyrosine Rak (54 kDa) expressed nuclear and perinuclear regions of the cell in 2 
different breast cancer cell lines inhibits growth and causes G(1) arrest of the cell cycle (Meyer 
et al. 2003).  
 
STAT3 cytoplasmic localization was detected in the pathogenesis of mantle cell lymphoma 
(MCL) tumours. STAT3 nuclear localization of STAT3 was shown in node-negative breast 
cancer  associated with a better prognosis(differentiation and apoptosis) by tissue microarray 
analysis (Dolled-Filhart, Camp et al. 2003). 
 
Akt/PKB intranuclear translocation is an important step in signalling pathways that mediate cell 
proliferation (Borgatti, et al. 2000). No Akt is able to phosphorylate efficiently its nuclear targets 
in senescent cells (Lorenzini, et al. 2002). p70S6K is localized both in the cytosol and, after 
cytokine stimulation, also in nucleus in factor-dependent hematopoietic M-07e cells 
(Fleckenstein et al 2003). 
 
1.3 Interaction Proteomics and Pathway Building 
 
It is widely acknowledged that proteins rarely act as single isolated species when performing 
their functions in vivo. The analysis of proteins with known functions indicates that proteins 
involved in the same cellular processes often interact with each other. Following this 
observation, one valuable approach for elucidating the function of an unknown protein is to 
identify other proteins with which it interacts, some of which may have known activities. On a 
large scale, mapping protein-protein interactions has not only provided insight into protein 
function but facilitated the modeling of functional pathways to elucidate the molecular 
mechanisms of cellular processes(Zhu, Bilgin et al. 2003) 
 
We are interested to understand some aspects of the regulatory network of signalling pathways 
and their role in the development of diseases. One of the most prevailing change on the protein 
level is protein phosphorylation. In many cases it reflects the activation state of the protein. It is 
controlled by kinase activities leading to phosphorylation and phosphatase activities, which in 
turn remove the phosphate groups. To understand how a given activation signal growth factor, 
cytokine, morphogene or drug, activates different signalling pathways. By classical methods, 
this would require an extremely large number of time consuming experiments. Antibody array 
potentially allows the identification of all of the proteins that carry those modifications in a single 
experiment. 
 
1.3.1   BMP2 signalling 
 
BMP2, member of the transforming growth factor-ß (TGFß) super-family, is a multifunctional 
molecule regulating the growth, proliferation, differentiation, invasion and apoptosis in various 
target cells. Many researchers have shown to play a role in cell proliferation and differentiation 
in development(Nakamura, et al. 2003;Stoeger, et al. 2002;Tsuda, et al. 2003;Waite, et al. 
2003;Pohl, et al. 2003;Bain, et al. 2003;Maguer-Satta, et al. 2003).  
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BMP2, as other member of the TGF-β family elicits its cellular response through formation of 
heteromeric complexes of specific type I and type II serine/threonine kinase receptors. Five type 
II receptors and seven type I receptors, also termed activin receptor-like kinases (ALKs) have 
thus far been identified. The type II receptor is a constitutively active kinase, which upon ligand-
mediated heteromeric complex formation phophorylates particular serine and threonine residues 
in the type I receptor juxtamembrane region (also termed the GS-domain). The type I 
serine/threonine kinase thereby becomes activated and transduces signals downstream; type I 
acts thus downstream of type II receptor and has been shown to determine signalling specificity 






Figure 1.3: Activation of R- and Co-Smads. Upon ligand-induced heteromeric complex 
formation and activation of type I and type II receptors, R-Smads are phosphorylated and form 
heteromeric complexes with Co-Smads that translocate into nucleus, where they control the 
expression of target genes in a cell type specific manner. Nonactivated Smads can be 
retained in cytoplasm through association with microtubules (MT). The recruitment of Smad2 
to the TGF-β receptor complex has been shown to involve a FYVE domain containing protein 
termed Smad anchor for receptor activation (SARA). Transcriptional modulation by Smads is 
achieved through complex formation with, e.g. transcriptional coactivators like p300/CBP and 
interacting transcription factors. R- and Co-Smads appear to form preferentially trimers 
consisting of one Co-Smad and two R-Smads. However, Smad complexes with other 





Smads are pivotal intracellular nuclear effectors of transforming growth factor-beta (TGF-beta) 
family members. Ligand-induced activation of TGF-beta family receptors with intrinsic 
serine/threonine kinase activity trigger phosphorylation of receptor-regulated Smads (R-Smads), 
whereas Smad2 and Smad3 are phosphorylated by TGF-beta, and activin type I receptors, 
Smad1, Smad5 and Smad8, act downstream of BMP type I receptors. Activated R-Smads form 
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heteromeric complexes with common-partner Smads (Co-Smads), e.g. Smad4, which 
translocate efficiently to nucleus, where they regulate, in co-operation with other transcription 
factors, coactivators and corepressors, the transcription of target genes. Inhibitory Smads act in 
most cases in an opposite manner from R- and Co-Smads. Like other components in the TGF-
beta family signalling cascade, Smad activity is intricately regulated. The multifunctional and 
context dependency of TGF-beta family responses are reflected in the function of Smads as 
signal integrators. Certain Smads are somatically mutated at high frequency in particular types 
of human cancers. Gene ablation of Smads in the mouse has revealed their critical roles during 
embryonic development, from the following table 1.1 can understand the Binding partners of 










Binding proteins Smad  Functional properties 
Membrane component    
ALK-1, - 2, - 3, - 6 
ALK-4, - 5, - 7 
SARA  
Smad1,5, 6, 7, 8
Smad2, 3, 6, 7


























Smad1, 2, 3, 4
Smad1,5 










Wnt signal transducer; 
linking E-cadherin to the 
actin cytoskelton 
Calcium binding protein 
E3 ligase for ubiquitination 
WD repeat protein 
MAPKKK  
Transcriptional 




Smad1, 2, 3, 4  
MH2 




























Homeodomain containing protein 
 
Zinc finger containing protein 
Nuclear proto-oncogene product 
Forkhead-associated domain 
containing nuclear protein 
Nuclear proto-oncogene product 
Homeo-domain containing protein  
Transcription factor    
ATF-2 
c-Fos  
















b-ZIP containing protein 
Ap-1 family member 
Ap-1 family member 
Zinc finger containing protein
 
Glucocorticoid receptor 
                                                                                                                    


























Smad1, 2, 3, 4
Smad3 















Vitamin D receptor 
Adenoviral oncoprotein 
Zinc finger containing protein 
Winged-helix containing protein 






Zinc finger containing protein 
Runt-domain-containing protein 
NF-κ B/Rel family 







Helix-loop-helix leucine zipper 






Table 1.1:   Binding partners of Smads. Abbreviations: ALK, activin-receptor-like kinase; AML, acute 
myeloid leukemia; AP, activator protein; ATF, activating transcription factor; CBFA, core-binding factor A; 
CBP, CREB-binding protein; CREB, cAMp-responsive element-binding protein; E1A; early region 1A; Evi, 
ecotropic virus integration; FAST, forkhead activin signal transducer; Gli, glioblastoma gene product; 
HMG, high mobility group: Hoxc-8, homeobox gene c-8; Lef, lymphoid enhancer factor; MH, Mad 
Homology; MSG, melanocyte-specific gene or mad-supporting gene; ND, not determined: OAZ, Olf1/EBF 
associated zinc finger; PEBP2, polyomavirus-enhancer-binding protein; PY, PPXY motif; SARA, Smad 
anchor for activation; SIP, Smad-interacting protein; Ski/SnoN, Sloan-Kettering avian retrovirus/ski-
related novel gene; Smurf, Smad ubiquination regulatory factor; STRAP, serine/threonine kinase 
receptor-associated protein; TAK, TGF-β ctivated kinase; Tcf, T-cell factor; TFE, transcription factor mu 







TGF-β family members have been shown to activate small GTp-binding proteins and MAP 
kinases in certain cells, as shown in Fig. 1.4 (Itoh et al. 2000). 
 
 
Crosstalk with Smad signalling may also result from the ability of TGF-β to activate signalling 
pathways independently of Smads . TGF-β can activate ERK MAP kinase, p38 MAP kinase and 
JNK, although the extent and kinetics of activation differ among different cell lines and types. 
The MAP kinase kinase kinase TAK1, which is rapidly activated by TGF-β  but is also involved 
in other signalling pathways, may initiate these signalling cascades. The activation of p38 MAP 
kinase and JNK can enhance Smad signalling through either Smad phosphorylation or the 
phosphorylation of c-Jun and ATF-2, which are transcription factors that cooperate with Smad3, 
resulting in functional crosstalk with Smad-mediated transcription at defined promoters (Derynck 




                                                                                                                    











Figure 1.4: TGF-β receptor-initiated signalling cascades. TGF-β activates the Smad 
pathway as well as other signalling pathways. One example of a downstream transcription 
factor target for the different activated MAPK are indicated. Possible TGF-β  receptor-induced 
responses that are independent of (Smad-mediated) transcription, as well as cross-talk 
between different downstream effector pathways are not indicated. Abbreviations: ATF, 
activating transcription factor; ERK, extracellular regulated kinase; JNK, c-Jun N-terminal 
kinase; TAB, TAK1-binding protein; TAK, TGF-β  activated kinase; TGF-β , transforming 





In addition, TGF-β can activate or stabilize the small GTPases RhoAand RhoB; these may in 
turn have roles in several responses to TGF-β, for example through a requirement of RhoB for 
activation of JNK Finally, TGF-β  induces an interaction of protein phosphatase 2A with S6 
kinase, which regulates protein translation and growth control, decreasing its activity. Although 
the mechanisms of activation by TGF-β and the roles of these non-Smad signalling cascades 
remain to be better characterized, these observations indicate that inactivation of the Smad 




                                                                                                                    
















Figure 1.4: TGF-β -induced signalling through Smads, and several non-Smad 
signalling mechanisms. After ligand-induced activation of the receptor, Smad2 and/or 
Smad3 interact transiently with the TRI receptor (RI), and this interaction is stabilized by 
the FYVE protein SARA. Smad2 and Smad3 are phosphorylated on their C terminals by T
RI, and then dissociate from the receptor to form a heterotrimeric complex comprising two 
receptor-activated Smads and Smad4. This complex then translocates into nucleus, where 
it interacts at the promoter with transcription factors with sequence-specific DNA binding to 
regulate gene expression. The heteromeric Smad complex also interacts with the 
CBP/p300 transcriptional coactivator, which connects the Smad complex with the general 
transcription factors (GTF). Smad7 inhibits activation of Smad2 and/or Smad3 by the 
receptors, and Smad7 expression is induced on stimulation of one of several signalling 
pathways—for example, in response to EGF, interferon-β (IFN--β ) or tumor necrosis 
factor--β  (TNF-β ). Several other signalling pathways also regulate both signalling by 
Smads and Smad-mediated gene expression, as exemplified here by the activation of JNK 
and p38 MAP kinase signalling in response to various stress signals, and β -catenin 
signalling in response to Wnt proteins. TGF-β also induces activation of Ras, RhoB and 
RhoA, as well as of TAK1 and protein phosphatase 2A, which leads to the activation of 
several MAP kinase pathways and the downregulation of S6 kinase activity. The 
mechanisms of activation of these non-Smad signalling events and how they connect to 
the heteromeric TGF-β receptor complex remain to be characterized (Derynck  et al. 2001). 
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However, the molecular mechanisms of activation and inhibition of signal transduction from 
BMP2 to multifunctional positive and negative mediators of cells such as phospho-p70S6 and 
phospho-Akt (PI3K signalling), phospho-p38 (p38 network), phospho-ERK and phospho-JNK 
(MAPK pathway), phospho-Tyrosine (tyrosine-kinase network), phospho-STAT3 (Jak/stat 
network), and phospho-Smad1,2,3 (smad network) in U937 are not well characterized. More 
importantly, the modulation of phosphorylation and the subcellular localization  have not been 
investigated. And also while the role of BMP in development and bone formation is being well 
characterized, little information is known about its role in tumor.  
  
This study is to compare two different conditions of BMP2 signalling by using antibody 
microarray, one long time and high concentration of BMP2 treatment to U937 cells. This first 
experiment verified the BMP2 induction of apoptosis in U937 cells by observing cell number and 
FACS, obtaining 2000 ng/ml BMP2 treatment for 3 days as the optimal concentration and 
incubation time; the other selected short time and lower concentration of BMP2 treatment to 
MCF7 cells by using the lower concentration of BMP2(100ng/ml) for 4h in MCF-7 cells.  
 
1.3.2 Effect of STI571 on cell signalling  
 
STI571, as an inhibitor of the Bcr/Abl, c-Kit, and platelet-derived growth factor receptor kinases 
(Buchdunger E et al, 2000) has been shown to inhibit the growth of Bcr/Abl-positive leukemic 
cells (Druker B. J. et al. 1996). However (Yu, Krystal et al. 2002) indicated the exposure of 
Bcr/Abl+ cells to STI571 has not in general been associated with down-regulation of the Bcr/Abl 
protein, they reported that Exposure of K562 cells to concentrations of STI571 that minimally 
induced apoptosis ( 200 nM) resulted in early suppression (i.e., at 6 h) of p42/44 MAPK 
phosphorylation followed at later intervals (lager than or =24 h) by a marked increase in p42/44 
MAPK phosphorylation/activation. 
 
Importantly, clinical trials have now demonstrated that STI571, when administered at doses of 
larger than 300 mg/day, achieves clinical remissions in the large majority of patients with CML 
(e.g., 96%; Ref. Druker B. J.,et al 2001). In addition, preclinical studies have demonstrates that 
the combination of STI571 with established chemotherapeutic drugs (e.g., ara-C) results in 
enhanced toxicity in Bcr/Abl-positive leukemias (Thiesing J et al 2000); Fang G., et al (2000) 
findings raise the possibility that combining STI571 with such agents might lead to enhanced 
activity in CML and/or circumvention of drug resistance. In this context, Vigneri and Wang (2001) 
reported recently that coadministration of STI571 with leptomycin, an inhibitor of the nuclear 
export sequence receptor, resulted in increased killing of cells expressing Bcr/Abl. However, in 
this study optimal killing occurred in cells exposed to 10 µM STI571, which is above 
concentrations obtained in the plasma of patients receiving this agent (Druker B. J., et al. 2001). 
 
In order to overcome problems of STI drug treatment as discussed above, various combination 
strategies may be possible. To identify important interactions relevant for STI571 treatment, it is 
interesting how different signal pathways are effected by STI571. I therefore treated the human 
leukemia cell line K562 with STI571 and studied the changes in signalling protein 
phosphorylation and localization using the phosphorylation antibody array. As in the other 
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1. 4   Aim 
 
Development of an optimized antibody array that facilitates the analysis of proteins and their 
modifications in cellular tracts. With this array system it should be possible to analyse a 
selection of proteins in parallel and qualitatively and quantitatively compare the phosphorylation 
state of the selected proteins with a sensitivity and specificity comparable to westernblot 
analysis. After initial experiments with array designs on microscope glass slides, the focus of the 
technical development was shifted to miniaturized glass chips, that can be mounted on the 
bottom of standard micro-reaction tubes (ArrayTube, Clondiag, Jena). With this ArrayTube 
system an optimized antibody array protocol could be developed using nano-gold particle-
mediated silver staining for detection of bound antibodies.  
 
After optimization of the system the general applicability of the array system were demonstrated 
in application examples. The three application models represent signalling processes important 
in the regulation of cellular proliferation: response of cellular signalling to BMP2 treatment and 
changes in signalling pathway activation after treatment with STI571. In addition, selective 
purification of cytoplasmic and nuclear protein extracts were used to assign the proteins to the 
specific cellular compartment.  
 
The protein analyzed in the application examples included: phospho-p70S6 and phospho-Akt 
(PI3K signaling), phospho-p38, phospho-ERK and phospho-JNK (MAPK pathway), phospho-
Tyrosine (tyrosine-kinase activity), phospho-STAT3 (Jak/stat network), and phospho-Smad1 
and phospho-Smad 2,3 (Smad network).  
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2.1.1 Cell Lines 
 
Leukemia cell line K562 and breast cell line MCF-7 were kindly provided by Dr Joachim 





STI571 was kindly provided by Prof. Pachmann and prepared as a 10 mM stock solution in 
sterile DMSO (Merck Darmstadt, Germany). BMP2 was kindly provided by Dr. Clement stored 
at -20°C, and dissolved in sterile water as a 1mg/ml stock solution before use. Stock solutions 
were then diluted in RPMI medium to achieve the desired final concentration. In all of the cases, 
final concentrations of DMSO were < 0.1% and did not modify responses of cells to STI571.  
 
Biotinamidocaproate N-hydroxysuccinimide ester was purchased from SIGMA D2643; 
Streptavidin-Gold EM.STP5 and LM/EM Silver Enhancement Kit SEKL15 were purchased from 
British BioCell; dist.PLANO, Germany. BSA from SIGMA; Milk Powder from Roth GmbH, 





phospho-p70S6 kinase (Thr389), phospho-Akt (Ser473), phospho-STAT3 (Ser727), phospho-
Tyrosine (Tyr100), phospho-SAPK/JNK (Thr183/Tyr185), phospho-p42/44 MAPK 
(Thr202/Tyr204), phospho-p38 (Thr180/Tyr182) and p38 MAPK purchased from Cell Signalling 
Technology; c-Myc, phospho-Smad1 (Ser463/465) and phospho-Smad2/3 (Ser433/435), β-actin, 
secondary antibodies antigoat, mouse, rabbit purchased from Santa Cruz Biotechnology.        
 
 
2.1.4 Protein-molecular weight marker 
 
206 kDa Myosin 
124 kDa ß-galactosidase 
83 kDa BSA 
42.3 kDa Carbonic anhydrase 
32.2 kDa Soybean trypsin inhibitor 
18.8 kDa Lysozyme 
7 kDa Aprotinin 
 
 




The Clondiag ArrayTube™ platform (AT) was selected for the preparation of antibody arrays. In 
the AT platform the array chip is positioned at the bottom of a standard 1.5 ml micro reaction 
tube. This allows us to use all the standard laboratory equipment for heating, cooling and 
shaking, as well as centrifugation of 1.5 ml reaction tubes. Together with conventional microliter 
pipetors everything needed to perform the experiment. The only additional equipment required 
is a dedicated ArrayTube™ reader. If, as presented here, silver staining is used for detection, 
the costs for the reader are fairly low, in particular when compared with fluorescence readers 
                                                                                                                    
                                                                                                                                           13 
used for other array platforms with fluorescence labelling. The ArrayTubes™ are prepared and 
setup by Clondiag. Clondiag offers two choices for chip preparation, spotting of substances or in 
situ synthesis of oligomers. For the preparation of antibody arrays commercially available 
antibodies (Cell Signalling Technology, Beverly, MA; Santa Cruz Biotechnology, Santa Cruz, CA) 
were used and the spotted micro arrays were taken to set up the ArrayTubes™.  
 
Antibody Spotting 
For spotting an equal volume of antibody-spotting-buffer (Clondiag) was added to the PBS 
antibody preparations. All antibodies were obtained at concentrations of at least 1 µg/µl (or 
higher). We also included a second set of spots containing a 1:5 dilution for each antibody. The 
antibodies were spotted using a conventional split-pin micro-arrayed (BioRobotics MicroGrid II) 
onto glass based array substrate containing a three dimensional epoxy activated surface. After 
spotting, fresh prepared arrays were left in humid environment at room temperature to allow for 
covalent binding of the antibodies on the activated substrates. The quality of spotting (spots) 
was monitored by spot size analysis. Arrays were then mounted in ArrayTubes™ and sealed 
under inert gas atmosphere. 
 
 
2.2   Methods 
 
 
2.2.1 Cell Culture 
 
K562, MCF-7 and U937 human cancer cells were cultured in RPMI 1640 supplemented with 
10% heat-inactivated FCS (Hyclone, Logan, UT). They were maintained in a 37°C, 5% CO2, fully 
humidified incubator, passed twice weekly, and prepared for experimental procedures when in 
log-phase growth (4 x 105 cells/ml). 
 
 
2.2.2 Cell numbers and Experimental format 
 
Logarithmically growing cells were placed in sterile plastic T-flasks (Corning, Corning, NY) to 
which the designated drugs were added and the flasks placed back in the incubator for intervals 
ranging from 4 to 72 h. 50 µl cell sample was collected and added into 20 ml of 0.9% NaCl tube 
for counting of cell numbers in cell count reader. 
At the end of the incubation period, cells were transferred to sterile centrifuge tubes, pelleted by 




2.2.3 Cytoplasmic and Nuclear protein Extracts 
 
K562, MCF-7 and U937 human cancer cellular proteins were obtained from cell culture cells as 
cytoplasmic or nuclear fractions using a buffer system that allows lysis of cells in two steps. In 
the first step only the plasma membrane is lysed, leaving nucleus intact. The nuclei are pelleted 
by centrifugation. The supernatant contains the cytoplasmic protein lysate. To obtain nuclear 
proteins, the nuclei are washed repeatedly and then lysed using the nuclear lysis buffer B which 
described in details as follows: 
 
K562, MCF-7 and U937 human cancer cells (105 to 106) were collected from culture cells and 
washed with 10 ml PBS by centrifugation with 1500 x g for 5 min. The cell pellet was 
resuspended in 1 ml PBS and transfered to 1.5 ml tube by centrifugation for 15 sec, buffer 
removed. The cell pellet was resuspended in 400 µl ice cold buffer A (cytoplasmic lysis buffer) 
and left on ice for 15 min (cells should swell). 25 µl of Np-40 (10%solution) was added and 
vortexed for 10 sec by centrifugation for 30 sec in 9000 rpm. Supernatant in 1.5 ml tube for 
cytoplasmic proteins was added 0.11 volume of ice cold buffer C and mixed thoroughly by 
centrifugation for 15 min at maximum speed.  
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Nuclear pellet was washed in 500 µl of ice cold buffer A and 20 µl Np-40 and votexed for 10 sec 
followed by a centrifugation with 9000 rpm for 30 sec. The pellet was resuspended in 50 µl of 
buffer B and rotated or shaken for 15-20 min at 4°C. Samples were centrifuged for 5 min and 
supernatants collected and frozen in aliquots of 10 µl (-70 C).  
 
 
Buffer A (lysis buffer) 
 
10 mM Hepes pH 7.9 
10 mM KCl 
0.1 mM EDTA 
0.1 mM EGTA 
1 mM DTT 
0.5 mM PMSF 
 
 
Buffer B (nuclear extract buffer) 
 
20 mM Hepes pH 7.9 
0.4 mM NaCl 
1 mM EDTA 
1 mM EGTA 
1 mM DTT 




Buffer C (cytoplasmic extract buffer) 
 
 
0.3 M Hepes pH7.9 
 
1.4 M KCL 




 2.2.4 Determination of Protein Concentration 
 
Protein concentration was determined according to Bradford (1976). Several dilutions of protein 
standards (BSA) containing from 1 to 100 µg/ml were prepared. 0.1 ml of standard samples and 
appropriately diluted samples were placed in dry test tubes. 0.1 ml sample buffer was used as a 
negative control. 1.0 ml diluted dye reagent was added to each tube and mixed several times by 
gentle inversion. After 15 min, OD595 values versus reagent negative control were measured. 
OD595 versus concentration of standard was plotted. The protein of interest was calculated 
from the standard curve using the Microsoft Excel5 software. 
 
 2.2.5 Ponceau S Staining  
 
After PAGE, proteins were visualised by Ponceau.S staining. The proteins were stained by 
incubation in Ponceau.S solution for 5 min with agitation, followed by incubation in destaining 
water, until protein bands were visible on a colourless background.  
 
 
 2.2.6 Western Analysis  
 
Equal amounts of protein (20 µg) were boiled for 10 min, separated by SDS-PAGE (5% stacker 
and 10% resolving), and electroblotted to nitrocellulose. After blocking in PBS-T (0.05%) and 
5% milk for 1h, the blots were incubated in fresh blocking solution with an appropriate dilution of 
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primary antibody for 4h. The source and dilution of antibodies were as follows: phospho-Akt 
1:200, phospho-STAT3 (1:100), phospho-Tyrosine (1:100), phospho-p42/44 MAPK (1:200), 
phospho-p38 (1:200), phospho-Smad1 (1:100) and β-actin (1:1000). Blots were washed 3 x 5 
min in PBS-T and then incubated with a 1:2000 dilution of horseradish peroxidase-conjugated 
secondary antibody for 1h. Blots were again washed 3 x 5 min in PBS-T and then developed by 
ECL chemiluminescence.  
 
 
 2.2.7 Immunoprecipitation 
 
The protein G Sepharose beads were equilibrated in TBS for 30 min, pelleted by centrifugation 
with 2292 x g for 3 min and washed twice with TBS. The remainder of protein G Sepharose was 
stored inTBS with 0.02% NaN3 at 4°C. 500 µl (700 ug/ml) of control cytoplasmic extract in K562 
cells incubated with 10 µl of phospho-Tyrosine specific antibody for 1.5h on a rotator at 4°C. 40 
µl of protein A/G added to the antibody linked antigen for 1h on a rotator at 4°C. The sepharose 
beads were washed twice by centrifugation with 2500g for 5 min with washing buffer, followed 
by the addition of loading buffer. Prior to loading on an SDS gel, the samples were boiled for 10 
min in loading buffer.  
 
  
2.2.8 Cy3 and Cy5 Staining in SDS-PAGE 
 
In order to examine the efficiency of antibody labelling, 5µl of original anti-goat secondary antibody 
was incubated with 2µl of Cy3 or Cy5 mono-reactive dye on a shaker for 1h at RT. The reaction 
was stopped by the addition of loading buffer to each sample. Prior to loading on an SDS gel, 
samples were boiled for 10 min in loading buffer (Figure 61).  
 
 
2.2.9 Cy3 and Cy5 Staining of Microscope-Slide-Size Array  
 
 
To compare slide quality and storage conditions of slides at different temperature and time. 
20°C for a couple of months or even longer were used between epoxy and aldehyde slide; 
 
To compare protein labelled time and amounts between one kind of protein (or antibody) and 
the whole protein based on relative fluorenscence after labelling proteins: One kind of protein 
(or antibody),  20ng of protein was needed 0.01 µl of Cy3 or Cy5 mono-reactive dye, (but 
usually adding up to Cy3 or Cy5  mono-reactive dye 2µl. Therefore, free dye existing). However, 
the whole protein of cells (more than 1mg/ml) was needed about 50µg using 2-3µl of Cy3 or 
Cy5  mono-reactive dye; One kind of protein or antibody labeled half hour and two hours 
separately. However, the whole protein of cells compared among half, two and four hours.The 
labelled protein can be stored at –20°C more than one week for reaction later; 
 
To compare stop reagent using and without using stopping reagent. Stopping reagent 
separately was incubated in SDS-PAGE and microscope-slide-size array for 5 min and 15 min; 
 
To compare protein purification with different methods in order to delete free dye: G25, G50, 
microcon10, 30 and 50 were used for protein purification which result was checked by protein 
concentration measure (CCB);  
 
To compare results between deletion and undeletion of free mono-reactive dye Cy3 and Cy5-
labelled antibodies, mono-reactive dye Cy3 and Cy5-labelled mixed antibodies were separately 
incubated and washed completely with each step; Only Cy5 free mono-reactive dye was 
incubated;  
 
To compare blocking time. Blocking time half to one hour under PBS-0.5%Tween-BSA was 
used; Blocking slide were stored at –20°C several days afterwards to use for reaction.  
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To compare reaction volume and time.  7µl, 12-15µl and 20 µl of incubation volume under 
different reaction time 1, 2 and 3 hours were used to react at room temperature and 4°C 
overnight separately;  
 
To compare washing volume and time. Big volume (30 ml) three times was washed at room 
temperature or in the dark overnight or shake up and down by hand with vortex several times, or 
at 4°C overnight. 
 
 
 2.2.10 Cy3 and Cy5 Staining of mini-Arrayslide 
 
Minislide-protein microarray was divided into about 126 minislides in one normal slide, each 
including different rerpeating spotted antibodies (each spotting 1.5µl) and Cy3 mono-reactive 
dye markers at four corners. 
 
50 µg of protein was labelled with 2µl of Cy3 or Cy5  mono-reactive dye separately on a shaker 
for h at RT. The minislide was blocked with 80-100 µl of 5 % milk powder (fresh) on a shaker for 
1.5h. At least 40 µl volume of 50 ug protein labelled Cy3 and Cy5  mono-reactive dye were 
mixed together for checking cytoplasm and nucleus at the same time and was reacted with 
minislide in 96 plate for 1h. The reacted minislide was washed with 300 µl of PBS-0.5%Tween 
buffer in 96 plate on a shaker for 30 min twice. Finally the minislide was put on fluorescent 
image reader for scanning. 
  
 
2.2.11 Silver staining of mini-Arrayslide 
 
50 µg of cellular proteins are diluted to a final volume of 25 µl in buffer (extraction buffer or PBS). 
For biotinylation 1 µl of NHS-succinimid-Biotin (SIGMA) (100 µg/µl in ultra pure DMSO; water 
free) was added and left at room temperature for 1h. Reaction was stopped adding 2% BSA. 
Finally, the volume was adjusted to 100 µl with PBS (2% milk powder or 2% BSA).  
 
Arrayslide was blocked with 5% milk powder in PBS for at least 5 minutes at 30° C shaking at 
750 rpm (Eppendorf Thermomixer™). Arrays are incubated with the protein extracts for 2h at 
room temperature. After incubation arrays are washed 3 times for 5 min with 500 µl PBS-
0.5%Tween. 
 
50 µl of solution A and 50 µl of solution B from silver enhancement kit were combined 
immediately before use and added to Arrayslide to reaction.  
 
 
2.2.12 Silver staining in Arraytube 
 
 
2.2.12.1 Biotinylation of Cellular Proteins 
  
50 µg of cellular proteins are diluted to a final volume of 25 µl in buffer (extraction buffer or PBS). 
If other buffers than indicated below are used for protein extraction, a change of buffers may be 
necessary before biotinylation (Tris-based buffers can not be used for biotinylation!). For 
biotinylation 1 µl of NHS-succinimid-Biotin (SIGMA) (100 µg/µl in ultra pure DMSO; water free) 
was added and left at room temperature for 1h. Reaction was stopped adding 2%BSA. Protein 
preparations were left at room temperature for another 15 minutes to ensure complete 
consumption of the biotinylation reagent. Finally, the volume was adjusted to 100 µl with PBS 
(2% milk powder or 2% BSA). Biotinylated proteins are then ready to add to blocked 
ArrayTubes™ for binding. 
 
 
2.2.12.2 Incubation of Protein Extracts  
              
Before incubation with protein extracts, antibody arrays must be blocked. After spotting most of 
the activated surface is still freely accessible and has a high capacity for protein binding. For 
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this reason, our arrays were blocked with 5% milk powder in PBS for at least 5 minutes at 30° C 
shaking at 750 rpm (Eppendorf Thermomixer™). Not all milk powder can be used, so I 
recommend tests with various milk powders (Sigma). In this case best results were obtained 
with a milk powder that fully dissolved into a clump free white colored solution at 5% in PBS. 
Blocking solution is then replaced by the biotinylated protein extract in PBS (supplemented with 
2% milk powder or BSA). Arrays are incubated with the protein extracts for 2h at room 
temperature. Alternatively, I also obtain good results with an overnight incubation at 4°C. After 
incubation arrays are washed 3 times for 5 min with 500 µl PBS.  
 
 
 2.2.12.3 Silver Staining 
 
The bound biotinylated proteins are detected in a two step detection process. In the first step, 
streptavidin gold nanoparticles (British BioCell, Plano) are bound to the biotin groups. In the 
second step, a silver precipitate is formed around the gold particles. This step is monitored 
online in the ArrayTube™ Reader, which allows to detect the onset of sliver precipitation. In this 
way errors resulting from saturation effects from final point measurements can be avoided.  
 
Before incubation with the streptavidin gold particles tubes are again blocked with PBS (5% milk 
powder) for 15 min. Blocking solution is replaced by 100 µl of streptavidin gold particles in PBS 
and tubes are incubated for 30 min at 30° C shaking at 350 rpm. Excess streptavidin gold is 
removed in 3 wash steps. with 200 µl of PBS-tween (0.1%) for 10 min at 20° C with 750 rpm 
three times. For silver staining 100 µl silver developing solution is added. The silver developing 
solutions contains equal amounts of silver enhancer and developer, which are combined directly 
before use (here I used the reagents from British BioCel, distributed in Germany by Plano. 
Other reagents may work equally well). Tubes are placed into the ArrayTube™ Reader and 
recording of pictures is started. Pictures are taken every minute for 40 minutes to 1 h. 
 
50 µl of solution A and 50 µl of solution B from silver enhancement kit were combined 
immediately before use and added to ArrayTube to start silver development, collect images for 
40 min to 1h at 1 min interval and analysis of images with appropriate software e.g. Partisian 
IconoClust from Clondiag.  
 
 
2.2.13 Statistical Analysis 
 
For each experiment, 40 exposures are obtained and all are evaluated by the IconoClust 
software. This software can automatically produce data including mean, background, Sigma etc. 
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3   Results 
 
 
3.1 Antibody Array Technologies 
 
 
3.1.1 Cy3 and Cy5 of SDS-PAGE, Microscope-Slide-Size Array and mini-Arrayslide 
 
One important factor for antibody array is the efficiency of antibody labelling. In order to 
examine the labelling efficiency, 5µl of original anti-goat secondary antibody was incubated with 
2 µl of Cy3 mono-reactive dye or Cy5 mono-reactive dye (taken from a stock dilution to 50 µl) 
on a shaker for 1h at RT. Fractionation of the reaction mix by SDS-PAGE was followed by 
visulization under normal light ( because of high Cy5 concentration decided which blue band 
can be seen in normal light) and revealed two bands, as shown in Fig. 3.1. These bands 
correspond to the heavy and light chains. This result demonstrates good labelling efficiency and 







Figure 3.1: Cy5 staining in SDS-PAGE. 5µl of original anti-goat secondary antibody was 
labelled with 2µl of Cy5 on a shaker for 1h at RT. Because of the high Cy5 concentration 
blue bands of labeled proteins can be seen in normal light, upper arrow indicating light 
chain, lower arrow indicating heavy chain. 
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At present, most antibody array technologies were used Cy3 and Cy5 staining of microscope-
slide-size arrays. Because antibody array is a new technology, standardisation is needed for 
setting up. This part aim was to summarise the protocol in details under different conditions. 


































                                                                                                                    











3.2 C      3.2 D 
 
Figure 3.2: Cy3 or Cy5 staining of microscope-slide-size antibody array. Array was 
spotted by Quantifoil (Jena). Different reaction conditions are shown 3.2 A-D as detailed 
in the text. Black signals are positive reaction. Each line represented one kind of 
antibody including PanErk, p-MEK1, p-MEK2, p-p44/42 MAP kinase, p-p38, p-Smad1, p-
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To compare slide quality and storage conditions of slides at different temperature and time. 
20°C for a couple of months or even longer were used between epoxy and aldehyde slide. The 
result showed that slides can be stored efficiently at –20°C for a couple of months or even 
longer and epoxy slides are more sensitive than aldehyde slides for slide quality;   
 
To compare protein labelled time and amounts between one kind of protein (or antibody) and 
the whole protein based on relative fluorenscence after labelling proteins. One kind of protein 
(or antibody),  20ng of protein was needed 0.01 µl of Cy3 or Cy5 mono-reactive dye, (but 
usually adding up to Cy3 or Cy5  mono-reactive dye 2µl. Therefore, free dye existing). However, 
the whole protein of cells (more than 1mg/ml) was needed about 50µg using 2-3µl of Cy3 or 
Cy5  mono-reactive dye; One kind of protein or antibody labeled half hour and two hours 
separately. However, the whole protein of cells compared among half, two and four hours.The 
labelled protein can be stored at –20°C more than one week for reaction later; The results 
demonstrates the same between labeling time of half hour and two hours. However, the whole 
protein of cells compared among half, two and four hours. The results demonstrates better for 
longer time labeling. The labelled protein can be stored at –20°C more than one week later for 
reaction. The result demonstrated that stored protein reaction is almost the same as before; 
 
To compare stop reagent using and without using stopping reagent. Stopping reagents 
separately were incubated in SDS-PAGE and microscope-slide-size array for 5 min and 15 min. 
The result showed that hydroxylamin make dye disappeared under the observation of SDS-
PAGE. For stopping time between 5min and 15 min, the result demonstrated that the long time 
stopping reaction signaling (15 min) is weaker than the short time stopping reaction (5 min); 
Without using stop reagent, the result demonstrates the same as 5 min stopping and has not 
appeared a crosstalking reaction (from literature, stopping reagent hydroxylamin easily makes 
dye disconnected from protein); 
 
To compare protein purification with different methods in order to delete free dye: G25, G50, 
microcon10, 30 and 50 were used for protein purification checked by protein concentration 
measure (CCB). The result showed that G25 and G50 make protein dilution, and only 
microcon10 is the best because of no protein leaking out;    
 
To compare results between deletion and undeletion of free mono-reactive dye Cy3 and Cy5-
labelled antibodies, mono-reactive dye Cy3 and Cy5-labelled mixed antibodies were separately 
incubated and washed completely with each step. The result demonstrates the same as before 
mixture reaction and indicate no crosstalking reaction between  mono-reactive dye Cy3 and 
Cy5-labelled antibodies. Only Cy5 free mono-reactive dye was incubated. only Cy5 free dye 
was incubated. The result demonstrates nothing. Therefore, free dye cannot affect the result;  
 
To compare blocking time. Blocking time half to one hour under PBS-0.5%Tween-BSA was 
used; Blocking slide were stored at –20°C several days afterwards to use for reaction. The 
result demonstrates the same as before; Some negative-result slide can be repeated to be used;  
 
To compare reaction volume and time. 7µl, 12-15µl and 20 µl of incubation volume under 
different reaction time 1, 2 and 3 hours were used to react at room temperature and 4°C 
overnight separately. 7µl of reaction volume makes one spotting line dropping for 18*18cm 
cover. 12-15µl of reaction volume is very optimal for 18*18cm cover. 20 µl of reaction volume 
makes cover moving and reaction liquid out for 18*18cm cover; Reaction time used 1, 2 and 3 
hours at room temperature and 4°C overnight separately. The results demonstrate the same. 
 
To compare washing volume and time. Big volume (30 ml) three times was washed at room 
temperature or in the dark overnight or shake up and down by hand with vortex several times, or 
at 4°C overnight. Washing at room temperature in the dark overnight makes some spots moving; 
Washing steps can shake up and down by hand and also vortex several times, the result is the 






                                                                                                                    




Miniarray slide was developed in the next step. One result with Cy3 staining of mini-Arrayslide is 
shown in Fig. 3.3. The advantage of this technology is that the binding reaction and labelling 
reaction can be performed in a very small volume and that the handling in tubes and microtitre 






Figure 3.3: Cy3 staining of antibody array in mini-Arrayslide. Control K562 cell protein 
extraction with labelled Cy3  mono-reactive dye was reacted with minislide. Every four 
repeating spots represented one kind of antibody including p-MEK1, p-MEK2, p-p44/42 MAP 








Nano-gold particles-mediated silver staining of mini-Arrayslide is an altrernative new technology 
for detection of bound molecules. One example of silver staining in mini-Arrayslide was shown 
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Figure 3.4: Silver staining of mini-Arrayslide. Array was spotted by Quantifoil. This is one 
example of protein extracts from control K562 cells incubated with mini-arrayslide by 
visulization under microscope revealing black positive results. Each four repeating spots 
represented one kind of antibody including p-MEK1, p-MEK2, p-p44/42 MAP kinase, p-p38, p-







3.1.2 Data Analysis 
 
The pictures obtained were analyzed using the PARTISAN IconoClust image analysis software 
from Clondiag. This software automatically recognises the arrays and overlays a grid to 
measure the intensities for each spot. All pictures were combined to generate time curves for 
the increasing signals of all samples (spots). This time course was then used to assign 
differences in signal intensities. In comparison with pictures taken after a given period of 








                                                                                                                    





Figure 3.5: Different time point pictures and values. Upper pictures were shown 6,12, 17, and 20 
minute points of 2000 ng/ml U937 BMP2 treatment for 3 days. Lower graph dsiplays increase of signal 








                                                                                                                    






As an example of an ArrayTube™ antibody array were presented.  p70S6 kinase, Akt, STAT3, 
SAPK/JNK, p44/42 MAP kinase, Tyrosine, Smad1 and Smad2/3 are detected only when 
phosphorylated. For p38 MAP kinase, two antibodies were selected to spot: one 
phosphorylation specific and one binding the protein independent of phosphorylation. An 
antibody directed against c-Myc was used total antobody. All antibodies were spotted at two 
concentrations four times each (undiluted: 1 volume antibody stock + 1 volume spotting buffer; 
and at a 1:5 dilution). A description of the antibodies with supplier and position on the array is 





Figure 3.5: A description of the antibodies with supplier and position on the array. 
p70S6 kinase, Akt, STAT3, SAPK/JNK, p44/42 MAP kinase, Tyrosine, Smad1 and Smad2/3 
should be detected only when phosphorylated. For p38 MAP kinase two antibodies were 
selected to spot one phosphorylation specific and one binding the protein independent of 
phosphorylation. As reference an antibody directed against c-Myc independent of 
phosphorylation. All antibodies were spotted at two concentrations four times each (undiluted: 
1 volume antibody stock + 1 volume spotting buffer; and at a 1:5 dilution).  
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One successful enlargement example of silver staining arraytube is shown in Fig. 3.7. The result 














Figure 3.7: One successful picture of silver staining of array-tube. One example of silver 
staining picture. Protein extracts from the human leukemia cell line U937 using the protocol for 
the preparation of cytoplasmic protein extracts, the result of silver staining clearly 











Different parameters were changed for comparison of different protocols, such as change of 
protein concentration produces the same result, reflecting the technology sensitive and stable.  This result 
was shown in Fig. 3.8    
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Figure 3.8 Change different parameters.   Change of protein concentration produces the same 





The same protein (twice amounts) divided into two parts and reacted in 2 tubes, The result of 
pictures and evaluations are the same, as shown in Fig. 3.9. The experiment demonstrates the 
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Figure 3.9-a: Pictures on silver staining by array-tube. The same protein (twice 
amounts) divided into 2 parts and incubated in 2 tubes, showing the results of 




                                                                                                                    







Figure 3.9-b: Evaluation on silver staining by array-tube. The same protein (twice 
amounts) divided into 2 parts and incubated in 2 tubes, showing the results of 
evaluation are the same. 
 
The ArrayTube™ platform with small arrays of phosphoprotein specific antibodies were used 
and spotted in quadruplets on glass chip substrates coated with a three dimensional epoxy 
activated reactive surface. The ArrayTube™ antibody arrays were incubated with protein 
extracts from the human leukemia cell line U937. Changes in phosphorylation of signalling 
proteins were induced by incubation with the bone morphogenetic protein BMP2. After 
incubation, Smad1, ERK, Akt, STAT3 and Tyrosine phosphorylation could be detected which 
correlates well with results obtained by western blotting and Cy3/Cy5 staining. In summary, the 
ArrayTube™ platform can be used for antibody arrays aimed at the detection of intracellular 
proteins and their respective phosphorylation state.  
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3.2 Modulation of Phosphorylation and localization in BMP2 treated U937 cells  
 
 
In order to discover the optimal BMP2 concentration and incubation time in U937 cells, first 
different BMP2 concentrations were selected from 50 ng/ml, 100 ng/ml, 300 ng/ml, 500 ng/ml, 
1000 ng/ml, 1500 ng/ml to 2000 ng/ml under different incubation time from 10 min, 30 min, 2hr, 
4h to 24h and examined the cell mumbers, this result shows the significant decrease of the cell 
number is only 2000 ng/ml BMP2 treatment for 24h(data not shown).  
 
Different BMP2 concentrations were selected from 50 ng/ml, 100 ng/ml, 300 ng/ml, 500 ng/ml, 
1000 ng/ml, 1500 ng/ml to 2000 ng/ml for 3 days to examine dead cells and cell cycle by 
FACS.Treatment with high concentrations of the bone morphogenetic protein BMP2 in the 
human leukemia cell line U937 induces apoptosis, whereas treatment with lower levels of BMB2 
lead to differentiation of the cells. This experiment verified that 2000 ng/ml BMP2 treatment is 
the best condition for the induction of apoptosis in U937 cells from dead cells and cell cycle 
analysis by FACS (data not shown). 
 
 
Ponceau S staining of cytoplasmic and nuclear proteins in control U937 cells separated on SDS-
PAGE gel. The result of Ponceau S staining shows weaker distribution in nucleus (e) than 
cytoplasm (g) in control U937 cells the same as antibody arraytube present in both nucleus (b) and 
cytoplasm (a) in Fig. 3.12. From this result it can be known that antibody microarray technology 





Figure 3.12: Comparison between Ponceau S staining and microarray in U937 cells. 
Ponceau S staining of cytoplasmic and nuclear proteins of control U937 cells separated on 
SDS-PAGE gel. The result of Ponceau S staining shows weaker distribution in nucleus (e) 
than cytoplasm (g) in control U937 cells the same as antibody arraytube present in both 
nucleus (b) and cytoplasm (a). 
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3.2.1 Total p-Tyrosine and p-p38, p38 Increased: Cytoplasm and Nucleus 
Increasing 
 
Phospho-p38 and phospho-Tyrosine displayed increase in cytoplasm and nucleus of 2000 
ng/ml BMP2 treated U937 cells for 3 days, when compared with control U937 cells. Total protein 
(sum of cytoplasm and nucleus) levels of phospho-p38 and phospho-Tyrosine are higher in 
BMP2 treated U937 cells than in control cells. The cytoplasmic & nuclear change pattern of p38 
is similar with that of phospho-p38. This result demonstrates the consistence between protein 








Phospho-ERK and phospho-JNK displayed increase in cytoplasm and un-changed in nucleus of 
2000 ng/ml BMP2 treated U937 cells for 3 days, when compared with control U937 cells. Total 
protein (sum of cytoplasm and nucleus) levels of phospho-ERK and phospho-JNK are higher in 
BMP2 treated U937 cells than in control cells, whereas the cytoplasmic activities of ERK and 
JNK are higher and nuclear activities of ERK and JNK un-changed in BMP2 treated U937 cells 






3.2.3 Total p-Akt Increased: Cytoplasm Increasing and Nucleus Decreasing 
  
 
Phospho-Akt displayed increase in cytoplasm and slightly decrease in nucleus of 2000 ng/ml 
BMP2 treated U937 cells for 3 days, when compared with control U937 cells. Total protein (sum 
of cytoplasm and nucleus) level of phospho-Akt is higher in BMP2 treated U937 cells than in 
control cells, whereas the cytoplasmic activity of akt is higher in BMP2 treated U937 cells than 
in control cells and nuclear activity is lower in BMP2 treated U937 cells than in control cells, as 
shown in Fig. 3.13, 3.14.  
 
Western blotting analysis of phosphorylation and localization of BMP2 treated U937 cells with 
phospho-Akt antibody, the higher phospho-Akt expression in cytoplasm at line 1 and the very 
lower phospho-Akt expression in nucleus at line 2, as shown in Fig. 3.15(f). This result is 
consistent with antibody microarray (Figure 3.15b, d). Western blotting analysis of BMP2 treated 
U937 cells with actin antibody, the same amount of actin expression displayed in cytoplasm at 
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Figure 3.15: p-Akt(ser473) modulation of phosphorylation and localization in BMP2 treated U937 
cells. (a-d) Antibody micro-array analysis of p-Akt, untreated (a,c) and treated (b,d) with 
2000ng/ml BMP2 for 3 days. (a,b) Cytoplasm; (c,d) Nucleus. Position of p-Akt antibody is marked 
with frame and arrow. (e) Graphic display of numerical value analysis. BMP2 treated U937 cells 
displayed the increase in cytoplasm and the slight decrease in nucleus. Total protein (sum of 
cytoplasm and nucleus) level of phospho-Akt is higher in BMP2 treated U937 cells than in control 
cells. Each column indicates a mean of four measurements with standand deviations. (f) Western 
blotting analysis of phosphorylation and localization of BMP2 treated U937 cells with phospho-Akt 
antibody, the higher phospho-Akt expression in cytoplasm at line 1 and the very lower phospho-
Akt expression in nucleus at line 2. This result is consistent with antibody microarray (b, d). (g) 
Western blotting analysis of BMP2 treated U937 cells with actin antibody, the same amount of 
actin expression displayed in cytoplasm at line 1 and in nucleus at line 2. 
 
3.2.4 Total p-Smad1, p-Smad2/3, c-Myc and p-STAT3 Unchanged: Cytoplasm 
Decreasing and Nucleus Increasing 
    
Phospho-Smad1, p-Smad2/3, c-Myc and p-STAT3 displayed decrease in cytoplasm and 
increase in nucleus of 2000 ng/ml BMP2 treated U937 cells for 3 days, when compared with 
control U937 cells. Total protein (sum of cytoplasm and nucleus) levels of phospho-Smad1, p-
Smad2/3, c-Myc and p-STAT3 were not altered between control and BMP2 treated cells, 
whereas the nuclear activities of Smad1, Smad2/3, c-Myc and STAT3 are higher in BMP2 
treated U937 cells than in control cells and cytoplasmic activities of Smad1, Smad2/3, c-Myc 
and STAT3 are lower in BMP2 treated U937 cells than in control cells, as shown in Fig. 3.13, 
3.14.  
 
Western blotting analysis of phosphorylation and localization of BMP2 treated U937 cells with 
phospho-smad1 antibody, the similar amount of phospho-smad1 expression displayed in 
cytoplasm at line 1 and in nucleus at line 2, as shown in Fig. 3.16(f). This result is consistent 
with antibody microarray (Figure 3.16b, d). Western blotting analysis of BMP2 treated U937 
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cells with actin antibody, the same amount of actin expression displayed in cytoplasm at line 1 




Figure 3.16: p-Smad1(ser 463/465) modulation of phosphorylation and localization in BMP2 
treated U937 cells. (a-d) Antibody micro-array analysis of p-Smad1(ser 463/465), untreated (a,c) 
and treated (b,d) with 2000ng/ml BMP2 for 3 days. (a,b) Cytoplasm; (c,d) Nucleus. Position of p- 
Smad1(ser 463/465) antibody is marked with frame and arrow. (e) Graphic display of numerical 
value analysis. BMP2 treated U937 cells displayed the decrease in cytoplasm and the increase in 
nucleus. Total protein (sum of cytoplasm and nucleus) level of phospho-Smad1 was not altered 
between control and BMP2 treated cells. Each column indicates a mean of four measurements 
with standand deviations. (f) Western blotting analysis of phosphorylation and localization of 
BMP2 treated U937 cells with phospho-smad1 antibody, the similar amount of phospho-
smad1 expression displayed in cytoplasm at line 1 and in nucleus at line 2. This result is 
consistent with antibody microarray (b, d). (g) Western blotting analysis of BMP2 treated 
U937 cells with actin antibody, the same amount of actin expression displayed in 
cytoplasm at line 1 and in nucleus at line 2. 
 
 
Western blotting analysis of phosphorylation and localization of BMP2 treated U937 cells with 
phospho-STAT3 antibody, the higher amount of phospho-STAT3 expression displayed in 
cytoplasm at line 1 and the lower amount of phospho-STAT3 expression in nucleus at line 2, as 
shown in Fig. 3.17(f). This result is consistent with antibody microarray (Figure 3.17b, d). 
Western blotting analysis of BMP2 treated U937 cells with actin antibody, the same amount of 
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Figure 3.17: p-STAT3 (ser 727) modulation of phosphorylation and localization in BMP2   
treated U937 cells. (a-d) Antibody micro-array analysis of p-STAT3, untreated (a,c) and 
treated (b,d) with 2000ng/ml BMP2 for 3 days. (a,b) Cytoplasm; (c,d) Nucleus. Position of p-
STAT3 antibody is marked with frame and arrow. (e) Graphic display of numerical value 
analysis. BMP2 treated U937 cells displayed the slight decrease in cytoplasm and the slight 
increase in nucleus. Total protein (sum of cytoplasm and nucleus) level of phospho-STAT3 is 
almost the same in BMP2 treated U937 cells as in control cells. Each column indicates a 
mean of four measurements with standand deviations. (f) Western blotting analysis of 
phosphorylation and localization of BMP2 treated U937 cells with phospho-STAT3 antibody, 
the higher amount of phospho-STAT3 expression displayed in cytoplasm at line 1 and the 
lower amount of phospho-STAT3 expression in nucleus at line 2. This result is consistent with 
antibody microarray (b, d). (g) Western blotting analysis of BMP2 treated U937 cells with actin 
antibody, the same amount of actin expression displayed in cytoplasm at line 1 and in nucleus 
at line 2. 
 
 
3.2.5 Total p-P70S6 Unchanged: Cytoplasm Increasing and Nucleus Decreasing 
 
 
Phospho-p70S6 displayed increase in cytoplasm and decrease in nucleus of 2000 ng/ml BMP2 
treated U937 cells for 3 days, when compared with control U937 cells. Total protein (sum of 
cytoplasm and nucleus) level of phospho-p70S6 was not altered in control and BMP2 treated 






                                                                                                                    









Figure 3.13:  Antibody micro-array analysis of phosphorylation and localization in 
control and BMP2 treated U937 cells.  Untreated (a,c) and treated (b,d) with 2000ng/ml 
BMP2 for 3 days. (a,b) Cytoplasm; (c,d) Nucleus. Positions of p38, p-p38, p-Smad2/3, p-
Smad1, p-ERK, p-JNK, p-STAT3, p-Akt and p-p70S6 antibodies are marked with frame and 





















                                                                                                                    

















































Figure 3.14: Graphic numerical value analysis of phosphorylation and localization 
modulation in BMP2 treated U937 cells.  P-p38, p38 and p-Tyr100 displayed the increase in 
cytoplasm and nucleus of BMP2 treated U937 cells. Total protein (sum of cytoplasm and nucleus) 
level of p-p38, p38 and phospho-Tyrosine100 are higher in BMP2 treated U937 cells than in control 
U937 cells. p-ERK (thr202/tyr204) and p-JNK(thr183/tyr185) displayed the increase in cytoplasm 
and unchanged in nucleus in BMP2 treated U937 cells. Total protein (sum of cytoplasm and 
nucleus) level of p-ERK and p-JNK are higher in BMP2 treated U937 cells than in control cells. p-
Akt(ser473) displayed the increase in cytoplasm and the slight decrease in nucleus in BMP2 treated 
U937 cells. Total protein (sum of cytoplasm and nucleus) level of phospho-Akt is higher in BMP2 
treated U937 cells than in control cells. p-Smad1, p-Smad2/3, c-Myc and p-STAT3 displayed the 
increase in cytoplasm and the decrease in nucleus in BMP2 treated U937 cells. Total protein (sum 
of cytoplasm and nucleus) level of p-Smad1, p-Smad2/3, c-Myc and p-STAT3 were not altered 
between control and BMP2 treated cells. P-p70S6(thr389) displayed the increase in cytoplasm and 
the decrease in nucleus in BMP2 treated U937 cells. Total protein (sum of cytoplasm and nucleus) 
levels of phospho-p70S6 was not altered in control and BMP2 treated cells. Each column indicates 
a mean of four measurements with standand deviations. Different antibodies have different 
affinities, arrow indicating each antibody quantity  value 1 position. 
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Ponceau S staining of cytoplasmic and nuclear proteins in control MCF-7 cells separated on SDS-
PAGE gel. The result of Ponceau S staining shows similar size distribution in nucleus (c) and 
cytoplasm (d) in control MCF-7 cells. Using the antibody arraytube for phosphorylated proteins, most 
proteins are present in both nucleus (b) and cytoplasm (a) in Fig. 3.18. From this result it can be 










Figure 3.18: Comparison between Ponceau S staining and micorarray in MCF-7 cells. 
Ponceau S staining of cytoplasmic and nuclear proteins in control MCF-7 cells 
separated on SDS-PAGE gel. The result of Ponceau S staining shows similar size 
distribution in nucleus (c) and cytoplasm (d) in control MCF-7 cells. Using the antibody 
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3.3.1 Total p-JNK, p-Smad1, p-Smad2/3, p-p38 and p38 Unchanged: 
Cytoplasm Increasing and Nucleus Decreasing 
 
p-JNK, p-Smad1, p-Smad2/3, p-p38 and p38 displayed increase in cytoplasm and 
correspondingly decrease in nucleus of 100ng/ml BMP2 treated MCF-7 cells for 4hr, when 
compared with control MCF-7 cells. Total protein (sum of cytoplasm and nucleus) levels of p-
JNK, p-Smad1, p-Smad2/3, p-p38 and p38 are almost the same in BMP2 treated MCF-7 cells 
as in control cells, shown in Fig. 3.22-23.  
 
Western blotting analysis of phosphorylation and localization of control and BMP2 treated MCF-
7 cells with phospho-Smad1 antibody, the similar amount of phospho-Smad1 expression 
displayed in nucleus of control MCF-7 cells at line 1 and in nucleus of BMP2 treated MCF-7 
cells at line 2, as shown in Fig. 3.21(f). This result is consistent with antibody microarray (Figure 
3.21c, d). Western blotting analysis of control MCF-7 cells with actin antibody, the same amount 
appeared in nucleus of control MCF-7 cells at line 1 and in nucleus of BMP2 treated MCF-7 






Figure 3.21: p-Smad1(ser 463/465) modulation of phosphorylation and localization in BMP2 
treated MCF-7 cells. (a-d) Antibody micro-array analysis of p-Smad1(ser 463/465), untreated (a,c) 
and treated (b,d) with 100ng/ml BMP2 for 4h. (a,b) Cytoplasm; (c,d) Nucleus. Position of p- 
Smad1(ser 463/465) antibody is marked with frame and arrow. (e) Graphic display of numerical 
value analysis. BMP2 treated MCF-7 cells displayed unchanged in cytoplasm and the little 
decrease in nucleus. Total protein (sum of cytoplasm and nucleus) level of phospho-Smad1 was 
not significantly altered in BMP2 treated cells compared with control. Each column indicates a 
mean of four measurements with standand deviations. (f) Western blotting analysis of 
phosphorylation and localization of control and BMP2 treated MCF-7 cells with phospho-Smad1 
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antibody, the similar amount of phospho-Smad1 expression displayed in nucleus of control MCF-7 
cells at line 1 and in nucleus of BMP2 treated MCF-7 cells at line 2. This result is consistent with 
antibody microarray (c, d). (g) Western blotting analysis of control MCF-7 cells with actin antibody, 
the same amount appeared in nucleus of control MCF-7 cells at line 1 and in nucleus of BMP2 




3.3.2 p-Tyrosine, p-STAT3, p-ERK and p-P70S6 Increased: Cytoplasm Increasing 
and nucleus unchanged  
 
Phospho-Tyrosine, p-STAT3, p-ERK and p-P70S6 displayed increase in cytoplasm and 
unchanged in nucleus 100ng/ml BMP2 treated MCF-7 cells for 4hr, when compared with control 
MCF-7 cells. Total protein (sum of cytoplasm and nucleus) levels of p-Tyrosine, p-STAT3, p-
ERK and p-P70S6 have increase in BMP2 treated MCF-7 cells compared with control cells, 
whereas cytoplasmic activities of phospho-p38, p-Tyrosine, p-STAT3, p-ERK and p-P70S6 are 
higher in BMP2 treated MCF-7 cells than in control cells, the nuclear activities of phospho-p38, 
p-Tyrosine, p-STAT3, p-ERK and p-P70S6 are unchaged in BMP2 treated MCF-7 cells than in 
control cells, as shown in Fig. 22-23.  
 
Western blotting analysis of phosphorylation and localization of control and BMP2 treated MCF-
7 cells with phospho-Tyrosine specific antibody, the similar amount of phospho-Tyrosine 
expression displayed in nucleus of control MCF-7 cells at line 1 and in nucleus of BMP2 treated 
MCF-7 cells at line 2, as shown in Fig. 3.19(f). This result is consistent with antibody microarray 
(Figure 3.19 c, d). Western blotting analysis of control MCF-7 cells with actin antibody, the same 
amount appeared in nucleus of control MCF-7 cells at line 1 and in nucleus of BMP2 treated 
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Figure 3.19: p-Tyr100 modulation of phosphorylation and localization in BMP2 treated MCF-7 
cells. (a-d) Antibody micro-array analysis of p-Tyr100, untreated (a,c) and treated (b,d) with 
100ng/ml BMP2 for 4h. (a,b) Cytoplasm; (c,d) Nucleus. Position of p-Tyr100 antibody is marked 
with frame and arrow. (e) Graphic display of numerical value analysis. BMP2 treated MCF-7 cells 
displayed the increase in cytoplasm and and unchanged in nucleus. Total protein (sum of 
cytoplasm and nucleus) level of phospho-Tyrosine  was higher in BMP2 treated MCF-7 cells than 
control cells. Each column indicates a mean of four measurements with standand deviations. (f) 
Western blotting analysis of phosphorylation and localization of control and BMP2 treated MCF-7 
cells with phospho-Tyrosine specific antibody, the similar amount of phospho-Tyrosine expression 
displayed in nucleus of control MCF-7 cells at line 1 and in nucleus of BMP2 treated MCF-7 cells at 
line 2. This result is consistent with antibody microarray (c, d). (g) Western blotting analysis of 
control MCF-7 cells with actin antibody, the same amount appeared in nucleus of control MCF-7 




Western blotting analysis of phosphorylation and localization of control and BMP2 treated MCF-7 
cells with phospho-STAT3 antibody, the similar amount of phospho-STAT3 expression displayed in 
nucleus of control MCF-7 cells at line 1 and in nucleus of BMP2 treated MCF-7 cells at line 2, as 
shown in Fig. 3.20(f). This result is consistent with antibody microarray (Figure 3.20c, d). Western 
blotting analysis of control MCF-7 cells with actin antibody, the same amount appeared in nucleus of 









Figure 3.20: p-STAT3 (ser 727) modulation of phosphorylation and localization in 
BMP2 treated MCF-7 cells. (a-d) Antibody micro-array analysis of p-STAT3, untreated 
(a,c) and treated (b,d) with 100ng/ml BMP2 for 4h. (a,b) Cytoplasm; (c,d) Nucleus. Position 
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of p-STAT3 antibody is marked with frame and arrow. (e) Graphic display of numerical 
value analysis. BMP2 treated MCF-7 cells displayed the decrease in cytoplasm and 
unchanged in nucleus. Total protein (sum of cytoplasm and nucleus) level of phospho-
STAT3 was higher in BMP2 treated MCF-7 cells than control cells. Each column indicates 
a mean of four measurements with standand deviations. (f) Western blotting analysis of 
phosphorylation and localization of control and BMP2 treated MCF-7 cells with 
phospho-STAT3 antibody, the similar amount of phospho-STAT3 expression displayed in 
nucleus of control MCF-7 cells at line 1 and in nucleus of BMP2 treated MCF-7 cells at line 
2. This result is consistent with antibody microarray (c, d). (g) Western blotting analysis of 
control MCF-7 cells with actin antibody, the same amount appeared in nucleus of control 
MCF-7 cells at line 1 and in nucleus of BMP2 treated MCF-7 cells at line 2. 
 
3.3.3Total c-Myc Unchanged: Nucleus Slightly Increasing and Cytoplasm 
Slightly Decreasing 
 
c-Myc displayed slightly increase in nucleus and slightly decrease in cytoplasm of 100ng/ml 
BMP2 treated MCF-7 cells for 4hr, when compared with control MCF-7 cells. Total protein (sum 
of cytoplasm and nucleus) level of c-Myc was not altered between BMP2 treated and control 
MCF-7 cells, whereas in BMP2 treated MCF-7 cells it was translocated into nucleus, as shown 
in Fig. 3.22-23. 
 
3.3.4 Total p-Akt Unchanged: Nucleus and Cytoplasm unchanged 
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Figure 3.22:  Antibody micro-array analysis of phosphorylation and localization in 
control and BMP2 treated MCF7 cells.  Untreated (a,c) and treated (b,d) with 100ng/ml 
BMP2 for 4h. (a,b) Cytoplasm; (c,d) Nucleus. Positions of p38, p-p38, p-Smad2/3, p-Smad1, 









                                                                                                                    





Figure 3.23: Graphic numerical value analysis of phosphorylation and localization 
modulation in BMP2 treated MCF7 cells. phospho-p38 and p38, p-JNK, p-Smad1, p-
Smad2/3 displayed the increase in cytoplasm and the decrease in nucleus of BMP2 treated 
MCF7 cells. Total protein (sum of cytoplasm and nucleus) level of phospho-p38 and p38, p-
JNK, p-Smad1, p-Smad2/3 were not significantly changed in BMP2 treated MCF-7 cells and 
control cells. c-Myc displayed the slight decrease in cytoplasm and the slight increase in 
nucleus of BMP2 treated MCF7 cells. Total protein (sum of cytoplasm and nucleus) level of 
c-Myc was not significantly altered between BMP2 treated MCF-7 cells and control cells. p-
Tyrosine, p-STAT3, p-ERK and p-P70S6 displayed the increase in cytoplasm and 
unchanged in nucleus of BMP2 treated MCF7 cells. Total protein (sum of cytoplasm and 
nucleus) level of p-p38, p-Tyrosine, p-STAT3, p-ERK and p-P70S6 were increased in BMP2 
treated cells. P-Akt displayed unchanged in cytoplasm and nucleus of BMP2 treated MCF7 
cells. Each column indicates a mean of four measurements with standand deviations. 







3.4 Modulation of Phosphorylation and localization in STI571 treated K562 cells  
 
 
3.4.1 Total p-Akt and p-P70S6 Decreased: Cytoplasm and Nucleus Decreasing 
 
Phospho-Akt and phospho-p70S6 displayed decrease in both cytoplasm and nucleus of 0.2 µM 
STI571 treated K562 cells for 24hr, when compared with control K562 cells. Total protein (sum 
of cytoplasm and nucleus) levels of phospho-Akt and phospho-p70S6 are lower in treated K562 




                                                                                                                    




3.4.2 Total p-p38, p38, c-Myc, p-Tyrosine, p-Smad1 and p-Smad2/3 
Increased: Cytoplasm and Nucleus Increasing 
 
Phospho-p38, p38, c-Myc, phospho-Tyrosine, phospho-Smad1 and phospho-Smad2/3 
displayed increase in cytoplasm and nucleus of 0.2 µM STI571 treated K562 cells for 24hr, 
when compared with control K562 cells. Total protein (sum of cytoplasm and nucleus) levels of 
phospho-p38, p38, c-Myc, phospho-Tyrosine, phospho-Smad1 and phospho-Smad2/3 are 
higher in STI571 treated K562 cells than in control cells, as shown in Fig. 3.27-28.  
 
Western blotting analysis of phosphorylation and localization of control K562 cells with phospho-
Tyrosine specific antibody showed not strong phospho-Tyrosine specific expression in nucleus 
at line 2 and in cytoplasm at line 1 in Fig. 3.24(f). This result is consistent with antibody 
microarray (Figure 3.24a,c). Immunoprecipitation analysis of phosphorylation in control K562 
cells with phospho-Tyrosine specific antibody, three bands in cytoplasm at line 1, as shown in 
Fig. 3. 25. This result is consistent with western blotting (Figure 24(f)). Western blotting analysis 
of control K562 cells with actin antibody detected the same amount in nucleus at line 2 and in 






Figure 3.24: p-Tyr100 modulation of phosphorylation and localization in STI571 
treated K562 cells. (a-d) Antibody micro-array analysis of p-Tyr100, untreated (a,c) and 
treated (b,d) with 0.2 µM STI571 for 24h. (a,b) Cytoplasm; (c,d) Nucleus. Position of p-
Tyr100 antibody is marked with frame and arrow. (e) Graphic display of numerical value 
analysis. STI571 treated K562 cells displayed the increase in cytoplasm and nucleus. Total 
protein (sum of cytoplasm and nucleus) level of phospho-Tyrosine is higher in STI571 
treated cells than in control. Each column indicates a mean of four measurements with 
standand deviations. (f) Western blotting analysis of phosphorylation and localization of 
control K562 cells with phospho-Tyrosine specific antibody, showing not strong phospho-
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Tyrosine concentration in nucleus at line 2 and  in cytoplasm at line 1. The result is 

















Figure 3.25: phospho-Tyrosine immunoprecipitation analysis of 
cytoplasm in control K562 cells. Three bands are visible in cytoplasm of 




Western blotting analysis of phosphorylation and localization of control K562 cells with phospho-
p38 antibody showed not strong phospho-p38 expression in nucleus at line 2 and in cytoplasm 
at line 1 in Fig. 3.26(f). This result is consistent with antibody microarray (Figure 3.26a,c).  
Western blotting analysis of control K562 cells with actin antibody detected the same amount in 








                                                                                                                    





Figure 3.26: p-p38(thr180/tyr182) modulation of phosphorylation and localization 
in STI571 treated K562 cells. (a-d) Antibody micro-array analysis of p-p38, untreated 
(a,c) and treated (b,d) with 0.2 µM STI571 for 24h. (a,b) Cytoplasm; (c,d) Nucleus. 
Position of p-p38 antibody is marked with frame and arrow. (e) Graphic display of 
numerical value analysis. STI571 treated K562 cells displayed the increase in 
cytoplasm and nucleus. Total protein (sum of cytoplasm and nucleus) level of 
phospho-p38 is higher in STI571 treated cells than in control. Each column indicates a 




   3.4.3 Total p-STAT3 and p-JNK Increased: Cytoplasm Increasing and Nucleus   
Unchanged 
    
Phospho-STAT3 and p-JNK displayed increase in cytoplasm and un-changed in nucleus of 0.2 
µM STI571 treated K562 cells for 24hr, when compared with control K562 cells. Total protein 
(sum of cytoplasm and nucleus) levels of phospho-STAT3 and phospho-JNK are higher in 
STI571 treated K562 cells than in control cells, as shown in Fig. 3. 27-28.  
 
 
3.4.4 Total p-ERK Increased: Cytoplasm Decreasing and Nucleus Increasing 
 
  
Phospho-ERK displayed increase in nucleus and little decrease in cytoplasm of 0.2 µM STI571 
treated K562 cells for 24hr, when compared with control K562 cells. Total protein (sum of 
cytoplasm and nucleus) level of phospho-ERK is higher in STI571 treated K562 cells than in 
control cells, whereas the nuclear activity of ERK is higher  and cytoplasmic activity lower of 
STI571 treated K562 cells than in control cells, as shown in Fig. 3.27-28. 
 
                                                                                                                    










Figure 3.27:  Antibody micro-array analysis of phosphorylation and localization in control 
and STI571 treated K562 cells.  Untreated (a,c) and treated (b,d) with 0.2 µM STI571 for 24h. 
(a,b) Cytoplasm; (c,d) Nucleus. Positions of p38, p-p38, p-Smad2/3, p-Smad1, p-ERK, p-JNK, p-





                                                                                                                    





Figure 3.28: Graphic numerical value analysis of phosphorylation and localization 
modulation in STI571 treated K562 cells. p-ERK(thr202/tyr204) displayed the decrease in 
cytoplasm and the increase in nucleus of STI571 treated K562 cells. Total protein (sum of 
cytoplasm and nucleus) level of p-ERK is higher in STI571 treated K562 cells than in control 
cells.  p-JNK(thr183/tyr185) and p-STAT3 (ser 727) displayed the increase in cytoplasm and 
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unchanged in nucleus of STI571 treated K562 cells. Total protein (sum of cytoplasm and 
nucleus) level of phospho-JNK is higher in STI571 treated K562 cells than in control cells. p-
p38, p38, c-Myc, p-Tyrosine, p-Smad1 and p-Smad2/3 displayed the increase in cytoplasm 
and nucleus of STI571 treated K562 cells. Total protein (sum of cytoplasm and nucleus) 
level of p-p38, p38, c-Myc, p-Tyrosine, p-Smad1 and p-Smad2/3 are higher in STI571 
treated cells than in control. p-Akt(ser473) and p-p70S6(thr389) displayed the decrease in 
cytoplasm and nucleus of STI571 treated K562 cells. Total protein (sum of cytoplasm and 
nucleus) level of phospho-Akt and p-P70S6 are lower in STI571 treated K562 cells than in 
control cells.  Each column indicates a mean of four measurements with standand 
deviations. Different antibodies have different affinities, arrow indicating each antibody 
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4    Discussion 
 
4.1 Antibody array technologies 
 
 “Array technologies that will provide reliable analytical tool on the protein level, will allow us to 
collect the necessary information on protein modifications and alterations in protein complexes 
present at given regulatory states of cells for studying the cell signalling and functions. Analysis 
of gene expression on the protein level and of post-translational protein modifications is 
essential for understanding different cellular functions of proteins and to follow the time course 
of signalling processes inside a cell. The increasing number of highly specific antibodies not just 
for individual proteins but also for protein modifications like site specific phosphorylation 
provides good tools to analyze this processes in details” (Stefan Wolfl, 2003).  
 
To facilitate studies of protein function, we have developed miniaturized assays that 
accommodate extremely low sample volumes and enable the rapid, simultaneous processing of 
many antibodies. A high-precision robot designed to manufacture complementary DNA 
microarrays was used to spot antobidies onto chemically derivatized glass slides at extremely 
lower and high spatial densities.  
 
Cy3 and Cy5 staining of microscope-slide-size array is suitable for a large of antibody analysis.  
The protocol already was seen in paper, however, standand of this technology has not been set 
up.  
 
In this these, to compare slide quality and storage conditions of slides at different temperature 
and time. 20°C for a couple of months or even longer were used between epoxy and aldehyde 
slide. The result showed that slides can be stored efficiently at –20°C for a couple of months or 
even longer. From the point it can be deduced that this technology has very high robotness;   
epoxy slides are more sensitive than aldehyde slides for slide quality. From the point it can be 
suggested that epoxy slide is more suitable for reaction.  
 
To compare protein labelled time and amounts between one kind of protein (or antibody) and 
the whole protein based on relative fluorenscence after labelling proteins. One kind of protein 
(or antibody),  20ng of protein was needed 0.01 µl of Cy3 or Cy5 mono-reactive dye, (but 
usually adding up to Cy3 or Cy5  mono-reactive dye 2µl. Therefore, free dye existing). However, 
the whole protein of cells (more than 1mg/ml) was needed about 50µg using 2-3µl of Cy3 or 
Cy5  mono-reactive dye; One kind of protein or antibody labeled half hour and two hours 
separately. However, the whole protein of cells compared among half, two and four hours.The 
labelled protein can be stored at –20°C more than one week for reaction later; The results 
demonstrates the same between labeling time of half hour and two hours. However, the whole 
protein of cells compared among half, two and four hours. The results demonstrates better for 
longer time labeling. The labelled protein can be stored at –20°C more than one week later for 
reaction. The result demonstrated that stored protein reaction is almost the same as before. 
From the point it can be indicated the labelling relationship between fluorenscence and protein 
and deduced the labeling time difference between one kind of protein and the whole protein,   
 
To compare stop reagent using and without using stopping reagent. Stopping reagents 
separately were incubated in SDS-PAGE and microscope-slide-size array for 5 min and 15 min. 
The result showed that hydroxylamin make dye disappeared under the observation of SDS-
PAGE. For stopping time between 5min and 15 min, the result demonstrated that the long time 
stopping reaction signaling (15 min) is weaker than the short time stopping reaction (5 min); 
Without using stop reagent, the result demonstrates the same as 5 min stopping and has not 
appeared a crosstalking reaction (from literature, stopping reagent hydroxylamin easily makes 
dye disconnected from protein). From this point it can be indicated that stopping reagent 
hydroxylamin is not nessesary and even has bad effect on reaction. 
 
To compare protein purification with different methods in order to delete free dye: G25, G50, 
microcon10, 30 and 50 were used for protein purification checked by protein concentration 
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measure (CCB). The result showed that G25 and G50 make protein dilution, and only 
microcon10 is the best because of no protein leaking out;    
 
To compare results between deletion and undeletion of free mono-reactive dye Cy3 and Cy5-
labelled antibodies, mono-reactive dye Cy3 and Cy5-labelled mixed antibodies were separately 
incubated and washed completely with each step. The result demonstrates the same as before 
mixture reaction and indicate no crosstalking reaction between  mono-reactive dye Cy3 and 
Cy5-labelled antibodies. Only Cy5 free mono-reactive dye was incubated. only Cy5 free dye 
was incubated. The result demonstrates nothing. Therefore, free dye cannot affect the result. 
From this point it can be verified that microcon10 is best for protein purification and free dye has 
not effect on the result;  
 
To compare blocking time. Blocking time half to one hour under PBS-0.5%Tween-BSA was 
used; Blocking slide were stored at –20°C several days afterwards to use for reaction. The 
result demonstrates the same as before; Some negative-result slide can be repeated to be used. 
From the point it can be deduced that this technology has very high robotness;  
 
To compare reaction volume and time. 7µl, 12-15µl and 20 µl of incubation volume under 
different reaction time 1, 2 and 3 hours were used to react at room temperature and 4°C 
overnight separately. 7µl of reaction volume makes one spotting line dropping for 18*18cm 
cover. 12-15µl of reaction volume is very optimal for 18*18cm cover. 20 µl of reaction volume 
makes cover moving and reaction liquid out for 18*18cm cover; Reaction time used 1, 2 and 3 
hours at room temperature and 4°C overnight separately. The results demonstrate the same. 
From the point it can be deduced that the reaction volume is vey critical for microscope-slide-
size array; 
 
To compare washing volume and time. Big volume (30 ml) three times was washed at room 
temperature or in the dark overnight or shake up and down by hand with vortex several times, or 
at 4°C overnight. Washing at room temperature in the dark overnight makes some spots moving; 
Washing steps can shake up and down by hand and also vortex several times, the result is the 
same as the big washing volume three times; Washing at 4°C overnight, the result is also good. 
From the point it can be deduced that washing for microscope-slide-size array can be used 
different methods. 
 
Microarray is the best example for scientific research from big to small principle. Antibody arrays 
builded into the ArrayTube™ platform can be used to set up a relatively low cost system to 
analyze changes in phosphorylation of cellular proteins. With the ArrayTube™ set up it 
becomes possible to routinely analyze the phosphorylation of several proteins in parallel in a 
single experiment. And also, compared with western blotting, the change in Smad1, erk, akt, 
STAT3 and tyrosine phosphorylation were correlated well with ArrayTube results obtained in 
BMP2 treatment of the human leukemia cell line U937.  
 
This study has developed parameters, thresholds, and testing conditions of a novel silver 
staining system for quantitative detection of phosphorylation and localization on chip by labelling 
biotinylation of cellular proteins. Silver staining technology of antibody microarrays allow for 
high-throughput identification of protein phosphorylation. This method is sensitive, specific, 
reproducible, fast and cheap, presenting obvious advantages and may find wider uses in high-
throughput protein screenings in details as follows:  
 
Nano-gold-particle mediated silver staining technology of antibody microarray overcomes and 
avoids the error derived from two fluorescent Cy3 and Cy5 dyes occupying and competing for 
the same antibody at the same time;  
 
Quantification is possible with an on-line measurement of the silver precipitation step;  
 
1: 5 dilution of antibody not enough to use in array for analysis because of less sensitive, most 
signalling very weak and only little high, more importantly, which little high signaling compared 
with that of original antibodies not significant. From this point it can be verified silver staining of 
arraytube technology specific;  
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Every sample for repeating experiments, the result of pictures and evaluations are the same. 
From this point it can be indicated the technology reproducible; Silver staining of arraytube need 
the lower volume and the less amount of proteins and antibodies and also shorter time for 
reaction. From this point it can be reflected the technology sensitive, fast and cheap;  
 
The silver staining by labelling biotinylation to direct reaction and overcoming secondary 
antibody may bring unspecific reaction. From this point it can be indicated the technology 
specific; All the results in three cell lines are in consistence with cell numbers, FACS, western 
blotting, IP, Cy3 and Cy5 staining and references. From this point it can be demonstrated the 
technology accurate;  
 
p38 has the similar cytoplasmic & nuclear change pattern with phospho-p38 in three cell lines. 
From this point it can be shown the technology verifing the consistence between protein and 
phosphorylation;  
 
Ponceau S staining was used in comparison with antibody microarray showing the similar 
change patterns. From this point it can be known antibody microarray reflecting the global 
situation;  
 
Values of standard deviation in three cell lines all are small. From this point it can be reflected 
Arraytube technology accurate;  
 
The similar cytoplasmic & nuclear change patterns ( such as increasing or decreasing) 
compared with control often appear in the same signalling in three cell lines (such as pp70S6 
and p-Akt appear the same cytoplasmic & nuclear change pattern which all belong to PI3K 
signalling), the different patterns often appear in the different signallings in three cell lines such 
as between smad family and PI3K signalling. From this point it can be verified the silver staining 
of Arraytube technology and median normalization specific and accurate;  
 
Some reverse results obtained between nucleus and cytoplasm of experiment and control under 
different functions. From this point it can be known the technology reflect not only experimental 
features and functions but also control situation how to different from experiment;  
 
Here, I need to emphasize that every antibody has very lower signalling in three cell lines. From 
this point it can be verified silver staining of arraytube no or little unspecific reaction. 
 
It is very surprising that we obtained good results with the three dimensional epoxy activated 
surface available for the ArrayTube™ platform. Although previously much higher antibody 
activity and finally signal can be obtained when antibodies are spotted on biopolymer gel 
surfaces like agarose (Afanassiev et al., 2000) or immobilized nitrocellulose, the optimized 
combination of 3D surface and antibody preparation used here is of sufficient quality for highly 
sensitive detection of proteins and protein modifications.  
 
 
4.2 BMP2 signalling in U937 cells  
  
In the BMP2 signalling, besides most researches in the relationship of smad family as all known, 
many studies on BMP2 signalling with p21 relationship such as Xing et al. (2002) also confirmed 
that BMP2 mRNA has been shown to be expressed in the mammary gland and recently BMP2 
has been shown to inhibit MCF-7 proliferation as well as induce the expression of p21, and 
Ghosh-Choudhury N et al.(2000) indicated bone morphogenetic protein-2 induces cyclin kinase 
inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 
human breast cancer cells. BMP2 caused cell cycle arrest in the G1 phase which was 
associated with accumulation of p21CIP1/WAF1 and p27KIP1, and the subsequent apoptosis of 
myeloma cells (Kawamura, et al. 2002). 
 
Serveral papers about the relationship of BMP2 signalling with MAPK family as follows: Xing et 
al.(2002) demonstrates that ERK is involved in BMP2-induced osteoblastic differentiation in 
mesenchymal progenitor cells and ERK protein level is uphospho-regulated under BMP2 
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inducement. Ishisaki, A, et al (1999) suggested that BMP2 activate not only the Smad signalling 
but also the Ras/MAPK/Ap-1 pathway. These two signalling activations converge at the Ap-1 
level with Smad proteins regulating Ap-1 activity. Members of the Ap-1 and MAPK family are 
important mediators in BMP2 regulation of gene expression in osteoblasts. The net effect of 
BMP2 on gene expression depends on the intricate balance of these two signal transduction 
pathways. BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway 
that is negatively regulated by Smad6(Kimura, et al 2000). 
 
Recent studies have shown bone morphogenetic protein-2 induces apoptosis in human 
myeloma cells with modulation of STAT3 and BMP2-induced apoptosis in the mouse 
hybridomas, showed that BMP2 induced down-regulation of Bcl-X (L) through the inactivation of 
STAT3, resulting in the induction of apoptosis in myeloma(Kawamura, 2002). About the 
relationship of BMP2 signalling with PI3K family recently (Waite, et al. 2003) verified that BMP2 
exposure results in decreased PTEN protein degradation and increased PTEN levels.  
 
The signalling pathways by which BMP2 induces apoptosis has not been fully elucidated. This 
experiment first verified a BMP2 induction of apoptosis in U937 cells by observing cell number 
and FACS, obtaining the optimal concentration and incubation time about BMP2 that is 2000 
ng/ml BMP2 treatment for 3 days. The aim is to set up the BMP2 signalling network by the 
activation and inhibition of phosphoralytion with localization and function of serveral important 
signalling molecules in U937 cells by antibody microarray. 
  
 
4.2.1 BMP2 activates Akt, ERK and JNK pathway by increase of cytoplasmic 
phosphorylation in U937 cells 
 
Phospho-Akt displayed an increase of cytoplasmic phosphorylation and decrease of nucleus in 
BMP2 treated U937cells. Total protein (sum of cytoplasm and nucleus) level of phospho-Akt is 
higher in BMP2 treated U937 cells than in control cells, whereas the cytoplasmic activity of akt 
is higher in BMP2 treated U937 cells than in control cells and nuclear activity is lower in BMP2 
treated U937 cells than in control cells (Figure 3.18). This finding also was verified by other 
researchers. Lorenzini, et al. (2002) demonstrated that in senescent cells no Akt is able to 
phosphorylate efficiently their nuclear targets. The nuclear akt induced proliferation which 
demonstrated by the following paper. An active phosphatidylinositol 3-kinase (PI3K) has been 
shown in nucleus of different cell types. These findings strongly suggest that the intranuclear 
translocation of Akt/PKB is an important step in signalling pathways that mediate cell 
proliferation (Borgatti, et al. 2000). Akt controls cell growth through ist effects on the mTOR and 
p70S6 (in the cytoplasm) kinase pathways, as well as the cell cycle and cell proliferation 
through its direct action on the CDK inhibitors, p21 and p27 (in the nucleus), and indirectly by 
affecting the levels of cyclin D1 and p53. Akt is also major mediator of cell survival by directly 
inhibiting different pro-apoptotic signals such as Bad in the cytoplasm and the Forkhead family 
of transcription factors in the nucleus, or indirectly by modulating two central regulators of cell 
death such as p53 anf NF-kB. 
 
Phospho-JNK and phospho-ERK displayed increase in cytoplasm and unchanged in nucleus of 
BMP2 treated U937 cells, when compared with control U937 cells. Total protein (sum of 
cytoplasm and nucleus) levels of phospho-ERK and phospho-JNK are higher in BMP2 treated 
U937 cells than in control cells, whereas the cytoplasmic activities of ERK and JNK are higher 
and nuclear activities of ERK and JNK un-changed in BMP2 treated U937 cells than in control 
cells (Figure 3. 13-14). From this result it can be deduced that the BMP2 signalling pathway may 
be involved in the control of apoptosis most likely through mechanisms involving cytoplasmic 
activation of ERK/JNK/MAPK pathway in U937 cells.  
 
Phospho-ERK cytoplasmic localization related to apoptosis such as ERK activation plays an 
active role in mediating cisplatin-induced apoptosis of HeLa cells and functions upstream of 
caspase activation to initiate the apoptotic signal(Wang, et al. 2000).The nuclear localization for 
phospho-ERK related to proliferation as follows about Tarnawski, et al. (1998) in vitro models 
nuclear translocation of Erk-1 and -2 triggers cell proliferation. Some scholars also verified ERK 
about suppression of growth in cytoplasm such as Blockade of the mitogen-activated protein 
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(MAP) kinase pathway suppresses growth of colon cancer in vivo, demonstrating a direct link 
between the extracellular signal-regulated kinase ERK2 and the growth-promoting cell adhesion 
molecule, integrin alphavbeta6, in colon cancer cells. Down-regulation of beta6 integrin subunit 
expression inhibits tumour growth in vivo and MAP kinase activity in response to serum 
stimulation. In alphavbeta6-expressing cells ERK2 is bound only to the beta6 subunit. The 
increase in cytosolic MAP kinase activity upon epidermal growth factor stimulation is all 
accounted for by beta6-bound ERK. Deletion of the ERK2 binding site on the beta6 cytoplasmic 
domain inhibits tumour growth and leads to an association between ERK and the beta5 subunit. 
The physical interaction between integrin alphavbeta6 and ERK2 defines a novel paradigm of 
integrin-mediated signalling and provides a therapeutic target for cancer treatment (Ahmed, et 
al.2002). About ERK and apoptosis researches such as: ERK activation mediates cell cycle 
arrest and apoptosis after DNA damage independently of p53 (Tang, et al. 2002). Others also 
verified ERK apoptosis(Bondar, et al. 2002;Krystal, et al. 2002;Howells, et al.2002;Kim, et al. 
2003;Fujisaki, et al. 2002;Wrede, et al. 2002;Itoh, et al. 2002;Wan, et al. 2002;Chinni, et al. 
2002).  
 
JNK cytoplasmic localization functions as inhibitor of proliferation from Dickens, et al. (1997) 
verifying that a murine cytoplasmic protein that binds specifically to JNK [the JNK interacting 
protein-1 (JIP-1)] and caused cytoplasmic retention of JNK and inhibition of JNK-regulated gene 
expression. In addition, JIP-1 suppressed the effects of the JNK signalling pathway on cellular 
proliferation. Many papers studied about JNK on apoptosis such as Ohtsuka, et 
al.(2003 ;Chauhan, et al. 2003;Skutek, et al. 2003;Schroeter, et al. 2003;Tyagi, et al. 
2003;Smith, et al. 2003;Lei, et al. 2003 ;Xu, et al.2003;Lin, et al. 2003;Kang, et al. 2003;Saeki, 
et al. 2002).  
 
 
4.2.2 BMP2 activates Smad1 and Smad2/3 network, p38 network and c-Myc, Tyrosine 
network by increase of nuclear phosphorylation in U937 cells 
 
4.2.2.1 Smad1 and Smad2/3 network 
Phospho-Smad1 and phospho-Smad2/3 displayed decrease in cytoplasm and increase in 
nucleus of BMP2 treated U937 cells, Total protein (sum of cytoplasm and nucleus) levels of 
phospho-Smad1 and phospho-Smad2/3 were not altered in BMP2 treated cells compared with 
in control U937 cells, whereas the nuclear activities of Smad1 and Smad2/3 are higher in BMP2 
treated U937 cells than in control cells and cytoplasmic activities of Smad1and Smad2/3 are 
lower in BMP2 treated U937 cells than in control cells (Figure3. 13-14). This data indicated that 
the smad netwwork induced by BMP2 regulates cell cycle progression of U937 human leukemia 
cells maybe through the the nuclear translocation of phospho-Smad1 and phospho-Smad2/3.  
 
Although little papers about function of Smad1 with localization, Smad1 is multifuctional 
molecule from Sakae, Nishi et al. (1999) elucidated that Smad1 was highly expressed in 
proliferating chondrocytes and in those chondrocytes that are undergoing maturation. Smad2 
was strongly expressed in proliferating chondrocytes, whereas Smad3 was strongly observed in 
maturing chondrocytes(Sakou, Onishi et al. 1999). Smad3 related to senescence and tumor 
suppression that is the inhibition of proliferation from Chen, et al. (2000)  studies suggest that 
signalling from the cell surface to nucleus through Smad3 is a required component of the activin 
A-induced cell death process in liver cells. Vijayachandra, et al.(2003) indicated that Smad3 
regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis 
model.  
 
The observations here in my work maybe reflected smad3 not smad2 phosphorylation 
increasing in BMP2 treated U937 cells. Because Smad3 but not Smad2 or Smad4 induced 
senescence. From Chen et al. (2000) paper can be known that the v-ras (Ha)-transduced 
Smad3 null keratinocytes underwent rapid conversion from benign papilloma to malignant 
carcinoma when transplanted to a graft site on nude mice, whereas wild-type keratinocytes 
predominantly formed papillomas. These results link Smad3-mediated regulation of growth 
control genes to senescence in vitro and tumor suppression in vivo.   
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From this experiment displayed higher Smad1 and Smad3 phosphorylation co-expression of 
nucleus. It can be concluded that the BMP2 signalling pathway may be involved in the control of 
apoptosis most likely through mechanism involving coorperation of Smad1 and Smad3 by  
nuclear activation in Smad network in U937 cells. 
 
 
4.2.2.2 p38 network and c-Myc  
Phospho-p38 displayed increase in cytoplasm and nucleus of BMP2 treated U937 cells, when 
compared with control U937 cells. From this result it can be deduced that the BMP2 signalling 
pathway may be involved in the control of apoptosis most likely through mechanisms involving 
cytoplasmic and nuclear activation of p38 network in U937 cells (Figure 3.13-14).  
 
c-Myc displayed slightly decrease in cytoplasm and slightly increase in nucleus of BMP2 treated 
U937 cells. Total protein (sum of cytoplasm and nucleus) level of c-Myc was not altered 
between BMP2 treated U937 cells and control cells (Figure 3.13-14). Unfortunately, phospho-c-
Myc has not been done for comparision. 
 
This thesis demonstrates higher phospho-p38 and c-Myc co-expression in nucleus. From this 
result it can be deduced the BMP2 signalling pathway may be involved in the control of 
apoptosis most likely through mechanisms involving coorperation of c-Myc and p-p38 by nuclear 
activation in U937 cells. Nuclear localization of p38 kinase as apoptosis  and also related to c-
Myc, such as Deschesnes, et al. (2001) verifing a strong correlation between activation of p38 
and induction of c-Myc-dependent apoptosis in Rat-1 cells.  
 
 
4.2.2.3 Tyrosine network 
Phospho-Tyrosine displayed increase in nucleus and cytoplasm of BMP2 treated U937 cells. 
From this result it can be deduced that the BMP2 signalling pathway may be involved in the 
control of apoptosis most likely through mechanisms involving nuclear and cytoplasmic 
activation of tyrosine network in U937 cells (Figure 3. 13-14). 
 
Phospho-Tyrosine promote tumor cell growth, proliferation and angiogenesis(Shaheen, Davis et 
al. 1999; Wiener, Nakano et al. 1999; Harashima, Tanaka et al. 2001; Turetschek, Preda et al. 
2002). However, recently phospho-Tyrosine also has been shown to play an important role in 
the inhibition of a variety of human cancer(Meyer, Xu et al. 2003). Phospho-Tyrosine induced 
apoptosis such as Meyer, et al(2003) studied on Rak is a 54 kDa protein tyrosine kinase 
originally isolated from breast cancer cells and expressed in epithelial cells. It resembles the 
protooncogene Src structurally but lacks an amino-terminal myristylation site and localizes to 
the nuclear and peri nuclear regions of the cell. expression of Rak in 2 different breast cancer 
cell lines inhibits growth and causes G (1) arrest of the cell cycle. Others indicated phospho-
Tyrosine expression inductoin of apoptosis such as (Boudny, et al. 2003; Tomomura, et al. 2003; 
Luciano, et al. 2003; Belka, et al. 2003; Spiekermann, et al.2003). 
 
 
4.2.3 BMP2 inhibits p70S6 signalling by increase of cytoplasmic phosphorylation and 
decrease of nucleus in U937 cells 
 
BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels in 
PI3K signalling(Waite, et al. 2003). However, the molecular mechanisms of activation and 
inhibition of signal transduction from BMP2 to other mediators of PI3K signalling are not 
confirmed. Both p70S6 kinase (p70S6K) and Akt are kinases downstream of 
phosphatidylinositol 3 kinase (PI3K) (Miyakawa, et al.2003). 
 
Phospho-p70S6 displayed an increase of cytoplasmic phosphorylation and decrease of nucleus 
in BMP2 treated U937cells. Total protein (sum of cytoplasm and nucleus) level of phospho-
p70S6 was not altered in control and BMP2 treated cells (Figure 3. 13-14). The ribosomal 
protein S6 kinase (S6K) (one subfamily of ribosomal S6 kinases) belongs to the AGC family of 
Ser/Thr kinases and is known to be involved in the regulation of protein synthesis and the G 
(1)/S transition of the cell cycle (Valovka, et al. 2003).Fleckenstein, et al. (2003) shows in factor-
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dependent hematopoietic M-07e cells that p70S6K is localized both in the cytosol and, after 
cytokine stimulation, also in nucleus. Nuclear phospho-p70S6 localizaiton as G1 for growth 
because of Edelmann, et al (1996 ) using synchronized Swiss mouse 3T3 fibroblasts that p70 
S6 kinase (p70S6k) and mitogen-activated protein kinases (p42MAPK/p44MAPK) are not only 
activated at the G0/G1 boundary, but also in cells progressing from M into G1. p70S6k activity 
increases 20-fold in G1 cells released from G0. Throughout G1, S, and G2 it decreases 
constantly, so that during M phase low kinase activity is measured. The kinase is reactivated 
10-fold when cells released from a nocodazole-induced metaphase block enter G1 of the next 
cell cycle. p70S6k activity is dependent on permanent signalling from growth factors at all 
stages of the cell cycle. Immunofluorescence studies showed that p70S6k and become 
concentrated in localized spots in nucleus at certain stages in the cell cycle. Cell cycle-
dependent changes in p70S6k activity are associated with alterations in the phosphorylation 
state of the protein.  
 
From this result, it can be deduced that spatial control of cell cycle is through the retention of p-
p70S6 in the cytoplasm, thereby preventing them from physical contact with their substrates or 
partners. The BMP2 signalling pathway is involved in the control of apoptosis most likely 
through mechanisms involving the nuclear inhibiton by nuclear export in p70S6/Akt PI3K 
singaling in U937 cells.  
 
In my study shown, the same positive signaling pathway proteins are often observed the same 
cytoplasmic and nuclear change pattern of phosphorylated proteins such as nucleus increasing, 
or cytoplasm increasing, or nucleus & cytoplasm increasing or decreasing, etc, whereas total 
phosphorylated proteins can appear changed or un-changed such as one increasing, the other 
unchanged, function of these proteins appears the same. For activation and inhibition of specific 
functions of signaling pathways, it is not sufficient to know overall changes in phosphorylation 
patterns. Cellular distribution, e.g. cytoplasm or nucleus, is very significant and can show 
differential regulation and function even when the total amount of phosphorylated protein for one 
signaling protein is not changed.  
 
 
4.2.4 Possible intracellular relationship 
 
These findings clearly show that the activation of the p38 MAPK pathway and Smad network 
are involved in BMP2 signalling and led us to propose a co-operative model whereby BMP2-
induced activation stimulates not only a Smad pathway that targets Smad1 and Smad3 for an 
increase of the nuclear translocation but also a parallel p38 MAPK pathway and enhanced 
transactivation. The present study shows association and interactions of p38 MAPK with smad 
in nucleus which function as apoptosis seen in many papers (Watanabe, de Caestecker et al. 
2001; Lee, Hong et al. 2002; Takekawa, Tatebayashi et al. 2002; Fu, O'Connor et al. 2003; 
Hayes, Huang et al. 2003; Jono, Xu et al. 2003; Ohshima and Shimotohno 2003; Ungefroren, 
Lenschow et al. 2003; Yoo, Ghiassi et al. 2003). Such as: Transforming growth factor-beta 
(TGF-beta)-dependent apoptosis used GADD45b as an effector of TGF-beta-induced apoptosis 
that the proximal Gadd45b promoter is activated by TGF-beta through the action of Smad2, 
Smad3, and Smad4.that ectopic expression of GADD45b in AML12 murine hepatocytes is 
sufficient to activate p38 and to trigger apoptotic cell death, whereas antisense inhibition of 
Gadd45b expression blocks TGF-beta-dependent p38 activation and apoptosis (Hata, 
Nishimura et al. 2003) These results suggest that both Smad and p38 kinase signalling are 
concomitantly activated and responsible for BMP2-induced adipocytic differentiation by inducing 
and up-regulating phospho-pARgamma, respectively. Thus, BMP2 controls adipocytic 
differentiation by using two distinct signalling pathways that play differential roles in this process 
in C3H10T1/2 cells. 
 
This thesis also show that the BMP2 signalling pathway most likely through mechanisms 
involving nuclear inhibition of p70S6 signalling in U937 cells which reverse to nuclear activiation 
of Smad1 and Smad2/3 network by nuclear translocation. These results suggest that both Smad 
and p70S6 signalling are concomitantly activated and responsible for BMP2-induced apoptosis 
by induction and up-regulation of nuclear and cytoplasmic activities, respectively. Thus, BMP2 
                                                                                                                    
                                                                                                                                           57 
controls apoptosis by using two distinct signalling pathways that play differential roles in this 
process in U937 cells. 
 
In conclude, BMP2 would be useful as a novel therapeutic agent in the treatment of multiple 
myeloma both by means of its antitumor effect of inducing apoptotis and through its original 
bone-inducing activity, because bone lesions are frequently seen in myeloma patients 




4.3 BMP2 Signalling in MCF-7 cells 
 
Most experiments only verify the alteration of Total protein (sum of cytoplasm and nucleus) 
expression.  However, for many proteins, although Total protein (sum of cytoplasm and nucleus) 
expression apppears not or little changed, modulation of phosphorylation and localization inside 
directly decide on the difference of functions and signallings.  
 
In this study, because the lower concentration (100 ng/ml) of BMP2 treatment and short time 
(4h) of incubation was selected in MCF-7 cells. Under this condition, most total selective 
phosphorylated proteins appear not or little changed. However, modulation of phosphorylation 
and localization inside are big difference. This technology is the best method for analyzing 
multifunctional proteins and complicated signalling networks. Dr. Clement et al (2000) already 
tested the similar condition of BMP2 treatment in MCF-7 cells,  indicating BMP2 functions under 
this situation not relating to proliferation and apoptosis. 
 
 
4.3.1 BMP2 BMP2 activaites p70S6 and ERK signaling, Tyrosine and STAT3 
network by increase of cytoplasmic phosphorylation in MCF-7 cells  
 
4.3.1.1  p70S6 and ERK signaling 
p70S6 kinase (p70S6K) belong to multifunctional kinases downstream of phosphatidylinositol 3 
kinase (PI3K), such as  the 70-kDa ribosomal protein S6 kinase (p70S6K) is itself a dual 
pathway kinase, signalling cell survival as well as growth through differential substrates which 
include mitochondrial BAD and the ribosomal subunit S6, respectively (Harada, Andersen et al. 
2001). 
 
Phospho-p70S6 and ERK displayed increase in cytoplasm in BMP2 treated MCF-7 cells (Figure 
3. 22-23).  
 
ERK is involved in BMP2-induced osteoblastic differentiation in mesenchymal progenitor cells 
and ERK protein level is up-regulated under BMP2 inducement (Xing, et al. 2002). However, 
this experiment did not verify phospho-ERK localization. 
 
 
4.3.1.2 Tyrosine and STAT3 network 
Phospho-Tyrosine and phospho-STAT3 displayed little increase in cytoplasm and un-changed 
in nucleus of BMP2 treated MCF-7 cells. Total protein (sum of cytoplasm and nucleus) levels of 
p-Tyrosine and p-STAT3 have the little increase in BMP2 treated MCF-7 cells compared with 
control cells, whereas cytoplasmic activities of p-Tyrosine and p-STAT3 are higher in BMP2 
treated MCF-7 cells than in control cells, the nuclear activities of phospho-p38, p-Tyrosine and 
p-STAT3 are lower in BMP2 treated MCF-7 cells than in control cells (Figure 3. 22-23). From this 
result it can ne concluded that BMP2 signalling pathway may be involved in the control of the 
cell cycle progression (differentiation) most likely through mechanisms involving cytoplasmic 
activation of tyrosine and STAT3 networks in MCF-7 cells.  
 
My result also shows that phospho-STAT3 and phospho-Tyrosine regulated by BMP2 signalling 
in MCF-7 cells have the similar change patterns. Other paper also verified that Activation of 
STAT3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell 
carcinoma cells (Song, et al. 2003). STAT3 functions as inhibition of proliferation such as 
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Yamanaka, et al (1996) suggesting that STAT3 plays an essential role in the signals for growth 
arrest and macrophage differentiation through its receptor in a murine myeloid leukaemic cell 
line, M1. 
 
Based on BMP2 treated U937 cells displaying higher phospho-Tyrosine and phospho-STAT3 
co-expression in cytoplasm, the BMP2 signalling pathway may be involved in the control of cell 
cylce progress most likely through mechanisms involving the coorperation of Tyrosine-STAT 
network by cytoplasmic activation in MCF-7 cells. 
 
 
4.3.2 BMP2 inhibits p38, JNK and smad signalling by increase of cytoplasmic 
phosphorylation and decrease of nucleus in MCF-7 cells 
 
 
4.3.2.1  p38 and JNK 
 The c-Jun amino-terminal kinase (JNK) and p38 are a member of mitogen-activated protein 
(MAP) kinases that are implicated in the control of cell growth, proliferation, differentiaton and 
apoptosis. 
 
Phospho-p38 and phospho-JNK displayed increase in cytoplasm and little decrease in nucleus 
of BMP2 treated MCF-7 cells. Total protein (sum of cytoplasm and nucleus) levels of phospho-
p38 and phospho-JNK are almost the same in BMP2 treated MCF-7 cells as in control cells 
(Figure 3. 22-23). From this result it can be deduced that spatial control of cell cycle is through 
the retention of p-JNK and p-p38 in the cytoplasm, thereby preventing them from physical 
contact with their substrates or partners. BMP2 signalling pathway may be involved in the 
control of the cell cycle progression (differentiation) most likely through mechanisms involving 
inhibition of phospho-p38, phospho-ERK and phospho-JNK in MCF-7 cells. 
 
p38 kinase cytoplasmic localization functions as differentiation. Berenbaum, F et al (2003) 
verified Concomitant recruitment of ERK1/2 and p38 MAPK signalling pathway is required for 
activation of cytoplasmic phospholipase A2 via ATP in articular chondrocytes. Klekotka (2001) 
published that alpha 2 integrin subunit cytoplasmic domain-dependent cellular migration 
requires p38 MAPK. Khurana et al (2003) also verified p38 MAPK interacts with actin and 
modulates filament assembly during skeletal muscle differentiation. 
 
JNK cytoplasmic localization functions as inhibitor of proliferation from Dickens, et al. (1997) 
verifying that a murine cytoplasmic protein that binds specifically to JNK [the JNK interacting 
protein-1 (JIP-1)] and caused cytoplasmic retention of JNK and inhibition of JNK-regulated gene 
expression. JIP-1 suppressed the effects of the JNK signalling pathway on cellular proliferation.  
 
 
4.3.2.2  Smad1/Smad2/3 network   
Phospho-Smad1, 2/3 displayed little increase in cytoplasm and little decrease in nucleus of 
BMP2 treated MCF-7 cells, Total protein (sum of cytoplasm and nucleus) levels of phospho-
Smad2/3 were not altered in BMP2 treated MCF-7 cells and control cells (Figure 3. 22-23). 
From this result it can be deduced that the BMP2 signalling pathway may be involved in the 
control of the cell cycle progression (differentiation) most likely involving nuclear inhibition 
through cytoplasmic relocalization of phospho-Smad2/3 in MCF-7 cells. 
 
The observations here in my work maybe most smad2 not smad3 in cytoplasm of BMP2 treated 
MCF-7 cells. Because Smad2 was strongly expressed in proliferating chondrocytes, whereas 
Smad3 was strongly observed in maturing chondrocytes(Sakou, et al. 1999). 
 
 
4.3.3 BMP2 activates c-Myc signalling by increase of nuclear phosphorylation in 
MCF-7 cells  
c-Myc displayed increase in nucleus and decrease in cytoplasm of BMP2 treated MCF-7 cells. 
Total protein (sum of cytoplasm and nucleus) level of c-Myc was not altered between BMP2 
treated MCF-7 cells and control cells. From this result it can be deduced that the BMP2 
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signalling pathway may be involved in the control of the cell cycle progression (differentiation) 
most likely through mechanisms maybe involving the some activation of c-Myc in MCF-7 cells. 
Unfortunately, phospho-c-Myc has not been done for comparision (Figure 3. 22-23). 
 
Usually in the differentiation, total c-Myc not changed, however, little information about the 
alteration of localization in the differentiaon. Here, I showed the nuclear translocation. 
 
 
4.3.4 Possible intracellular relationship 
 
From all the above it can be concluded that increase co-expression in cytoplasmic 
phosphorylation of ERK, p70S6, STAT3 and Tyrosine are maybe involved in the cooperative 
signallings. Subsequent induction of differentiation and led us to propose a co-operative model, 
which is consistent with other study such as: Lehman et al.(2003) indicated that a kinase from 
the MEK/MAPK pathway also plays a role in p70S6K activation by GM-CSF in a hematopoietic 
cell, the neutrophil. Relationships of STAT3 and ERK co-expressed in G1 as follows: Wierenga, 
et al. (2003) indicated that the EPO-induced STAT3 serine 727 phosphorylation is mediated by 
a pathway involving MEK, ERK, and MSK1 in the EPO-dependent erythroid cell line ASE2. 
 
 
 4.4 Effects of STI571 on K562 Cells 
 
Yu, Krystal et al. (2002) indicated the exposure of Bcr/Abl+ cells to STI571 has not in general 
been associated with down-regulation of the Bcr/Abl protein, they reported that Exposure of 
K562 cells to concentrations of STI571 that minimally induced apoptosis (0.2 µM) resulted in 
early suppression (i.e., at 6 h) of p42/44 MAPK phosphorylation followed at later intervals (lager 
than or =24 h) by a marked increase in p42/44 MAPK phosphorylation/activation. In order to 
overcome problems of STI571 drug treatment, it is postulated that simultaneous interruption of 
additional targets in signaltransduction pathways may represent a more effectiive antileukemic 
therapy strategy. However, modulation of phosphorylation with localization and function from 
STI571 treatment in K562 cells are not elucidated.  
 
Therefore, in this study, by using antibody microarray and separation of cytoplasm and the 
nuclear protein, emphasis of differential phosphorylation and localization to multifunctional 
positive and negative mediators of cellular regulation was given such as phospho-p70S6 and 
phospho-Akt (PI3K signalling), phospho-p38 (p38 network), phospho-ERK and phospho-JNK 
(MAPK pathway), phospho-Tyrosine (tyrosine-kinase network), phospho-STAT3 (Jak/STAT 
network), and phospho-Smad1,2,3 (smad network) in K562 cells. 
 
 
4.4.1 STI571 inhibits Akt/p70S6 PI3K signalling by decrease of cytoplasmic and 
nuclear phosphorylation in K562 cells  
 
Phospho-Akt and phospho-p70S6 displayed decrease in cytoplasm and nucleus of STI571 
treated K562 cells (Figure 3.27-28). From this result it can be concluded that the STI571 
treatment may be involved in the control of growth and proliferation most likely through 
mechanisms involving nuclear and cytoplasmic inhibition of akt/p70S6 signalling in K562 cells. 
  
Akt controls cell growth through ist effects on the mTOR and p70S6 (in the cytoplasm) kinase 
pathways, as well as the cell cycle and cell proliferation through its direct action on the CDK 
inhibitors, p21 and p27 (in the nucleus), and indirectly by affecting the levels of cyclin D1 and 
p53. Akt is also major mediator of cell survival by directly inhibiting different pro-apoptotic 
signals such as Bad in the cytoplasm and the Forkhead family of transcription factors in the 
nucleus, or indirectly by modulating two central regulators of cell death such as p53 anf NF-kB. 
 
From this result, it can be deduced that STI571 reduced growth by the decrease of Akt/p70S6 
PI3K signalling in K562 cells.  
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4.4.2 STI571 activates p38 MAPK pathway, c-Myc, Tyrosine and Smad1/Smad2/3 
networks by increase of cytoplasmic and nuclear phosphorylation in K562 cells  
 
Phospho-p38, p38,c-Myc, phospho-Tyrosine, phospho-Smad1 and phospho-Smad2/3 displayed 
increase in cytoplasm and nucleus of STI571 treated K562 cells (Figure 3. 27-28). From this 
result it can be deduced that the STI571 treatment may be involved in the control of growth and 
proliferation most likely through mechanisms involving nuclear and cytoplasmic activation of 
p38, c-Myc, Tyrosine and Smad1/Smad2/3 networks in K562 cells.  
 
Smad1 was highly expressed in proliferating chondrocytes and in those chondrocytes that are 
undergoing maturation. Smad2 was strongly expressed in proliferating chondrocytes(Sakou, 
Onishi et al. 1999), whereas Smad3 was mainly observed in maturing chondrocytes. Therefore, 
the  observations here in my work maybe mostly smad2 not smad3 in nucleus for proliferation. 
About the relationship of p38 is related to proliferation such as high glucose mediated effects on 
endothelial cell proliferation occur via p38 MAP kinase(McGinn, Saad et al. 2003). 
  
 
4.4.3 STI571 activates pathway by increase of nuclear phosphorylation and 
decrease of cytoplasm in K562 cells  
 
Phospho-ERK displayed increase in nucleus and little decrease in cytoplasm of STI571 treated 
K562 cells. Total protein (sum of cytoplasm and nucleus) level of phospho-ERK is higher in 
STI571 treated K562 cells than in control cells, whereas the activity of ERK is higher in nucleus 
and lower in cytoplasm of STI571 treated K562 cells than in control cells (Figure 3. 27-28). From 
this result it can be known that the STI571 treatment may be involved in the control of growth 
and proliferation most likely through mechanisms involving the nuclear activation of ERK in 
K562 cells. 
 
This result is consistent with other finding that treatment of Bcr-Abl-expressing cells with STI571 
elicits a cytoprotective MAPK activation response(Yu, Krystal et al. 2002). However, ERK 
modulation of phosphorylation with localization and function from STI571 treatment in K562 
cells not clear. Phospho-ERK nuclear localization related to proliferation as follows about 




4.4.4 STI571 activates STAT3 network and JNK/MAPK pathway by increase of 
cytoplasmic phosphorylation in K562 cells  
 
Phospho-STAT3 and p-JNK displayed increase of cytoplasm and un-changed in nucleus of 
STI571 treated K562 cells. Total protein (sum of cytoplasm and nucleus) level of phospho-
STAT3 and phospho-JNK are higher in STI571 treated K562 cells than in control cells, whereas 
the activity of STAT3 and phospho-JNK are higher in cytoplasm and un-changed in nucleus of 
STI571 treated K562 cells than in control cells (Figure 3. 27-28). From this result it can be 
concluded that the STI571 treatment may be involved in the control of growth and proliferation 
most likely through mechanisms involving cytoplasmic activation of STAT3 and JNK network in 
K562 cells. 
  
STAT3 located in cytoplasm which functions as proliferation in STI-treated K562, because 
Poselova, Evdonin et al. (1998) studied the intracellular distribution of STAT1 and STAT3 
transcription factors in normal fibroblasts (REF) and in E1A + Ha-Ras transformed cells by 
means of indirect immunofluorescence. The obtained data evidence that in REF cells, in 
response to the growth factor addition, STAT1 and STAT3 proteins are redistributed from 
cytoplasmto nucleus. In transformants E1A + Ha-Ras, however, significantly different pictures 
can be seen: while STAT1 is found to be constitutively localized in the cell nucleus, STAT3 is 
predominantly revealed in the cytoplasm. The data obtained from fractionation of subcellular 
structures confirm in general the immunofluorescence results on the cytoplasmic localization of 
STAT3 protein in E1A + Ha-Ras transformants. Thus, transformation of REF cells with E1A + 
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Ha-Ras oncogenes causes a constitutive activation of STAT1 and STAT3 transcription factors, 
the proteins, however, being distributed in different cell compartments. 
 
 
4.4.5 Possible intracellular relationship 
 
Extracellular signal-regulated protein kinase (ERK)-dependent and ERK-independent pathways 
target STAT3 on serine-727. Here, my observations in this work that STI571 activates STAT3 
independently of -ERK and PI-3K signal transduction, which is consistent with other studies as 
follows: Activation of ERKs or PI-3K are not required for insulin induced STAT3 phosphorylation 
or transactivation by using utilising the specific MEK inhibitor PD098059 and the PI-3K inhibitor 
wortmannin, although previous studies have suggested a role for MAP kinases (ERKs) and PI-
3K in STAT activation(Coffer, van Puijenbroek et al. 1997). Van Puijenbroek et al. (1999) also 
indicated regulation of STAT3-mediated transactivation occurs independently of p21ras-ERK 
signalling.  
 
In this thesis, high levels of c-Myc and phospho-Tyrosine were detected in nucleus and 
cytoplasm, which is consistent with Minami, Nakagawa et al. (1995) studied on Syk protein 
tyrosine kinase (PTK) physically associated with IL-2 receptor by -induced proliferative signals 
in peripheral blood lymphocytes. cDNA expression studies the activation of Syk PTK results in 
the induction of the c-Myc gene, an event critical for the cell proliferation. Papers about the 
positive relationships between c-Myc and smad in proliferation as follows: Direct interaction of c-
Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15 
(Ink4B). Others also demonstrated the relationships (Chen, et al. 2002; Kowalik 2002; Yagi,  et 
al. 2002; Baldwin, et al. 2003). 
 
From the result, it can be deduced that the observed phosphorylation suppression of the nuclear 
Akt and p70S6 PI3K singaling in the presence of activated nuclear p38/ERK pathway, c-Myc, 
tyrosine and Smad1/ Smad2/3 networks resulted in reduced growth and increased proliferation 
in response to STI571 treatment in K562 cells, which is consistent with other study such as: 
Wang, B. et al. also (2002) indicated that a positive p38 mitogen-activated protein kinase 
pathway and a negative phosphoinositide 3-kinase-Akt pathway induced novel cytoplasmic 
proteins of nontypeable Haemophilus influenzae up-regulation of human MUC5AC mucin 
transcription.  
 
It also can be concluded that increase of nuclear phosphorylation of p38/ ERK MAPK pathway, 
(c-Myc), tyrosine, Smad1/ Smad2/3 networks and increase in cytoplasmic phosphorylation of 
STAT3 network and JNK MAPK pathway maybe involved in cooperative signalling.  Subsequent 




4.5 Models of Signalling Protein and Cellular Response 
 
This study could demonstrate with the newly developed antibody array, how BMP2 and STI571 
influence phosphorylation and localization of signalling proteins. The proteins analyzed included 
phospho-p70S6 and phospho-Akt (PI3K signalling), phospho-p38 (p38 network), phospho-ERK 
and phospho-JNK (MAPK pathway), phospho-Tyrosine (tyrosine-kinase network), phospho-
STAT3 (Jak/stat network), and phospho-Smad1,2,3 (smad network) in human cancer cell lines.  
 
These findings that the induction of apoptosis in U937 cells under 2000 ng/ml BMP2 treatment 
for 3 days by using FACS and cell numbers indicates that the BMP2 pathway is involved in the 
control of apoptosis in U937 cells through multiple mechanisms involving: 
 
(1) Total phospho-Tyrosine and phospho-p38 increased with cytoplasmic and nuclear 
phosphorylation increasing; (2) Total phospho-ERK and phospho-JNK increased with 
cytoplasmic phosphorylation increasing and nucleus unchanged; (3) Total phospho-Akt 
increased with cytoplasmic phosphorylation increasing and nuclear phosphorylation decreasing; 
(4) Total phospho-Smad1, phospho-Smad2/3 and c-Myc unchanged with nuclear 
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phosphorylation increasing and cytoplasmic phosphorylation decreasing;(5) Total phospho-
p70S6 unchanged with cytoplasmic phosphorylation increasing and nuclear phosphorylation 
decreasing. From this I deduce that the BMP2 signalling in response to high doses of BMP2 
work most likely through mechanisms involving nuclear activation and cytoplasmic inhibition by 
the nuclear translocation of phospho-Smad1, phospho-Smad2/3 and c-Myc and also the nuclear 
inhibition through the cytoplasmic relocalization of phospho-p70S6 in U937 cells. 
This study indicates that nuclear activation of Smad1/Smad2/3, c-Myc, p38 MAPK and tyrosine 
networks may be involved in cooperative signalling and subsequent induction of apoptosis. This 
led to propose a model whereby a BMP2-signal stimulates not only Smad and c-Myc networks, 
seen by targeting phospho-Smad1 and phospho-Smad2/3, c-Myc by nuclear translocation, but 
also a parallel activation of the p38 MAPK pathway and tyrosine network with enhancement to 
nucleus by increase of nuclear and cytoplasmic phosphorylation in BMP2 treated U937 cells. 
Cytoplasmic activation of ERK/JNK MAPK pathway and Akt signalling may be involved also in 
the cooperative signalling whereby the BMP2signal stimulates not only the ERK/JNK MAPK 
pathway increase in cytoplasm and unchange in nucleus of phospho-ERK and phospho-JNK, 
but also Akt signalling, seen in the enhance of cytoplasmic phosphorylation and decrease of 
nuclear phosphorylation of Akt in BMP2 treated U937 cells. From this result it can be deduced 
that negative regulation maybe reflect from a nuclear decrease and unchanged in Akt/p70S6 
PI3K and ERK/JNK MAPK activity and a parallel nuclear increase of p38 MAPK pathway, 
Smad1/Smad2/3, c-Myc, and Tyrosine activity result in a BMP2 induced cell death in U937 







Figure 4.1: BMP2-induced Apoptosis Model in U937 cells.  BMP2-induced apoptosis differently 
activates MAPK pathway by p-ERK and p-JNK cytoplasmic increase and p-p38 nuclear and cytoplasmic 
increase, activates Smad network by p-Smad1 and p-Smad2/3 nuclear increase, also activates tyrosine 
network by p-Tyr nuclear and cytoplasmic increase and activates p-Akt signaling by cytoplasmic increase. 
It inhibits p70S6 singaling by p-p70S6 nuclear export of nuclear decrease and cytoplasmic increase.   
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In BMP2 signalling of MCF-7 cells under 100 ng/ml BMP2 treatment for 4h, these findings show 
that the BMP2 signalling pathway may be involved in the control of the cell cycle progression 
(differentiation) most likely through multiple mechanisms, involving: 
 
Phospho-p38 and p38, p-JNK, p-Smad1, p-Smad2/3 displayed the increase in cytoplasm and 
the decrease in nucleus of BMP2 treated MCF7 cells. Total protein (sum of cytoplasm and 
nucleus) level of phospho-p38 and p38, p-JNK, p-Smad1, p-Smad2/3 were not significantly 
changed in BMP2 treated MCF-7 cells and control cells. c-Myc displayed the slight decrease in 
cytoplasm and the slight increase in nucleus of BMP2 treated MCF7 cells. Total protein (sum of 
cytoplasm and nucleus) level of c-Myc was not significantly altered between BMP2 treated 
MCF-7 cells and control cells. p-Tyrosine, p-STAT3, p-ERK and p-P70S6 displayed the increase 
in cytoplasm and unchanged in nucleus of BMP2 treated MCF7 cells. Total protein (sum of 
cytoplasm and nucleus) level of p-p38, p-Tyrosine, p-STAT3, p-ERK and p-P70S6 were 
increased in BMP2 treated cells. P-Akt displayed unchanged in cytoplasm and nucleus of BMP2 
treated MCF7 cells. 
 
From this it can be deduced that BMP2 signalling in response to lower dose and short time of 
BMP2 treatment most likely through mechanisms involving inhibition by the cytoplasmic 
relocalization of phospho-JNK, phospho-p38 and phospho-Smad2/3 and also nuclear inhibition 
by the degradation of phospho-Smad1 in BMP2 treated MCF-7 cells. This result indicated that 
cytoplasmic activation of ERK/ MAPK pathway, p70S6 signalling, STAT3, and tyrosine are 
maybe involved in the cooperative signalling and the subsequent induction of differentiation and 
led to propose a co-operative model whereby BMP2-induced cytoplasmic activation stimulates  
p70S6 signalling, STAT3 and tyrosine networks that target phospho-p70S6, phospho-STAT3 
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Figure 4.2: BMP2-induced Differentiation Model in MCF7 cells. Short time and lower concentration 
BMP2 treatment to MCF7 cells (100 ng/ml for 4h) inhibits MAPK pathway and Smad network by p-ERK/p-
JNK/p-p38, p-Smad1 and p-Smad2/3 nuclear decrease and cytoplasmic increase, and inhibit Akt signaling 
by  nuclear and cytoplasmic unchange.  It activates p70S6 singaling, STAT3 and tyrosine network and c-





In  0. 2 µM STI571 treatment of K562 cells for 24h, my findings that the STI571 treatment may 
be involved in the control of growth and proliferationmost likely through multiple mechanisms, 
involving: 
 
 (1) Total phospho-Akt and phospho-p70S6 decreased with cytoplasm and nucleus 
decreasing;(2) Total phospho-p38, p38, c-Myc, phospho-Tyrosine, phospho-Smad1 and 
phospho-Smad2/3 increased with cytoplasm and nucleus increasing; (3) Total phospho-STAT3 
and phospho-JNK increased with cytoplasm increasing and nucleus un-changed; (4) Total 
phospho-ERK increased with nucleus increasing and cytoplasm decreasing in STI571 treated 




This results indicated that nuclear and cytoplasmic activation of p38/ ERK MAPK pathway, (c-
Myc), Tyrosine, Smad1/ Smad2/3 networks and cytoplasmic activation of STAT3 network and 
JNK MAPK pathway are maybe involved in the cooperative signalling and the subsequent 
induction of proliferation and led to propose a co-operative model whereby STI-induced 
activation stimulates not only p38/ERK pathway, c-Myc, tyrosine and smad network that target 
phospho-p38, phospho-ERK, c-Myc, phospho-Tyrosine, phospho-Smad1 and phospho-
Smad2/3 for the increase of nuclear and cytoplasmic phosphorylation but also STAT3 network 
and JNK/MAPK pathway for increase of cytoplasmic phosphorylation in STI571 treated K562 
cells. From this experiment it can be deduced STI571 treatment induced the observed nuclear 
and cytoplasmic suppression of Akt / p70S6 PI3K signalling target phospho- Akt and phospho-
p70S6 by the decrease of nuclear and cytoplasmic phosphorylation in K562 cells. In this thesis it can 
be deduced the negative nuclear regulation relationship from the observed phosphorylation 
suppression in nucleus of Akt / p70S6 PI3K signalling in the presence of activated nuclear 
p38/ERK MAPK pathway, c-Myc, tyrosine and Smad1/Smad2/3 networks resulted in 







                                                                                                                    




Figure 4.3: STI-inhibited cell growth and induced proliferation Model in K562 cells. 0.2um STI 
treatment to K562 cells differently activates MAPK pathway by p-ERK nuclear increase, p-JNK cytoplasmic 
increase and p-p38 nuclear and cytoplasmic increase, and also activates tyrosine network and Smad 
network by p-Tyr, p-Smad1 and p-Smad2/3 nuclear and cytoplasmic increase, and Jak/STAT pathway by 



























                                                                                                                    





Activity of proteins is not only regulated on the level of gene expression. An additional level for 
the regulation of protein activity is provided by secondary modifications. One of these 
modifications is protein phosphorylation. Added through kinases and removed by phosphatases 
the phosphorylation and thus the activity of proteins can be adjusted to various cellular 
conditions. In most cases changes in cellular activity are the result of various adjustments 
regulated and mediated through signaling pathways, in which the activity of many proteins can 
be changed by phosphorylation. Because the activities of many cellular proteins are changed in 
biological processes, it is of interest to study the phosphorylation of many proteins in parallel. In 
this work an antibody array utilizing phosphorylation specific antibodies was developed that 
allows the simultaneous detection of several phosphoproteins in parallel. 
 
The first part of the work describes the development and optimization of the antibody array 
technology. After initial experiments in which antibodies were spotted on epoxy activated 
microscope glass slides and binding of fluorescence labeled protein extracts was measured, the 
focus was shifted to a more miniaturized format. For this the ArrayTube platform from Clondiag 
(Jena) was chosen. In this system a chip is mounted at the base of a reaction tube and the 
binding of proteins to the spotted antibody is detected by silver staining. With this system it 
became possible to establish a reliable assay for protein detection in cellular protein extracts. 
Crucial points for the system are the quality of the antibody preparation needed for spotting and 
the labeling of cellular proteins in protein extracts. It could be demonstrates that salt free 
antibody preparations with a minimal antibody concentration of 1 mg/ml are compatible with the 
spotting and the Array-Tube chip surface and that N-hydroxy-succinimid-activated biotin is a 
suitable reagent for labeling of protein extracts.  
 
After successful optimization of the assay system a selection of phosphorylation specific 
antibodies was used to set up a signaling pathway array system. The proteins analyzed by this 
system include phospho-p70S6 kinase and phospho-Akt (PI3K/Akt-signaling-pathway), 
phospho-p38 (p38 map-kinase), phospho-ERK (ERK1,2 map-kinase) and phospho-JNK 
(SAPK/JNK MAPK-homolog), phospho-Tyrosine, phospho-STAT3 (Jak/Stat-signaling-pathway), 
and phospho-Smad1 and phospho-Smad2,3 (TGF∗/BMP/Smad-signaling-pathway). 
 
This array was used to analyze changes in protein phosphorylation patterns in three application 
examples: - BMB2 treatment of the leukemia cell line U937 (monocytes), - BMP2 treatment of 
the breast cancer cell line MCF-7, and - STI571 treatment of the leukemia cell line K562 (BCR-
Abl positiv).  
 
The effect of BMP2 treatment on U937 cells is strongly concentration dependent. Using 
concentrations from 50 ng/ml to 2000 ng/ml BMP2, I demonstrates by measuring cellular 
proliferation, counting cell numbers, and FACS analysis that at low concentrations BMP2 
controls proliferation whereas induction of apoptosis is observed at high concentrations of 
BMP2.  
 
Using the antibody array, and high dose BMP2 treatment I found: (1) Total phospho-Tyrosine 
and phospho-p38 increased resulting from parallel increase in cytoplasm and nucleus; (2) Total 
phospho-ERK and phospho-JNK increased resulting from an increase in cytoplasm whereas 
phosphorylation in nucleus remained unchanged; (3) Total phospho-Akt increased also resulting 
from an increase in cytoplasm but was accompanied by a decrease in nucleus; (4) Total 
phospho-Smad1, phospho-Smad2/3 and c-Myc were unchanged but increased in nucleus and 
decreased in cytoplasm . (5) Total phospho-p70S6 was unchanged but increased in cytoplasm 
and decreased in nucleus.  
 
Cytoplasmic activation of ERK/JNK MAPK pathway and Akt signalling may be involved also in 
the cooperative signalling whereby the BMP2signal stimulates not only the ERK/JNK MAPK 
pathway increase in cytoplasm and unchange in nucleus of phospho-ERK and phospho-JNK, 
but also Akt signalling, seen in the enhance of cytoplasmic phosphorylation and decrease of 
nuclear phosphorylation of Akt in BMP2 treated U937 cells. From this result it can be deduced 
that negative regulation maybe reflect from a nuclear decrease and unchanged in Akt/p70S6 
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PI3K and ERK/JNK MAPK activity and a parallel nuclear increase of p38 MAPK pathway, 
Smad1/Smad2/3, c-Myc, and Tyrosine activity result in a BMP2 induced cell death in U937 cells 
 
Treatment of MCF-7 cells with BMP2 (100 ng/ml) for 4h (under this condition BMP2 acts as a 
survival factor) showed a very different distribution of changes in phosphorylation: phospho-p38 
and p38, p-JNK, p-Smad1, p-Smad2/3 displayed the increase in cytoplasm and the decrease in 
nucleus of BMP2 treated MCF7 cells. Total protein (sum of cytoplasm and nucleus) level of 
phospho-p38 and p38, p-JNK, p-Smad1, p-Smad2/3 were not significantly changed in BMP2 
treated MCF-7 cells and control cells. c-Myc displayed the slight decrease in cytoplasm and the 
slight increase in nucleus of BMP2 treated MCF7 cells. Total protein (sum of cytoplasm and 
nucleus) level of c-Myc was not significantly altered between BMP2 treated MCF-7 cells and 
control cells. p-Tyrosine, p-STAT3, p-ERK and p-P70S6 displayed the increase in cytoplasm 
and unchanged in nucleus of BMP2 treated MCF7 cells. Total protein (sum of cytoplasm and 
nucleus) level of p-p38, p-Tyrosine, p-STAT3, p-ERK and p-P70S6 were increased in BMP2 
treated cells. P-Akt displayed unchanged in cytoplasm and nucleus of BMP2 treated MCF7 cells.  
 
These changes indicate a cooperative action of the different signaling pathways that is needed 
to maintain cellular homeostasis, which is only reflected in changes in the distribution of the 
phosphorylated forms of the proteins analyzed.  
 
In the third example the human leukemia cell line K562 was treated with 0.2 µM STI571 for 24h. 
STI571 is a protein tyrosine kinase inhibitor that specifically inhibits the kinase activity of the 
BCR-Abl fusion protein that is expressed in K562 cells. Treatment with STI571 has an 
antiproliferative effect on these cells, which leads to the following changes in the phospho-
proteins analyzed: (1) Decrease of total phospho-Akt and phospho-p70S6 results from parallel 
decrease in cytoplasm and nucleus; (2) Increase in total phospho-p38, p38, c-Myc, phospho-
Tyrosine, phospho-Smad1 and phospho-Smad2/3 results from parallel increase in cytoplasm 
and nucleus; (3) Total phospho-STAT3 and phospho-JNK increased resulting from an increase 
in cytoplasm whereas the concentration in nucleus remained un-changed; (4) Total phospho-
ERK increased resulting from an increase in nucleus while in parallel the concentration in 
cytoplasm decreased.  
 
These changes show that growth inhibition of the phospho-Tyrosine-kinase BCR-Abl by STI571 
affects the activity of several signaling pathways. This could be either the result of a direct 
influence on these signaling pathways but could also reflect an indirect cellular response to the 
inhibitory effects of STI571.  
 
The results obtained with the phospho-protein-specific antibody array give a global view in the 
changes of signal-pathway activation reflected in the amount of selected phosphorylated 
proteins from the pathways analyzed. In combination with the selective purification of protein 
extracts from different cellular compartments, in this work nucleus or cytoplasm, this technology 
allows the rapid analysis of changes in concentration and localization of the respective proteins 
and their phosphorylation state. The information obtained in the application examples was finally 
used to deduce general regulation models for the different treatments, which are also discussed 

















                                                                                                                    












Die Aktivität von Proteinen ist nicht nur auf der Ebene der Genexpression reguliert. Eine weitere 
Ebene der Regulation ist durch nachfolgende Modifikationen möglich. Eine dieser 
Modifikationen ist Proteinphosphorylierung. Hinzugefügt durch Kinasen und entfernt durch 
Phosphatasen kann die Phosphorylierung und damit die Aktivität der Proteinen an verschiedene 
zelluläre Konditionen angepasst werden. In den meisten Fällen sind Änderungen in der 
zellulären Aktivität das Ergebnis verschiedener Anpassungen, die durch Signalwege vermittelt 
und reguliert werden. Da die Aktivität vieler zellulärer Proteine in biologischen Prozessen 
verändert wird, ist es von Interesse die Phosphorylierung vieler Proteine nebeneinander zu 
untersuchen. In dieser Arbeit wurde ein Antikörperarray entwickelt, der 
phosphoryleirungsspezifische Antikpörper nutzt und den gleichzeitigen Nachweis mehrerer 
Signalproteine ermöglicht.  
 
Der erste Teil der Arbeit beschreibt die Entwicklung und die Optimierung der 
Antikörperarraytechnologie. Nach anfänglichen Experimenten mit Antikörpern, die auf epoxy-
Aktivierten Objektträger gespottet wurden, wurde der Schwerpunkt auf ein stark miniaturisiertes 
Format gelegt. Dafür wurde das Array-Tube-System der Fa. Clondiag CT GmbH Jena gewählt. 
In diesem System wird der Array-Chip am Boden eines Reaktionsgefäßes angebracht und das 
Binden der Proteine an die gespotteten Antikörper durch Silberfärbung nachgewiesen. Mit 
diesem System wurde es möglich eine verlässliche Methode für den Nachweis von Proteinen in 
Zellextrakten aufzubauen. Entscheidende Punkte für das System sind die Qualität der 
Antikörperpräparation und die Markierung der zellulären Proteine in den Proteinextrakten. Es 
konnte gezeigt werden, dass salzfreie Antikörperpräparationen mit einer minimalen 
Konzentration von 1 mg/ml Antikörper für das Spotten auf die genutzte, epoxy-Aktivierte 
Oberfläche geeignet sind, bzw. dass N-hydroxy-succinimid-Aktiviertes Biotin ein geeignetes 
Reagenz für die Markierung der Proteine ist.  
 
Nach der erfolgreichen Optimierung der Methode wurden verschieden 
phosphroylierungsspezifische Antikörper ausgewählt. Die Proteine die dann nachgewiesen 
werden konnten waren: phospho-p70S6 Kinase und phospho-Akt (PI3K/Akt-Signalweg), 
phospho-p38 (p38 MAp-Kinase), phospho-ERK (ERK1,2 MAp-Kinase) und phospho-JNK 
(SAPK/JNK MAPK-homolog), phospho-Tyrosine, phospho-STAT3 (Jak/Stat-Signalweg), und 
phospho-Smad1 und phospho-Smad2,3 (TGF-∗/BMP/Smad-Signalweg).  
 
Der Array wurde genutzt, um Änderungen in der Proteinphsophorylierung in drei 
Anwendungsbeispielen zu untersuchen: - BMP2 Behandlung der Leukämie-Zelllinie U937 
(Monozyten), BMP2 Behandlung der Brustkrebszelllinie MCF-7 und STI571 Behandlung der 
Leukämie-Zelllinie K562 (BCR-abl positive Leukämie Zelllinie).  
 
Die BMP2 Wirkung in U937 Zellen ist stark abhängig von der Konzentration. Ich konnte durch 
Proliferationsmessungen und FACS-Analyse zeigen, dass niedrige BMP2-Konzentrationen zur 
Proliferation führen, während hohe Konzentrationen von BMP2 Apoptosis in U937 Zellen 
induzieren. 
 
Mit dem Antikörperarray und hohen Dosen BMP2 ergab sich folgendes Bild: (1) Zunahme von 
gesamt phospho-Tyrosin und phospho-p38-MAPK und gleichzeitige Zunahme in cytoplasma 
und Kern; (2) Zunahme von gesamt phospho-ERK und phospho-JNK aufgebaut aus Zunahme 
im Cytoplasma ohne Änderung im Kern; (3) Zunahme von gesamt phospho-Akt, bei Zunahme 
im Cytoplasma und Abnahme im Kern; (4) Keine Änderung von gesamt phospho-STAT3, 
phospho-Smad1, phospho-Smad2/3 und c-Myc, jedoch Zunahme im Kern und Abnahme im 
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Cytoplasma; (5) Keine Änderung für gesamt phsopho-p70S6 Kinase, jedoch Zunahme im 
Cytoplasma und Abnahme im Kern. 
 
In diesem Beispiel scheint das BMP2 Signal nicht nur STAT3, Smad und Myc-Netzwerke zu 
aktivieren sondern auch zu einer parallelen Aktivierung des p38 MAPK-Signalwegs und von 
Phosphotyrosinen zu führen, die mit einer verstärkten Translokation der entsprechenden 
Proteine in den Kern in BMP2 behandelten U937 Zellen verbunden ist, während 
phosphoryliertes Akt und p70S6-Kinase überwiegend im Cytoplasma lokalisiert waren. Die 
Abnahme der Akt/p70S6 Kinasen und der Erk/JNK -MAp-Kinasen im Kern und eine parallele 
Zunahme der Aktivität von p38-MAp-Kinase, Smad1/Smad2/3, STAT3 und c-Myc im Kern ist 
assoziiert mit dem durch BMP2 vermittelten Zelltod.  
 
Behandlung von MCF-7 Zellen mit BMP2 (100ng/ml) für 4h (unter diesen Bedingungen wirkt 
BMP2 als Überlebensfaktor) zeigt eine sehr unterschiedliche Verteilung der Änderungen in der 
Phsophorylierung: (1) Nahezu keine Änderung für die gesamt Menge (Cytoplasma und Nukleus) 
von phospho-p38 MAPK, phospho-ERK, phospho-p70S6, phospho-STAT3 und phospho-
Tyrosin, jedoch einen geringfügigen Anstieg dieser phosphorylierten Proteine im Cytoplasma 
und eine geringfügige Abnahme im Kern; (2) Gesamt c-Myc war unverändert aber geringfügig 
höher im Kern, ein Hinweis auf eine Translokation des Proteins; (3) Die gesamt Menge an 
phospho-Akt, phospho-JNK , phospho-Smad2/3 war unverändert, nahm jedoch im Cytoplasma 
zu, bei gleichzeitiger Abnahme im Kern.  
 
Diese Änderungen weisen auf eine kooperative Anpassung der verschiedenen Signalwege hin, 
die zur Aufrechterhaltung der zellulären Homäostase erforderlich ist, diese spiegelt sich nur in 
der Verteilung der phosphorylierten Formen der analysierten Proteine wieder.  
 
Im dritten Anwendungsbeispiel wurde die menschliche Leukemiezelllinie K562 mit 0,2 µM 
STI571 für 24h behandelt. STI571 ist ein Tyrosinkinaseinhibitor, der spezifisch die Aktivität der 
Kinase BCR-Abl hemmt, die in K562 Zellen als Fusionsprotein exprimiert wird. Behandlung mit 
STI571 hat einen proliferationshemmenden Effekt auf diese Zellen, der zu den folgenden 
Veränderungen in den untersuchten Phosphoproteinen führt: (1) Abnahme von gesamt 
phospho-Akt and phospho-p70S6 durch Abnahme in beiden Kompartimenten (Kern und 
Cytoplasma); (2) Zunahme in gesamt phospho-p38, p38, c-Myc, phospho-Tyrosin, phospho-
Smad1 und phospho-Smad2/3 durch Zunahme in Kern und Cytoplasma; (3) Zunahme von 
gesamt phospho-STAT3 und phospho-JNK durch eine Zunahme im Cytoplasma ohne 
Änderung im Kern; (4) Zunahme von phospho-ERK durch eine Zunahme im Kern bei 
gleichzeitiger Abnahme der Konzentration im Cytoplasma. 
 
Diese Änderungen zeigen, dass eine Inhibierung der phospho-Tyrosin-Kinase BCR-abl durch 
STI571 die Aktivität verschiedener Signalwege beeinflusst. Das kann das Ergebnis einer 
direkten Beeinflussung dieser Signalwege sein, könnte aber auch eine indirekte zelluläre 
Anpassung an die Inhibition der BCR-Abl Aktivität durch STI571 sein.  
 
Die Ergebnisse, die mit dem phosphoproteinspezifischen Antikörper erhalten wurden, geben 
einen Überblick über die Aktivierung verschiedener Signalwege, die sich in der Menge an 
phosporylierten Proteinen aus den untersuchten Signalwegen widerspiegelt. In Verbindung mit 
einer selektiven Aufreinigung der Proteine aus verschiedenen zellulären Kompartimenten, in 
dieser Arbeit Kern oder Cytoplasma, ermöglicht die Antikörperarray-Technologie die schnelle 
Untersuchung von Konzentrationsänderungen und der Lokalisierung der phosphorylierten 
Proteine. Die in den Anwendungsbeispielen erhaltenen Ergebnisse wurden anschließend 
genutzt, um Regulationsmodelle für die verschiedenen Behandlungen zu erstellen, die auch in 
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Substance Background Sigma CoG_y CoG_x Mean mean of 4 -
control-u-cyto 
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1:5 verd. 0,984291 0,03627 477 583 0,81783  
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phospho-p38 0,996955 0,05503 181 545 0,90948  
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Spot ID Substance Background Sigma CoG_y CoG_x Mean mean-cyto-bmp2 
112 1:100 verd. biotin anti rabbit IGG 0.984359 0.024978 91 290 0.785725 0.80916225 
113 1:100 verd. biotin anti rabbit IGG 0.996191 0.026507 91 332 0.809046 
114 1:100 verd. biotin anti rabbit IGG 0.998436 0.02776 93 374 0.817763 
115 1:100 verd. biotin anti rabbit IGG 0.991363 0.027247 91 418 0.824115 
106 1:20 verd. biotin anti rabbit IGG 0.987487 0.113089 130 549 0.663171 0.75935025 
107 1:20 verd. biotin anti rabbit IGG 0.977417 0.039944 137 590 0.822778 
110 1:20 verd. biotin anti rabbit IGG 0.920843 0.032932 90 209 0.757262 
111 1:20 verd. biotin anti rabbit IGG 0.960558 0.028866 89 250 0.79419 
78 1:5 verd. c-Myc 0.980572 0.032677 221 370 0.870902 0.87181925 
79 1:5 verd. c-Myc 1 0.026053 219 415 0.890861 
80 1:5 verd. c-Myc 0.999797 0.035106 221 459 0.849713 
81 1:5 verd. c-Myc 0.989317 0.032038 221 505 0.875801 
98 1:5 verd. p38 (mouse monoclonal 
10.1) 
0.954347 0.039242 132 207 0.624612 0.6756465 
99 1:5 verd. p38 (mouse monoclonal 
10.1) 
0.994964 0.041737 132 248 0.666418 
100 1:5 verd. p38 (mouse monoclonal 
10.1) 
0.999615 0.039516 133 292 0.698264 
101 1:5 verd. p38 (mouse monoclonal 
10.1) 
1 0.048341 135 334 0.713292 
20 1:5 verd. Phospho Stat3 6E4 0.986748 0.055563 434 460 0.787055 0.78278875 
21 1:5 verd. Phospho Stat3 6E4 0.980437 0.044136 434 500 0.80489 
22 1:5 verd. Phospho Stat3 6E4 0.982264 0.042203 434 543 0.777134 
23 1:5 verd. Phospho Stat3 6E4 0.999501 0.043582 436 588 0.762076 
10 1:5 verd. Phospho-Akt 4E2 0.979825 0.035753 479 545 0.79709 0.78046425 
11 1:5 verd. Phospho-Akt 4E2 0.980687 0.068618 482 584 0.763566 
14 1:5 verd. Phospho-Akt 4E2 0.961438 0.042308 430 200 0.749065 
15 1:5 verd. Phospho-Akt 4E2 0.960376 0.031038 431 245 0.812136 
88 1:5 verd. phospho-p38 (mouse 
monoclonal 9.1) 
0.99295 0.027023 179 292 0.85341 0.85977275 
89 1:5 verd. phospho-p38 (mouse 
monoclonal 9.1) 
0.990331 0.029309 178 332 0.860789 
90 1:5 verd. phospho-p38 (mouse 
monoclonal 9.1) 
1 0.074623 179 380 0.84666 
91 1:5 verd. phospho-p38 (mouse 
monoclonal 9.1) 
0.999865 0.037969 178 420 0.878232 
50 1:5 verd. Phospho-p44/42 MAP 
Kinase 
0.947002 0.027578 302 200 0.863239 0.90487675 
51 1:5 verd. Phospho-p44/42 MAP 
Kinase 
0.987041 0.029283 302 245 0.880891 
52 1:5 verd. Phospho-p44/42 MAP 
Kinase 
0.992567 0.020414 301 286 0.929279 
53 1:5 verd. Phospho-p44/42 MAP 
Kinase 
0.993569 0.028757 305 331 0.946098 
2 1:5 verd. Phospho-p70 S6 Kinase 0.972937 0.026478 475 197 0.720724 0.7558435 
3 1:5 verd. Phospho-p70 S6 Kinase 0.976966 0.021912 474 241 0.753065 
4 1:5 verd. Phospho-p70 S6 Kinase 0.982704 0.026143 476 283 0.760822 
5 1:5 verd. Phospho-p70 S6 Kinase 0.957244 0.027622 474 326 0.788763 
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40 1:5 verd. Phospho-SAPK/JNK 0.928691 0.033695 346 288 0.787044 0.79114425 
41 1:5 verd. Phospho-SAPK/JNK 0.946811 0.055057 347 330 0.773427 
42 1:5 verd. Phospho-SAPK/JNK 0.991817 0.031262 349 372 0.810901 
43 1:5 verd. Phospho-SAPK/JNK 0.992585 0.039088 348 416 0.793205 
30 1:5 verd. Phospho-Tyrosine 0.970453 0.059724 389 374 0.821944 0.80653375 
31 1:5 verd. Phospho-Tyrosine 0.967726 0.05626 391 413 0.809012 
32 1:5 verd. Phospho-Tyrosine 0.978995 0.058647 391 461 0.790752 
33 1:5 verd. Phospho-Tyrosine 0.923971 0.055619 392 499 0.804427 
58 1:5 verd. p-Smasd1 0.996056 0.032432 307 548 0.892845 0.86594775 
59 1:5 verd. p-Smasd1 0.987717 0.030149 308 590 0.861278 
62 1:5 verd. p-Smasd1 0.992112 0.040723 265 201 0.835567 
63 1:5 verd. p-Smasd1 0.986711 0.026803 261 245 0.874101 
68 1:5 verd. p-Smasd2/3 0.999933 0.033211 263 460 0.813635 0.776912 
69 1:5 verd. p-Smasd2/3 1 0.035798 264 503 0.78753 
70 1:5 verd. p-Smasd2/3 0.999031 0.026614 264 545 0.766614 
71 1:5 verd. p-Smasd2/3 0.999025 0.028572 266 588 0.739869 
116 2% Milchpulver 0.990947 0.054891 94 461 0.88098 0.8461575 
117 2% Milchpulver 0.986422 0.052716 95 504 0.86025 
118 2% Milchpulver 0.97185 0.049354 95 548 0.835909 
119 2% Milchpulver 0.94332 0.045811 95 591 0.807491 
82 c-Myc 0.987714 0.144251 223 546 0.384186 0.3909335 
83 c-Myc 0.998459 0.131558 224 589 0.347469 
86 c-Myc 0.971445 0.127705 175 205 0.363772 
87 c-Myc 0.979984 0.131303 177 247 0.468307 
102 p38 (mouse monoclonal 10.1) 1 0.078852 135 376 0.648825 0.63437025 
103 p38 (mouse monoclonal 10.1) 0.999153 0.08528 137 420 0.624251 
104 p38 (mouse monoclonal 10.1) 0.999932 0.077239 137 464 0.610529 
105 p38 (mouse monoclonal 10.1) 0.994854 0.092581 138 505 0.653876 
26 Phospho Stat3 6E4 0.896605 0.039003 387 200 0.310507 0.342697 
27 Phospho Stat3 6E4 0.906513 0.05222 387 241 0.327627 
28 Phospho Stat3 6E4 0.889367 0.037816 387 286 0.357627 
29 Phospho Stat3 6E4 0.899863 0.054408 389 329 0.375027 
16 Phospho-Akt 4E2 0.947274 0.043302 432 284 0.365788 0.39602925 
17 Phospho-Akt 4E2 0.937007 0.058226 431 328 0.413066 
18 Phospho-Akt 4E2 0.967959 0.053542 433 373 0.39741 
19 Phospho-Akt 4E2 0.970373 0.046489 433 414 0.407853 
92 phospho-p38 (mouse monoclonal 
9.1) 
0.999863 0.059662 179 462 0.591882 0.566185 
93 phospho-p38 (mouse monoclonal 
9.1) 
0.999933 0.054265 178 503 0.571201 
94 phospho-p38 (mouse monoclonal 
9.1) 
0.999391 0.070983 178 547 0.566159 
95 phospho-p38 (mouse monoclonal 
9.1) 
0.998342 0.065776 179 591 0.535498 
54 Phospho-p44/42 MAP Kinase 0.995806 0.08217 307 372 0.734074 0.7232085 
55 Phospho-p44/42 MAP Kinase 0.997824 0.08185 306 414 0.728738 
56 Phospho-p44/42 MAP Kinase 0.997325 0.066059 306 459 0.740848 
57 Phospho-p44/42 MAP Kinase 0.99396 0.069965 308 500 0.689174 
6 Phospho-p70 S6 Kinase 0.960626 0.027716 476 367 0.836557 0.837725 
7 Phospho-p70 S6 Kinase 0.977536 0.022415 476 410 0.872658 
8 Phospho-p70 S6 Kinase 0.985283 0.028278 478 455 0.833367 
9 Phospho-p70 S6 Kinase 0.99103 0.033883 477 500 0.808318 
44 Phospho-SAPK/JNK 0.987487 0.039106 349 458 0.4666 0.4567695 
45 Phospho-SAPK/JNK 0.988683 0.047176 349 505 0.492369 
46 Phospho-SAPK/JNK 0.99658 0.044002 349 545 0.444741 
47 Phospho-SAPK/JNK 0.988461 0.031866 349 589 0.423368 
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34 Phospho-Tyrosine 0.875825 0.044956 396 541 0.467806 0.458722 
35 Phospho-Tyrosine 0.946924 0.053715 394 585 0.44746 
38 Phospho-Tyrosine 0.875893 0.041304 345 200 0.435588 
39 Phospho-Tyrosine 0.92107 0.039392 347 245 0.484034 
64 p-Smasd1 0.986838 0.16465 261 287 0.553927 0.56703 
65 p-Smasd1 0.992497 0.162088 264 329 0.50966 
66 p-Smasd1 0.97264 0.161341 263 373 0.588911 
67 p-Smasd1 0.990003 0.164266 264 414 0.615622 
74 p-Smasd2/3 0.989385 0.04031 218 201 0.672337 0.71357475 
75 p-Smasd2/3 0.97736 0.035808 217 245 0.650868 
76 p-Smasd2/3 0.984695 0.029679 217 289 0.757985 
77 p-Smasd2/3 0.988983 0.029146 217 331 0.773109 
1 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0.900661 0.024438 479 156 0.848796 0.9600825 
12 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0.993165 0.007652 494 629 0.996867 
36 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0.99849 0.009208 410 626 0.997098 
48 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0.996349 0.009304 368 626 0.997569 
60 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0.99973 0.008216 321 629 0.997921 0.9739595 
72 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0.996303 0.012899 272 635 0.995201 
73 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0.969349 0.027873 224 158 0.907487 
84 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0.995199 0.013235 237 627 0.995229 
85 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0.951702 0.028523 181 160 0.88956 0.8771465 
96 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0.981888 0.024969 181 634 0.9413 
109 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0.871036 0.026115 89 160 0.821316 
120 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 










Substance mean of 4 -
control-u-cyto 
mean of  4 
u_2000-cyto 
sd-u-cyto-bmp2 STABW-control-u-cyto 1_mean of 4 -
control-u-cyto 
1_mean of  4 
u_2000-cyto 
1:100 verd. 
biotin anti rabbit 
IGG 
0,919161 0,785725 0,015872286 0,007837761 0,080839 0,214275
1:20 verd. biotin 
anti rabbit IGG 
0,56020475 0,80567 0,027822734 0,229169765 0,43979525 0,19433
1:5 verd. c-Myc 0,67885675 0,871129 0,016981274 0,018873999 0,32114325 0,128871





















0,93649425 0,863239 0,03965463 0,016070691 0,06350575 0,136761
                                                                                                                    












0,798034 0,827435 0,012600462 0,047554483 0,201966 0,172565
1:5 verd. p-
Smasd1 
0,74282625 0,891479 0,023240616 0,02202913 0,25717375 0,108521
1:5 verd. p-
Smasd2/3 
0,6128855 0,816376 0,032024485 0,01308037 0,3871145 0,183624
2% Milchpulver 0,98324325 0,88098 0,032253703 0,0113329 0,01675675 0,11902




0,77766825 0,648293 0,016282478 0,039283929 0,22233175 0,351707
Phospho Stat3 
6E4 
0,34431775 0,318449 0,026891219 0,01933539 0,65568225 0,681551
Phospho-Akt 
4E2 




0,90225875 0,583527 0,020517811 0,015034399 0,09774125 0,416473
Phospho-p44/42 
MAP Kinase 
0,91739775 0,736188 0,024793552 0,032597166 0,08260225 0,263812
Phospho-p70 
S6 Kinase 
0,926664 0,836557 0,025863105 0,014983349 0,073336 0,163443
Phospho-
SAPK/JNK 
0,8221825 0,476779 0,031063457 0,023134632 0,1778175 0,523221
Phospho-
Tyrosine 
0,720123 0,466202 0,021978632 0,031542879 0,279877 0,533798
p-Smasd1 0,35535925 0,553927 0,046976905 0,028969898 0,64464075 0,446073





0,84933142 0,849449 0,063293828 0,07154877 0,15066858 0,150551











Substance Valid Background QSV Sigma Mean 
 
 





0 0.883283 0.160523 0.022645 0.835577 
2 1:5 verd. 
Phospho-p70 
S6 Kinase 
0 0.934308 0.063669 0.070707 0.663756 
3 1:5 verd. 
Phospho-p70 
S6 Kinase 
0 0.954087 0.035395 0.072067 0.697226 
4 1:5 verd. 
Phospho-p70 
S6 Kinase 
0 0.971109 0.017712 0.044577 0.744865 
5 1:5 verd. 
Phospho-p70 
S6 Kinase 
0 0.977091 0.022932 0.049587 0.741938 
6 Phospho-p70 
S6 Kinase 
0 0.978806 0.004052 0.039759 0.862755 
7 Phospho-p70 
S6 Kinase 
0 0.990251 0.002224 0.029251 0.889446 
8 Phospho-p70 0 0.988390 0.003516 0.046638 0.861599 
                                                                                                                    




0 0.977021 0.007295 0.075334 0.807473 
10 1:5 verd. 
Phospho-Akt 
4E2 
0 0.974465 0.008795 0.095440 0.660651 
11 1:5 verd. 
Phospho-Akt 
4E2 





0 0.925111 0.031428 0.020666 0.861613 
14 1:5 verd. 
Phospho-Akt 
4E2 
0 0.939906 0.049073 0.065880 0.705860 
15 1:5 verd. 
Phospho-Akt 
4E2 
0 0.952985 0.026524 0.069745 0.718369 
16 Phospho-Akt 
4E2 
0 0.955348 0.010589 0.087391 0.739315 
17 Phospho-Akt 
4E2 
0 0.968360 0.002566 0.053659 0.806584 
18 Phospho-Akt 
4E2 
0 0.980769 -0.003614 0.062637 0.809666 
19 Phospho-Akt 
4E2 
0 0.992669 -0.002771 0.055269 0.820482 
20 1:5 verd. 
Phospho Stat3 
6E4 
0 0.996457 0.001492 0.052201 0.765286 
21 1:5 verd. 
Phospho Stat3 
6E4 
0 0.992954 0.003835 0.097253 0.749638 
22 1:5 verd. 
Phospho Stat3 
6E4 
0 0.984046 0.017201 0.117177 0.642179 
23 1:5 verd. 
Phospho Stat3 
6E4 
0 0.962867 0.006400 0.050892 0.737326 
26 Phospho Stat3 
6E4 
0 0.952941 0.030505 0.046483 0.636850 
27 Phospho Stat3 
6E4 
0 0.970187 0.011901 0.050534 0.648158 
28 Phospho Stat3 
6E4 
0 0.979085 -0.001616 0.060102 0.645834 
29 Phospho Stat3 
6E4 
0 0.989299 -0.009356 0.051358 0.639873 
30 1:5 verd. 
Phospho-
Tyrosine 
0 0.994955 -0.006045 0.053127 0.804049 
31 1:5 verd. 
Phospho-
Tyrosine 
0 0.996787 -0.004371 0.055007 0.809146 
32 1:5 verd. 
Phospho-
Tyrosine 
0 0.995680 -0.000702 0.048383 0.812770 
33 1:5 verd. 
Phospho-
Tyrosine 
0 0.993082 -0.002873 0.042327 0.791766 
34 Phospho-
Tyrosine 
0 0.980702 -0.002846 0.039407 0.754962 
35 Phospho-
Tyrosine 





0 0.932779 0.367586 0.040376 0.848272 
38 Phospho-
Tyrosine 
0 0.944810 0.018804 0.042780 0.715435 
39 Phospho-
Tyrosine 
0 0.963975 0.001872 0.043421 0.738442 
40 1:5 verd. 
Phospho-
SAPK/JNK 
0 0.982397 0.002493 0.060286 0.750750 
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41 1:5 verd. 
Phospho-
SAPK/JNK 
0 0.987121 -0.004765 0.047226 0.779033 
42 1:5 verd. 
Phospho-
SAPK/JNK 
0 0.982054 -0.010682 0.046081 0.772995 
43 1:5 verd. 
Phospho-
SAPK/JNK 
0 0.989973 -0.009295 0.062898 0.767762 
44 Phospho-
SAPK/JNK 
0 0.993093 -0.010002 0.062192 0.686150 
45 Phospho-
SAPK/JNK 
0 0.985710 -0.010813 0.050574 0.702899 
46 Phospho-
SAPK/JNK 
0 0.964082 -0.004320 0.044173 0.693636 
47 Phospho-
SAPK/JNK 





0 0.948089 0.435342 0.023977 0.879402 
50 1:5 verd. 
Phospho-p44/42 
MAP Kinase 
0 0.950245 0.016868 0.037525 0.704966 
51 1:5 verd. 
Phospho-p44/42 
MAP Kinase 
0 0.971546 -0.000086 0.045448 0.697277 
52 1:5 verd. 
Phospho-p44/42 
MAP Kinase 
0 0.981013 -0.006577 0.033697 0.725097 
53 1:5 verd. 
Phospho-p44/42 
MAP Kinase 
0 0.986386 -0.004307 0.043860 0.714525 
54 Phospho-p44/42 
MAP Kinase 
0 0.976604 -0.006548 0.064513 0.716186 
55 Phospho-p44/42 
MAP Kinase 
0 0.972816 -0.008286 0.063889 0.714325 
56 Phospho-p44/42 
MAP Kinase 
0 0.982586 -0.009574 0.062965 0.709714 
57 Phospho-p44/42 
MAP Kinase 
0 0.981912 0.000680 0.072895 0.716117 
58 1:5 verd. p-
Smasd1 
0 0.974875 0.062123 0.047582 0.571825 
59 1:5 verd. p-
Smasd1 





0 0.947477 0.376623 0.022907 0.877467 
62 1:5 verd. p-
Smasd1 
0 0.947491 0.013368 0.039504 0.592823 
63 1:5 verd. p-
Smasd1 
0 0.966345 -0.003797 0.042664 0.583845 
64 p-Smasd1 0 0.975369 -0.020893 0.042859 0.428638 
65 p-Smasd1 0 0.979550 -0.012665 0.046945 0.427980 
66 p-Smasd1 0 0.980637 -0.021370 0.039839 0.453394 
67 p-Smasd1 0 0.973347 -0.031113 0.042367 0.427485 
68 1:5 verd. p-
Smasd2/3 
0 0.968516 -0.019663 0.050772 0.575189 
69 1:5 verd. p-
Smasd2/3 
0 0.974898 0.057925 0.046050 0.580136 
70 1:5 verd. p-
Smasd2/3 
0 0.966221 0.375494 0.064868 0.529146 
71 1:5 verd. p-
Smasd2/3 










0 0.895890 0.089865 0.018474 0.865939 
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74 p-Smasd2/3 0 0.910094 -0.011416 0.032167 0.432951 
75 p-Smasd2/3 0 0.941087 -0.024621 0.031744 0.415181 
76 p-Smasd2/3 0 0.958170 -0.034448 0.038779 0.417864 
77 p-Smasd2/3 0 0.962968 -0.014258 0.038667 0.441221 
78 1:5 verd. c-Myc 0 0.971747 -0.016393 0.036968 0.485320 
79 1:5 verd. c-Myc 0 0.971330 -0.022126 0.047713 0.458623 
80 1:5 verd. c-Myc 0 0.948997 0.010019 0.047645 0.455364 
81 1:5 verd. c-Myc 0 0.948050 0.301705 0.044392 0.455044 
82 c-Myc 0 0.946627 0.418755 0.046383 0.576499 










0 0.874709 0.118264 0.028892 0.835233 
86 c-Myc 0 0.908857 0.034875 0.036256 0.596192 
87 c-Myc 0 0.942417 0.015198 0.061073 0.586479 




0 0.951267 0.004252 0.058470 0.618188 




0 0.963266 0.016900 0.063044 0.619937 




0 0.966722 0.007417 0.052065 0.634981 

























0 0.890905 0.134068 0.020863 0.848092 




0 0.883793 0.096445 0.048120 0.670540 




0 0.912634 0.055709 0.041221 0.686844 




0 0.933067 0.035532 0.056914 0.680710 




0 0.948797 0.029007 0.073622 0.712186 
102 p38 (mouse 
monoclonal 
10.1) 
0 0.948685 0.020424 0.030220 0.782124 
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103 p38 (mouse 
monoclonal 
10.1) 
0 0.942528 0.056606 0.037448 0.762721 
104 p38 (mouse 
monoclonal 
10.1) 
0 0.927518 0.376606 0.032499 0.749060 
105 p38 (mouse 
monoclonal 
10.1) 
0 0.903298 0.433502 0.034813 0.754216 
106 1:20 verd. biotin 
anti rabbit IGG 
0 0.890949 0.354484 0.086923 0.634316 
107 1:20 verd. biotin 
anti rabbit IGG 





0 0.797727 0.236725 0.022695 0.753143 
110 1:20 verd. biotin 
anti rabbit IGG 
0 0.834009 0.153793 0.040588 0.642696 
111 1:20 verd. biotin 
anti rabbit IGG 
0 0.869786 0.112697 0.057531 0.627134 
112 1:100 verd. 
biotin anti rabbit 
IGG 
0 0.889161 0.067274 0.049317 0.576831 
113 1:100 verd. 
biotin anti rabbit 
IGG 
0 0.905351 0.049297 0.049817 0.572207 
114 1:100 verd. 
biotin anti rabbit 
IGG 
0 0.910136 0.034584 0.034071 0.615726 
115 1:100 verd. 
biotin anti rabbit 
IGG 
0 0.854043 0.136053 0.040299 0.642343 
116 2% Milchpulver 0 0.846749 0.432867 0.031235 0.776015 
117 2% Milchpulver 0 0.861394 0.459775 0.068252 0.713116 
118 2% Milchpulver 0 0.842366 0.414432 0.028209 0.733470 



















0 0.943342 0.106184 0.022975 0.925612 
2 1:5 verd. 
Phospho-p70 
S6 Kinase 
0 0.982319 0.083004 0.061894 0.355894 
3 1:5 verd. 
Phospho-p70 
S6 Kinase 
0 0.995964 0.018995 0.082950 0.387161 
4 1:5 verd. 
Phospho-p70 
S6 Kinase 
0 0.999864 -0.009098 0.069649 0.420530 
5 1:5 verd. 
Phospho-p70 
S6 Kinase 
0 1.000.000 -0.017315 0.075168 0.427251 
6 Phospho-p70 
S6 Kinase 
0 0.999111 -0.025715 0.105033 0.540154 
7 Phospho-p70 
S6 Kinase 
0 0.999111 -0.027288 0.105081 0.504882 
8 Phospho-p70 
S6 Kinase 
0 0.999430 -0.027366 0.101319 0.539176 
9 Phospho-p70 
S6 Kinase 
0 0.991908 -0.026396 0.093059 0.529985 
10 1:5 verd. 0 0.989238 -0.008643 0.099398 0.403978 
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Phospho-Akt 
4E2 
11 1:5 verd. 
Phospho-Akt 
4E2 





0 0.996170 0.000024 0.005121 0.998613 
14 1:5 verd. 
Phospho-Akt 
4E2 
0 0.991427 0.042785 0.086978 0.424574 
15 1:5 verd. 
Phospho-Akt 
4E2 
0 0.999129 -0.009429 0.103157 0.481218 
16 Phospho-Akt 
4E2 
0 0.999954 -0.015220 0.114398 0.518046 
17 Phospho-Akt 
4E2 
0 1.000.000 -0.027229 0.090047 0.517194 
18 Phospho-Akt 
4E2 
0 1.000.000 -0.034021 0.082550 0.568144 
19 Phospho-Akt 
4E2 
0 1.000.000 -0.036500 0.081918 0.593505 
20 1:5 verd. 
Phospho Stat3 
6E4 
0 1.000.000 -0.032104 0.097934 0.548413 
21 1:5 verd. 
Phospho Stat3 
6E4 
0 1.000.000 -0.027521 0.089127 0.486331 
22 1:5 verd. 
Phospho Stat3 
6E4 
0 0.996854 -0.028657 0.099079 0.532413 
23 1:5 verd. 
Phospho Stat3 
6E4 
0 1.000.000 -0.028008 0.094598 0.551412 
26 Phospho Stat3 
6E4 
0 0.997552 0.001243 0.072626 0.433233 
27 Phospho Stat3 
6E4 
0 0.999932 -0.006704 0.073942 0.454541 
28 Phospho Stat3 
6E4 
0 0.999909 -0.020179 0.062650 0.476876 
29 Phospho Stat3 
6E4 
0 0.999909 -0.024323 0.085500 0.506516 
30 1:5 verd. 
Phospho-
Tyrosine 
0 1.000.000 -0.030855 0.106380 0.557599 
31 1:5 verd. 
Phospho-
Tyrosine 
0 1.000.000 -0.036143 0.066390 0.622892 
32 1:5 verd. 
Phospho-
Tyrosine 
0 1.000.000 -0.023432 0.105397 0.618688 
33 1:5 verd. 
Phospho-
Tyrosine 
0 0.999954 -0.028051 0.118481 0.503132 
34 Phospho-
Tyrosine 
0 0.997994 -0.024214 0.062417 0.749199 
35 Phospho-
Tyrosine 





0 0.998368 0.000033 0.004610 0.999390 
38 Phospho-
Tyrosine 
0 0.996284 -0.015839 0.056910 0.759533 
39 Phospho-
Tyrosine 
0 1.000.000 -0.019119 0.054082 0.779895 
40 1:5 verd. 
Phospho-
SAPK/JNK 
0 1.000.000 -0.026566 0.090064 0.530447 
41 1:5 verd. 
Phospho-
SAPK/JNK 
0 0.998997 -0.025737 0.091427 0.536716 
42 1:5 verd. 
Phospho-
0 1.000.000 -0.035503 0.066407 0.560445 
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SAPK/JNK 
43 1:5 verd. 
Phospho-
SAPK/JNK 
0 1.000.000 -0.036357 0.071894 0.595146 
44 Phospho-
SAPK/JNK 
0 1.000.000 -0.039642 0.063832 0.543522 
45 Phospho-
SAPK/JNK 
0 0.999977 -0.038145 0.096687 0.539131 
46 Phospho-
SAPK/JNK 
0 0.985583 -0.036449 0.085620 0.549694 
47 Phospho-
SAPK/JNK 





0 0.997620 -0.000000 0.003741 0.999306 
50 1:5 verd. 
Phospho-p44/42 
MAP Kinase 
0 0.998358 -0.014233 0.078843 0.437307 
51 1:5 verd. 
Phospho-p44/42 
MAP Kinase 
0 0.999977 -0.021801 0.065083 0.438665 
52 1:5 verd. 
Phospho-p44/42 
MAP Kinase 
0 1.000.000 -0.023124 0.067952 0.448438 
53 1:5 verd. 
Phospho-p44/42 
MAP Kinase 
0 0.996781 -0.019659 0.090479 0.463191 
54 Phospho-p44/42 
MAP Kinase 
0 0.999088 -0.032707 0.061147 0.530911 
55 Phospho-p44/42 
MAP Kinase 
0 1.000.000 -0.036277 0.073208 0.496425 
56 Phospho-p44/42 
MAP Kinase 
0 0.999297 -0.033256 0.089048 0.481498 
57 Phospho-p44/42 
MAP Kinase 
0 1.000.000 -0.036136 0.071833 0.486455 
58 1:5 verd. p-
Smasd1 
0 0.997144 -0.044442 0.064103 0.442071 
59 1:5 verd. p-
Smasd1 





0 0.999612 0.000007 0.001488 0.999773 
62 1:5 verd. p-
Smasd1 
0 0.997087 -0.026565 0.059527 0.413834 
63 1:5 verd. p-
Smasd1 
0 0.999819 -0.024796 0.066878 0.434147 
64 p-Smasd1 0 0.998951 0.008436 0.064519 0.363755 
65 p-Smasd1 0 0.997303 -0.016635 0.052680 0.410466 
66 p-Smasd1 0 0.998472 -0.021740 0.044935 0.414387 
67 p-Smasd1 0 0.992864 -0.024263 0.056025 0.398829 
68 1:5 verd. p-
Smasd2/3 
0 0.998678 -0.043086 0.051510 0.437469 
69 1:5 verd. p-
Smasd2/3 
0 0.999954 -0.037614 0.064564 0.406286 
70 1:5 verd. p-
Smasd2/3 
0 0.994642 -0.037669 0.066004 0.430146 
71 1:5 verd. p-
Smasd2/3 










0 0.959923 0.017397 0.009134 0.956348 
74 p-Smasd2/3 0 0.988395 -0.028214 0.053302 0.340455 
75 p-Smasd2/3 0 0.995285 -0.026640 0.050510 0.334492 
76 p-Smasd2/3 0 0.997948 -0.036934 0.051074 0.380577 
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77 p-Smasd2/3 0 0.999841 -0.034265 0.055796 0.380781 
78 1:5 verd. c-Myc 0 1.000.000 -0.043541 0.064997 0.408156 
79 1:5 verd. c-Myc 0 0.987616 -0.048533 0.057601 0.443121 
80 1:5 verd. c-Myc 0 0.993789 -0.048076 0.063456 0.432351 
81 1:5 verd. c-Myc 0 0.999590 -0.029169 0.087130 0.397386 
82 c-Myc 0 0.999547 -0.030073 0.087353 0.466787 










0 0.927644 0.045532 0.010684 0.912593 
86 c-Myc 0 0.974361 0.009720 0.085388 0.390786 
87 c-Myc 0 0.993844 -0.017802 0.056163 0.427764 




0 0.995212 -0.027146 0.055988 0.499900 




0 0.997294 -0.028764 0.052075 0.474785 




0 0.999773 -0.024711 0.070612 0.400506 

























0 0.983351 0.002456 0.043374 0.948172 




0 0.931565 0.031836 0.083335 0.477463 




0 0.969129 0.004225 0.077610 0.440004 




0 0.989573 -0.012582 0.064377 0.478203 




0 0.997811 -0.010839 0.095573 0.482296 
102 p38 (mouse 
monoclonal 
10.1) 
0 0.997983 -0.012803 0.036337 0.854758 
103 p38 (mouse 
monoclonal 
10.1) 
0 0.998313 -0.013576 0.044071 0.842833 
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104 p38 (mouse 
monoclonal 
10.1) 
0 0.997575 -0.011425 0.036330 0.869050 
105 p38 (mouse 
monoclonal 
10.1) 
0 0.995942 0.011772 0.120904 0.840162 
106 1:20 verd. biotin 
anti rabbit IGG 
0 0.997225 -0.024236 0.075575 0.490358 
107 1:20 verd. biotin 
anti rabbit IGG 





0 0.842841 0.136250 0.022658 0.821468 
110 1:20 verd. biotin 
anti rabbit IGG 
0 0.880812 0.067107 0.058092 0.483869 
111 1:20 verd. biotin 
anti rabbit IGG 
0 0.916416 0.038397 0.092995 0.443318 
112 1:100 verd. 
biotin anti rabbit 
IGG 
0 0.951785 0.001047 0.073338 0.436282 
113 1:100 verd. 
biotin anti rabbit 
IGG 
0 0.978374 -0.016944 0.063874 0.416787 
114 1:100 verd. 
biotin anti rabbit 
IGG 
0 0.989170 -0.013452 0.090548 0.398110 
115 1:100 verd. 
biotin anti rabbit 
IGG 
0 0.989466 -0.022049 0.101571 0.468813 
116 2% Milchpulver 0 0.989818 -0.017632 0.108079 0.503043 
117 2% Milchpulver 0 0.980052 -0.016950 0.085340 0.571915 
118 2% Milchpulver 0 0.964478 -0.011922 0.064432 0.575500 























   
1:100 verd. Biotin 
anti rabbit IGG 
0,971034 0,04763 80.000.000 331.000.000 0,639272  
1:100 verd. Biotin 
anti rabbit IGG 
0,970521 0,050034 80.000.000 378.000.000 0,65649  
1:100 verd. Biotin 
anti rabbit IGG 
0,985873 0,047545 79.000.000 420.000.000 0,660877  
1:20 verd. Biotin 
anti rabbit IGG 
0,989254 0,053654 124.000.000 554.000.000 0,649577 0,62481375 0,37518625 0,02491483
1:20 verd. biotin 
anti rabbit IGG 
0,976426 0,050608 125.000.000 595.000.000 0,639457  
1:20 verd. biotin 
anti rabbit IGG 
0,886163 0,045571 83.000.000 202.000.000 0,593749  
1:20 verd. biotin 
anti rabbit IGG 
0,924028 0,05055 81.000.000 248.000.000 0,616472  
1:5 verd. c-Myc 1.000.000 0,027716 211.000.000 377.000.000 0,493244 0,499714 0,500286 0,01081141
1:5 verd. c-Myc 0,999889 0,025018 210.000.000 421.000.000 0,493027  
1:5 verd. c-Myc 0,999978 0,025897 211.000.000 463.000.000 0,496871  
1:5 verd. c-Myc 0,999933 0,029648 212.000.000 510.000.000 0,515714  
1:5 verd. p38 
(mouse 
0,925357 0,024235 124.000.000 200.000.000 0,709251 0,7211055 0,2788945 0,01155259
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monoclonal 10.1) 
1:5 verd. p38 
(mouse 
monoclonal 10.1) 
0,958534 0,02414 126.000.000 244.000.000 0,714438  
1:5 verd. p38 
(mouse 
monoclonal 10.1) 
0,977963 0,025547 124.000.000 287.000.000 0,725683  
1:5 verd. p38 
(mouse 
monoclonal 10.1) 
0,980771 0,027615 129.000.000 331.000.000 0,73505  
1:5 verd. Phospho 
Stat3 6E4 
0,994853 0,025404 433.000.000 463.000.000 0,642432 0,636249 0,363751 0,00541902
1:5 verd. Phospho 
Stat3 6E4 
0,997193 0,023942 431.000.000 507.000.000 0,638069  
1:5 verd. Phospho 
Stat3 6E4 
0,994831 0,02379 431.000.000 551.000.000 0,634943  
1:5 verd. Phospho 
Stat3 6E4 
0,988792 0,025497 431.000.000 596.000.000 0,629552  
1:5 verd. Phospho-
Akt 4E2 
0,984292 0,027571 479.000.000 551.000.000 0,610794 0,6030635 0,3969365 0,01347877
1:5 verd. Phospho-
Akt 4E2 
0,977094 0,032722 474.000.000 595.000.000 0,593248  
1:5 verd. Phospho-
Akt 4E2 
0,905993 0,026316 430.000.000 200.000.000 0,5902  
1:5 verd. Phospho-
Akt 4E2 
































0,998619 0,032998 301.000.000 333.000.000 0,698705  
1:5 verd. Phospho-
p70 S6 Kinase 
0,849109 0,025299 475.000.000 198.000.000 0,473555 0,50286375 0,49713625 0,02091094
1:5 verd. Phospho-
p70 S6 Kinase 
0,897308 0,023232 475.000.000 245.000.000 0,505417  
1:5 verd. Phospho-
p70 S6 Kinase 
0,932248 0,023026 476.000.000 284.000.000 0,509595  
1:5 verd. Phospho-
p70 S6 Kinase 
0,964283 0,02909 476.000.000 331.000.000 0,522888  
1:5 verd. Phospho-
SAPK/JNK 
0,990686 0,049546 345.000.000 287.000.000 0,541682 0,5289495 0,4710505 0,01853309
1:5 verd. Phospho-
SAPK/JNK 
0,996034 0,041128 343.000.000 332.000.000 0,504781  
1:5 verd. Phospho-
SAPK/JNK 
0,99922 0,052727 343.000.000 376.000.000 0,524208  
1:5 verd. Phospho-
SAPK/JNK 
0,999513 0,047307 344.000.000 419.000.000 0,545127  
1:5 verd. Phospho-
Tyrosine 
0,996257 0,029585 386.000.000 378.000.000 0,668391 0,66543525 0,33456475 0,00623859
1:5 verd. Phospho-
Tyrosine 
0,99971 0,026471 387.000.000 419.000.000 0,668615  
1:5 verd. Phospho-
Tyrosine 
0,999867 0,022455 387.000.000 463.000.000 0,656079  
1:5 verd. Phospho-
Tyrosine 
0,982829 0,026824 388.000.000 506.000.000 0,668656  
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1:5 verd. p-
Smasd1 
0,999933 0,077381 299.000.000 551.000.000 0,404387 0,38581325 0,61418675 0,01401415
1:5 verd. p-
Smasd1 
0,999666 0,085219 300.000.000 596.000.000 0,386246  
1:5 verd. p-
Smasd1 
0,969006 0,076846 256.000.000 198.000.000 0,37068  
1:5 verd. p-
Smasd1 
0,987455 0,08811 254.000.000 244.000.000 0,38194  
1:5 verd. p-
Smasd2/3 
0,998507 0,023758 255.000.000 464.000.000 0,360082 0,3494875 0,6505125 0,00910219
1:5 verd. p-
Smasd2/3 
0,998485 0,036129 257.000.000 506.000.000 0,354072  
1:5 verd. p-
Smasd2/3 
0,999889 0,023125 255.000.000 551.000.000 0,342107  
1:5 verd. p-
Smasd2/3 
0,99971 0,022792 257.000.000 594.000.000 0,341689  
2% Milchpulver 0,988168 0,040773 81.000.000 464.000.000 0,809173 0,78968075 0,21031925 0,01905628
2% Milchpulver 0,982108 0,036584 81.000.000 507.000.000 0,801399  
2% Milchpulver 0,960472 0,035562 82.000.000 553.000.000 0,780599  
2% Milchpulver 0,935784 0,033388 81.000.000 595.000.000 0,767552  
c-Myc 1.000.000 0,09604 212.000.000 551.000.000 0,723886 0,709542 0,290458 0,02319275
c-Myc 0,999621 0,079353 211.000.000 598.000.000 0,734624  
c-Myc 0,952429 0,072673 165.000.000 201.000.000 0,688921  
c-Myc 0,977094 0,100214 166.000.000 243.000.000 0,690737  
p38 (mouse 
monoclonal 10.1) 
0,998351 0,036091 125.000.000 377.000.000 0,812277 0,81369875 0,18630125 0,01226536
p38 (mouse 
monoclonal 10.1) 
0,999889 0,035769 123.000.000 422.000.000 0,826232  
p38 (mouse 
monoclonal 10.1) 
0,998775 0,032261 124.000.000 467.000.000 0,818878  
p38 (mouse 
monoclonal 10.1) 
0,998619 0,040237 123.000.000 508.000.000 0,797408  
Phospho Stat3 
6E4 
0,937344 0,032529 386.000.000 199.000.000 0,311448 0,32518575 0,67481425 0,00936926
Phospho Stat3 
6E4 
0,967513 0,031173 386.000.000 243.000.000 0,32881  
Phospho Stat3 
6E4 
0,984291 0,028202 385.000.000 290.000.000 0,332517  
Phospho Stat3 
6E4 
0,994318 0,024247 385.000.000 333.000.000 0,327968  
Phospho-Akt 4E2 0,942135 0,032125 431.000.000 285.000.000 0,429151 0,43242825 0,56757175 0,00292649
Phospho-Akt 4E2 0,969029 0,040753 432.000.000 329.000.000 0,436176  
Phospho-Akt 4E2 0,987901 0,039472 429.000.000 376.000.000 0,431562  
















0,996699 0,041708 168.000.000 595.000.000 0,623754  
Phospho-p44/42 
MAP Kinase 
0,999978 0,044776 301.000.000 376.000.000 0,529316 0,5086285 0,4913715 0,019392
Phospho-p44/42 
MAP Kinase 
0,999844 0,041702 302.000.000 419.000.000 0,520887  
Phospho-p44/42 
MAP Kinase 
0,999109 0,048491 299.000.000 466.000.000 0,494051  
Phospho-p44/42 
MAP Kinase 
0,998997 0,041227 300.000.000 505.000.000 0,49026  
Phospho-p70 S6 
Kinase 
0,980994 0,028572 476.000.000 374.000.000 0,546894 0,5228135 0,4771865 0,02793771
Phospho-p70 S6 
Kinase 
0,989572 0,030864 473.000.000 421.000.000 0,539685  
Phospho-p70 S6 
Kinase 
0,992335 0,028483 473.000.000 465.000.000 0,520205  
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Phospho-p70 S6 
Kinase 
0,993885 0,025576 474.000.000 508.000.000 0,48447  
Phospho-
SAPK/JNK 
0,999778 0,049143 345.000.000 465.000.000 0,540511 0,52601275 0,47398725 0,01832057
Phospho-
SAPK/JNK 
0,99951 0,054168 343.000.000 508.000.000 0,543076  
Phospho-
SAPK/JNK 
0,998775 0,068958 345.000.000 550.000.000 0,508294  
Phospho-
SAPK/JNK 
0,997972 0,070124 344.000.000 596.000.000 0,51217  
Phospho-Tyrosine 0,9584 0,024496 390.000.000 548.000.000 0,294526 0,28265175 0,71734825 0,01436544
Phospho-Tyrosine 0,973485 0,019885 388.000.000 592.000.000 0,265015  
Phospho-Tyrosine 0,955971 0,029012 344.000.000 202.000.000 0,27686  
Phospho-Tyrosine 0,976426 0,026826 346.000.000 242.000.000 0,294206  
p-Smasd1 0,997594 0,130823 256.000.000 287.000.000 0,497992 0,51131375 0,48868625 0,01626279
p-Smasd1 0,999443 0,12538 256.000.000 330.000.000 0,524759  
p-Smasd1 0,999513 0,144842 259.000.000 375.000.000 0,496501  
p-Smasd1 1.000.000 0,12337 256.000.000 422.000.000 0,526003  
p-Smasd2/3 0,965575 0,035339 212.000.000 201.000.000 0,464221 0,43330925 0,56669075 0,02135499
p-Smasd2/3 0,980414 0,029469 211.000.000 246.000.000 0,430907  
p-Smasd2/3 0,993226 0,033974 209.000.000 287.000.000 0,419504  




























































0,897237 0,031182 81.000.000 641.000.000 0,827117  
 
                                                                                                                    











Substance Background QSV Sigma Mean mean-m-cyto-bmp sd-m-cyto-bmp 1-m-cyto-bmp 
1:100 verd. biotin anti 
rabbit IGG 
0,957429 0,037743 0,056072 0,698753 0,71435075 0,01520994 0,28564925
1:100 verd. biotin anti 
rabbit IGG 
0,973067 0,034792 0,051628 0,703853   
1:100 verd. biotin anti 
rabbit IGG 
0,98233 0,027194 0,046538 0,727246   
1:100 verd. biotin anti 
rabbit IGG 
0,986725 0,027021 0,043333 0,727551   
1:20 verd. biotin anti 
rabbit IGG 
0,994636 0,019338 0,047136 0,798003 0,7102845 0,06576412 0,2897155
1:20 verd. biotin anti 
rabbit IGG 
0,971355 0,050736 0,071598 0,699691   
1:20 verd. biotin anti 
rabbit IGG 
0,898928 0,094754 0,0604 0,638602   
1:20 verd. biotin anti 
rabbit IGG 
0,930187 0,047104 0,055593 0,704842   
1:5 verd. c-Myc 0,998723 0,046631 0,030814 0,621777 0,634799 0,02140388 0,365201
1:5 verd. c-Myc 0,993502 0,035685 0,066459 0,666743   
1:5 verd. c-Myc 1.000.000 0,043264 0,026225 0,6237   
1:5 verd. c-Myc 0,990714 0,043567 0,05908 0,626976   
1:5 verd. p38 (mouse 
monoclonal 10.1) 
0,960604 0,020174 0,021648 0,795908 0,83684125 0,03189102 0,16315875
1:5 verd. p38 (mouse 
monoclonal 10.1) 
0,98182 0,013164 0,020052 0,832936   
1:5 verd. p38 (mouse 
monoclonal 10.1) 
0,994756 0,012229 0,021204 0,845936   
1:5 verd. p38 (mouse 
monoclonal 10.1) 
0,998108 0,009443 0,024921 0,872585   
1:5 verd. Phospho Stat3 
6E4 
0,977155 0,024825 0,033687 0,722501 0,675519 0,0690048 0,324481
1:5 verd. Phospho Stat3 
6E4 
0,993434 0,026862 0,039263 0,71495   
1:5 verd. Phospho Stat3 
6E4 
0,995285 0,030507 0,038227 0,690576   
1:5 verd. Phospho Stat3 
6E4 
0,981835 0,065421 0,04291 0,574049   
1:5 verd. Phospho-Akt 
4E2 
0,995622 0,03245 0,055733 0,684005 0,71552 0,11495733 0,28448
1:5 verd. Phospho-Akt 
4E2 
0,998472 0,067313 0,076127 0,57319   
1:5 verd. Phospho-Akt 
4E2 
0,963534 0,021766 0,028047 0,761924   
1:5 verd. Phospho-Akt 
4E2 
0,963061 0,011187 0,023739 0,842961   
1:5 verd. phospho-p38 
(mouse monoclonal 9.1) 
0,991413 0,016468 0,030951 0,810882 0,82409775 0,0120014 0,17590225
1:5 verd. phospho-p38 
(mouse monoclonal 9.1) 
0,990895 0,013918 0,026711 0,820225   
1:5 verd. phospho-p38 
(mouse monoclonal 9.1) 
0,997814 0,012674 0,033667 0,825698   
1:5 verd. phospho-p38 
(mouse monoclonal 9.1) 
0,994636 0,011998 0,030053 0,839586   
1:5 verd. Phospho-
p44/42 MAP Kinase 
0,992909 0,01071 0,029962 0,847885 0,8906115 0,03426161 0,1093885
1:5 verd. Phospho-
p44/42 MAP Kinase 
0,997538 0,007979 0,025909 0,878222   
1:5 verd. Phospho-
p44/42 MAP Kinase 
0,999407 0,005554 0,024258 0,914732   
1:5 verd. Phospho-
p44/42 MAP Kinase 
0,99943 0,007873 0,041663 0,921607   
1:5 verd. Phospho-p70 
S6 Kinase 
0,917077 0,040602 0,037143 0,674029 0,7235675 0,05235058 0,2764325
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1:5 verd. Phospho-p70 
S6 Kinase 
0,929845 0,03234 0,034834 0,69937   
1:5 verd. Phospho-p70 
S6 Kinase 
0,993744 0,026303 0,033552 0,725338   
1:5 verd. Phospho-p70 
S6 Kinase 
0,999549 0,015791 0,0378 0,795533   
1:5 verd. Phospho-
SAPK/JNK 
0,991255 0,024022 0,050872 0,740345 0,73347925 0,01412561 0,26652075
1:5 verd. Phospho-
SAPK/JNK 
0,939862 0,027363 0,053803 0,72113   
1:5 verd. Phospho-
SAPK/JNK 
1.000.000 0,025255 0,051722 0,722366   
1:5 verd. Phospho-
SAPK/JNK 
0,998039 0,021063 0,057971 0,750076   
1:5 verd. Phospho-
Tyrosine 
0,999775 0,00676 0,018931 0,890499 0,88996075 0,00451533 0,11003925
1:5 verd. Phospho-
Tyrosine 
0,992202 0,007067 0,031859 0,883416   
1:5 verd. Phospho-
Tyrosine 
1.000.000 0,006455 0,02356 0,892931   
1:5 verd. Phospho-
Tyrosine 
0,997295 0,006212 0,031022 0,892997   
1:5 verd. p-Smasd1 1.000.000 0,122971 0,059966 0,492835 0,49537075 0,00466202 0,50462925
1:5 verd. p-Smasd1 0,997461 0,115464 0,058836 0,498239   
1:5 verd. p-Smasd1 0,995126 0,129884 0,05513 0,49018   
1:5 verd. p-Smasd1 0,999977 0,12527 0,060241 0,500229   
1:5 verd. p-Smasd2/3 1.000.000 0,099042 0,038915 0,474643 0,458613 0,01530999 0,541387
1:5 verd. p-Smasd2/3 0,975262 0,110529 0,03021 0,464435   
1:5 verd. p-Smasd2/3 1.000.000 0,112174 0,018928 0,457003   
1:5 verd. p-Smasd2/3 0,995714 0,120932 0,030687 0,438371   
2% Milchpulver 0,983593 0,00828 0,032847 0,909098 0,87075275 0,03225717 0,12924725
2% Milchpulver 0,974974 0,025265 0,050163 0,882032   
2% Milchpulver 0,960648 0,042783 0,044965 0,858038   
2% Milchpulver 0,925011 0,067 0,041049 0,833843   
c-Myc 1.000.000 0,006533 0,063853 0,883587 0,83398825 0,03317877 0,16601175
c-Myc 0,997927 0,012848 0,097295 0,821308   
c-Myc 0,995782 0,013493 0,062145 0,815229   
c-Myc 0,996418 0,012791 0,05275 0,815829   
p38 (mouse monoclonal 
10.1) 
0,99715 0,018669 0,044036 0,781739 0,792147 0,00934304 0,207853
p38 (mouse monoclonal 
10.1) 
1.000.000 0,016235 0,05592 0,803922   
p38 (mouse monoclonal 
10.1) 
0,998837 0,017372 0,058496 0,788821   
p38 (mouse monoclonal 
10.1) 
0,99329 0,016725 0,052484 0,794106   
Phospho Stat3 6E4 0,994756 0,293675 0,043039 0,276941 0,28968625 0,01418266 0,71031375
Phospho Stat3 6E4 0,99373 0,249154 0,04036 0,307952   
Phospho Stat3 6E4 0,990264 0,282852 0,022657 0,280139   
Phospho Stat3 6E4 0,934648 0,259882 0,028184 0,293713   
Phospho-Akt 4E2 0,992928 0,069526 0,051893 0,569036 0,58299425 0,01254115 0,41700575
Phospho-Akt 4E2 0,993821 0,059559 0,061482 0,598861   
Phospho-Akt 4E2 0,955974 0,061234 0,05649 0,585463   
Phospho-Akt 4E2 0,977109 0,060985 0,069973 0,578617   
phospho-p38 (mouse 
monoclonal 9.1) 
0,999796 0,050829 0,067425 0,641822 0,601079 0,03651183 0,398921
phospho-p38 (mouse 
monoclonal 9.1) 
0,993776 0,058303 0,068461 0,614452   
phospho-p38 (mouse 
monoclonal 9.1) 
0,999635 0,066646 0,076836 0,592679   
phospho-p38 (mouse 
monoclonal 9.1) 
0,995144 0,080521 0,083991 0,555363   
Phospho-p44/42 MAP 
Kinase 
0,999111 0,115178 0,038596 0,453383 0,437403 0,01346586 0,562597
Phospho-p44/42 MAP 0,993109 0,121441 0,061241 0,439755   
                                                                                                                    




0,980527 0,127305 0,035755 0,435822   
Phospho-p44/42 MAP 
Kinase 
0,984832 0,142298 0,044164 0,420652   
Phospho-p70 S6 Kinase 0,956705 0,06321 0,028104 0,571055 0,54188775 0,01963213 0,45811225
Phospho-p70 S6 Kinase 0,98517 0,088094 0,054947 0,533048   
Phospho-p70 S6 Kinase 0,977417 0,071792 0,026509 0,534948   
Phospho-p70 S6 Kinase 0,996192 0,074274 0,025842 0,5285   
Phospho-SAPK/JNK 0,980301 0,072 0,067288 0,56265 0,5077425 0,07008605 0,4922575
Phospho-SAPK/JNK 1.000.000 0,078859 0,064476 0,553872   
Phospho-SAPK/JNK 1.000.000 0,103546 0,063847 0,504601   
Phospho-SAPK/JNK 0,999773 0,157545 0,052741 0,409847   
Phospho-Tyrosine 0,999592 0,20575 0,025326 0,333884 0,3075615 0,02081607 0,6924385
Phospho-Tyrosine 0,982467 0,266907 0,022111 0,285387   
Phospho-Tyrosine 0,993284 0,256995 0,027917 0,298182   
Phospho-Tyrosine 0,992946 0,234181 0,027364 0,312793   
p-Smasd1 0,999617 0,036548 0,097028 0,642025 0,6420925 0,03009513 0,3579075
p-Smasd1 1.000.000 0,045835 0,129663 0,619024   
p-Smasd1 1.000.000 0,046944 0,088005 0,622698   
p-Smasd1 0,996534 0,024952 0,071195 0,684623   
p-Smasd2/3 0,997824 0,107761 0,033248 0,473494 0,49401675 0,01645004 0,50598325
p-Smasd2/3 0,996466 0,099274 0,028439 0,4886   
p-Smasd2/3 0,991154 0,086241 0,03563 0,510512   
p-Smasd2/3 0,991632 0,088377 0,033488 0,503461   
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,912905 0,032069 0,02387 0,854355 0,91456425 0,04014776 0,08543575
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,997697 0,004158 0,027548 0,934426   
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,999134 0,003765 0,041416 0,935719   
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,999482 0,004454 0,02829 0,933757   
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,99927 0,005589 0,044376 0,910016 0,92134575 0,0101917 0,07865425
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,99728 0,004882 0,026497 0,919449   
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,975885 0,00538 0,03272 0,92117   
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,990706 0,004449 0,027694 0,934748   
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,958413 0,007896 0,032357 0,910203 0,8540685 0,0642775 0,1459315
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,969106 0,008451 0,039891 0,908753   
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,86311 0,096285 0,036594 0,791146   
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 







                                                                                                                    











Substance Background QSV Sigma Mean mean-m-nu-con sd-m-nu-con 1-mean-m-nu-con 
1:100 verd. biotin anti 
rabbit IGG 
0,976471 1.100.999 0,065448 0,461112 0,489059 0,02278294 0,510941
1:100 verd. biotin anti 
rabbit IGG 
0,951742 0,978392 0,051954 0,480017  
1:100 verd. biotin anti 
rabbit IGG 
0,954432 0,872261 0,079413 0,509823  
1:100 verd. biotin anti 
rabbit IGG 
0,987543 0,937464 0,073373 0,505284  
1:20 verd. biotin anti 
rabbit IGG 
0,992111 0,998337 0,096941 0,491247 0,49475975 0,04195834 0,50524025
1:20 verd. biotin anti 
rabbit IGG 
0,990496 0,767041 0,105174 0,555123  
1:20 verd. biotin anti 
rabbit IGG 
0,922096 1.093.436 0,093823 0,46416  
1:20 verd. biotin anti 
rabbit IGG 
0,933769 1.061.621 0,089214 0,468509  
1:5 verd. c-Myc 0,956724 2.208.622 0,021933 0,262308 0,2583685 0,00638324 0,7416315
1:5 verd. c-Myc 0,999794 2.269.017 0,020389 0,255655  
1:5 verd. c-Myc 0,914325 2.315.702 0,02293 0,250734  
1:5 verd. c-Myc 0,970003 2.228.133 0,024785 0,264777  
1:5 verd. p38 (mouse 
monoclonal 10.1) 
0,969935 0,185911 0,026828 0,839225 0,83689175 0,00388206 0,16310825
1:5 verd. p38 (mouse 
monoclonal 10.1) 
0,984245 0,191746 0,037871 0,834288  
1:5 verd. p38 (mouse 
monoclonal 10.1) 
0,952689 0,186168 0,035218 0,841086  
1:5 verd. p38 (mouse 
monoclonal 10.1) 
0,974925 0,187954 0,031741 0,832968  
1:5 verd. Phospho Stat3 
6E4 
0,934663 0,802863 0,042294 0,561791 0,5499145 0,03319934 0,4500855
1:5 verd. Phospho Stat3 
6E4 
0,971811 0,794494 0,046101 0,563234  
1:5 verd. Phospho Stat3 
6E4 
0,931315 0,976883 0,070875 0,500774  
1:5 verd. Phospho Stat3 
6E4 
0,965738 0,73598 0,048117 0,573859  
1:5 verd. Phospho-Akt 
4E2 
0,951596 0,762242 0,065278 0,562664 0,548476 0,0287784 0,451524
1:5 verd. Phospho-Akt 
4E2 
0,965375 0,73687 0,075522 0,572578  
1:5 verd. Phospho-Akt 
4E2 
0,919954 0,995093 0,036086 0,507316  
1:5 verd. Phospho-Akt 
4E2 
0,866369 0,767312 0,050361 0,551346  
1:5 verd. phospho-p38 
(mouse monoclonal 9.1) 
0,921844 0,922083 0,059981 0,510534 0,47001375 0,02833973 0,52998625
1:5 verd. phospho-p38 
(mouse monoclonal 9.1) 
0,975581 1.066.327 0,038694 0,468554  
1:5 verd. phospho-p38 
(mouse monoclonal 9.1) 
0,958101 1.168.672 0,042391 0,449357  
1:5 verd. phospho-p38 
(mouse monoclonal 9.1) 
0,998234 1.205.739 0,055813 0,45161  
1:5 verd. Phospho-
p44/42 MAP Kinase 
0,918748 0,971604 0,048388 0,49539 0,526647 0,04876938 0,473353
1:5 verd. Phospho-
p44/42 MAP Kinase 
0,934302 0,989119 0,041327 0,486515  
1:5 verd. Phospho-
p44/42 MAP Kinase 
0,920041 0,852619 0,03732 0,530722  
1:5 verd. Phospho-
p44/42 MAP Kinase 
0,963789 0,710735 0,057031 0,593961  
1:5 verd. Phospho-p70 
S6 Kinase 
0,930265 2.058.014 0,035936 0,301467 0,31475 0,01307042 0,68525
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1:5 verd. Phospho-p70 
S6 Kinase 
0,918878 1.883.064 0,035337 0,308898  
1:5 verd. Phospho-p70 
S6 Kinase 
0,92729 1.829.603 0,028783 0,316612  
1:5 verd. Phospho-p70 
S6 Kinase 
0,975806 1.804.187 0,046281 0,332023  
1:5 verd. Phospho-
SAPK/JNK 
0,912785 1.521.760 0,065907 0,382988 0,3693005 0,01285257 0,6306995
1:5 verd. Phospho-
SAPK/JNK 
0,991234 1.546.301 0,082602 0,374904  
1:5 verd. Phospho-
SAPK/JNK 
0,977342 1.680.293 0,074564 0,352919  
1:5 verd. Phospho-
SAPK/JNK 
0,936424 1.585.028 0,084529 0,366391  
1:5 verd. Phospho-
Tyrosine 
0,927348 0,767537 0,044706 0,575303 0,573185 0,00164086 0,426815
1:5 verd. Phospho-
Tyrosine 
0,911753 0,780675 0,039297 0,572234  
1:5 verd. Phospho-
Tyrosine 
0,935933 0,770357 0,045212 0,573603  
1:5 verd. Phospho-
Tyrosine 
0,948584 0,770647 0,052781 0,5716  
1:5 verd. p-Smasd1 0,993556 1.460.478 0,052034 0,387225 0,3724355 0,01388217 0,6275645
1:5 verd. p-Smasd1 0,926015 1.543.375 0,046103 0,366278  
1:5 verd. p-Smasd1 0,930894 1.596.287 0,033023 0,356198  
1:5 verd. p-Smasd1 0,934279 1.438.445 0,042103 0,380041  
1:5 verd. p-Smasd2/3 0,932989 2.965.489 0,022502 0,178958 0,17871375 0,007186 0,82128625
1:5 verd. p-Smasd2/3 0,964683 3.069.012 0,023505 0,171637  
1:5 verd. p-Smasd2/3 0,992664 3.049.379 0,019942 0,175749  
1:5 verd. p-Smasd2/3 0,941016 2.893.775 0,029441 0,188511  
2% Milchpulver 0,992249 0,384987 0,064162 0,750121 0,7548405 0,01578584 0,2451595
2% Milchpulver 0,990473 0,32363 0,061179 0,75084  
2% Milchpulver 0,967009 0,331701 0,061147 0,74088  
2% Milchpulver 0,958478 0,259751 0,061439 0,777521  
c-Myc 0,992065 0,965179 0,112489 0,488023 0,48590425 0,00481375 0,51409575
c-Myc 0,981814 0,992877 0,109312 0,481936  
c-Myc 0,977439 1.014.602 0,098786 0,481952  
c-Myc 0,976631 0,988221 0,110135 0,491706  
p38 (mouse monoclonal 
10.1) 
0,973956 0,293444 0,034407 0,780069 0,782698 0,00643885 0,217302
p38 (mouse monoclonal 
10.1) 
0,997492 0,309861 0,033678 0,791084  
p38 (mouse monoclonal 
10.1) 
0,998267 0,306133 0,039014 0,783729  
p38 (mouse monoclonal 
10.1) 
0,995184 0,289691 0,032014 0,77591  
Phospho Stat3 6E4 0,940264 1.487.043 0,040513 0,388797 0,42282825 0,02612733 0,57717175
Phospho Stat3 6E4 0,921546 1.351.012 0,047012 0,416389  
Phospho Stat3 6E4 0,895755 1.259.298 0,041487 0,43923  
Phospho Stat3 6E4 0,937026 1.235.161 0,046235 0,446897  
Phospho-Akt 4E2 0,89109 1.184.945 0,043309 0,450093 0,44087325 0,00698436 0,55912675
Phospho-Akt 4E2 0,916986 1.277.849 0,053025 0,438227  
Phospho-Akt 4E2 0,912327 1.291.968 0,045869 0,433541  
Phospho-Akt 4E2 0,934457 1.247.294 0,04258 0,441632  
phospho-p38 (mouse 
monoclonal 9.1) 
0,957463 0,582884 0,049607 0,61948 0,611138 0,01296965 0,388862
phospho-p38 (mouse 
monoclonal 9.1) 
0,996973 0,660735 0,05437 0,593119  
phospho-p38 (mouse 
monoclonal 9.1) 
0,996262 0,624319 0,055386 0,61034  
phospho-p38 (mouse 
monoclonal 9.1) 
0,983878 0,599799 0,042469 0,621613  
Phospho-p44/42 MAP 
Kinase 
0,988258 0,525511 0,042774 0,666745 0,65214425 0,01426587 0,34785575
Phospho-p44/42 MAP 0,93503 0,533233 0,054505 0,660998  
                                                                                                                    




0,947197 0,573497 0,043232 0,645103  
Phospho-p44/42 MAP 
Kinase 
0,976171 0,592828 0,037857 0,635731  
Phospho-p70 S6 Kinase 0,969066 0,840646 0,041345 0,550178 0,5620115 0,00866573 0,4379885
Phospho-p70 S6 Kinase 0,997409 0,805221 0,033118 0,564088  
Phospho-p70 S6 Kinase 0,977024 0,801737 0,038906 0,562807  
Phospho-p70 S6 Kinase 0,999404 0,775553 0,040436 0,570973  
Phospho-SAPK/JNK 0,945648 0,353605 0,051871 0,744224 0,72404475 0,01884331 0,27595525
Phospho-SAPK/JNK 0,962007 0,377237 0,055663 0,733675  
Phospho-SAPK/JNK 0,989808 0,394874 0,059697 0,716917  
Phospho-SAPK/JNK 0,974325 0,423606 0,052582 0,701363  
Phospho-Tyrosine 0,971127 1.630.934 0,034703 0,370527 0,3721625 0,00445518 0,6278375
Phospho-Tyrosine 0,992572 1.634.123 0,04017 0,370774  
Phospho-Tyrosine 0,930719 1.618.757 0,033671 0,368656  
Phospho-Tyrosine 0,937003 1.552.724 0,028666 0,378693  
p-Smasd1 0,90375 1.450.541 0,100056 0,355413 0,3715955 0,01950763 0,6284045
p-Smasd1 0,965761 1.429.725 0,0851 0,367184  
p-Smasd1 0,975709 1.257.509 0,126156 0,399896  
p-Smasd1 0,967328 1.473.151 0,134482 0,363889  
p-Smasd2/3 0,942919 2.388.876 0,025475 0,230148 0,233614 0,01938308 0,766386
p-Smasd2/3 0,930848 1.949.108 0,036246 0,261734  
p-Smasd2/3 0,923599 2.462.358 0,02104 0,218089  
p-Smasd2/3 0,964843 2.371.857 0,019726 0,224485  
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,924688 1.119.038 0,187 0,318534 0,76721125 0,30146548 0,23278875
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,989965 0,122723 0,049373 0,881399  
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,988327 0,104623 0,049053 0,900159  
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,878294 0,02191 0,041596 0,968753  
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,799794 2.731.872 0,071434 0,169691 0,72696175 0,37643154 0,27303825
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,996078 0,00275 0,005866 0,998471  
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,973287 0,142601 0,065653 0,868369  
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,993418 0,138367 0,06751 0,871316  
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,961931 0,144199 0,066105 0,866697 0,8564455 0,02613726 0,1435545
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,987209 0,153774 0,059636 0,855416  
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 
0,883133 0,1787 0,044824 0,821006  
Wisp2_129_158r(bio)_1,
25 µM, htag4(bio)_1,25 
µM 







                                                                                                                    













Substance Background QSV Sigma Mean mean-m-nu-bmp2 sd-m-nu-bmp2 1-mean-m-nu-bmp2
1:100 verd. biotin 
anti rabbit IGG 
0,910158 1.884.010 0,045124 0,295447 0,293294 0,00433036 0,706706
1:100 verd. biotin 
anti rabbit IGG 
0,910562 1.879.501 0,043082 0,295067  
1:100 verd. biotin 
anti rabbit IGG 
0,909582 1.945.232 0,043499 0,286816  
1:100 verd. biotin 
anti rabbit IGG 
0,913615 1.884.252 0,04661 0,295846  
1:20 verd. biotin anti 
rabbit IGG 
0,911178 1.685.619 0,033228 0,325142 0,33471075 0,01697376 0,66528925
1:20 verd. biotin anti 
rabbit IGG 
0,900178 1.775.375 0,034298 0,315681  
1:20 verd. biotin anti 
rabbit IGG 
0,890728 1.597.172 0,052271 0,348089  
1:20 verd. biotin anti 
rabbit IGG 
0,915143 1.564.510 0,050624 0,349931  
1:5 verd. c-Myc 0,990828 1.940.456 0,021789 0,271509 0,273382 0,01056101 0,726618
1:5 verd. c-Myc 0,997297 2.022.611 0,020974 0,26208  
1:5 verd. c-Myc 0,996123 1.917.309 0,028331 0,272335  
1:5 verd. c-Myc 0,994129 1.822.819 0,02605 0,287604  
1:5 verd. p38 
(mouse monoclonal 
10.1) 
0,987704 0,619277 0,090314 0,617799 0,46282375 0,1170956 0,53717625
1:5 verd. p38 
(mouse monoclonal 
10.1) 
0,990274 0,961432 0,077111 0,487836  
1:5 verd. p38 
(mouse monoclonal 
10.1) 
0,965304 1.370.953 0,048175 0,384943  
1:5 verd. p38 
(mouse monoclonal 
10.1) 
0,949086 1.481.288 0,041685 0,360717  
1:5 verd. Phospho 
Stat3 6E4 
0,974942 1.444.117 0,031653 0,364571 0,371402 0,02146327 0,628598
1:5 verd. Phospho 
Stat3 6E4 
0,966035 1.310.799 0,039042 0,394426  
1:5 verd. Phospho 
Stat3 6E4 
0,960563 1.388.896 0,031622 0,381665  
1:5 verd. Phospho 
Stat3 6E4 
0,991271 1.559.545 0,035809 0,344946  
1:5 verd. Phospho-
Akt 4E2 
0,931738 1.482.400 0,038276 0,362537 0,32903575 0,02667176 0,67096425
1:5 verd. Phospho-
Akt 4E2 
0,94142 1.610.982 0,029156 0,336866  
1:5 verd. Phospho-
Akt 4E2 
0,90781 1.785.662 0,025243 0,301429  
1:5 verd. Phospho-
Akt 4E2 
















0,970677 1.614.310 0,033727 0,334967  
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1:5 verd. Phospho-
p44/42 MAP Kinase 
0,946427 1.363.012 0,03674 0,379293 0,442498 0,05167282 0,557502
1:5 verd. Phospho-
p44/42 MAP Kinase 
0,974033 1.175.618 0,031455 0,424235  
1:5 verd. Phospho-
p44/42 MAP Kinase 
0,996433 1.009.352 0,029896 0,469754  
1:5 verd. Phospho-
p44/42 MAP Kinase 
0,997883 0,890356 0,022517 0,49671  
1:5 verd. Phospho-
p70 S6 Kinase 
0,856662 1.957.896 0,021703 0,267768 0,26675675 0,00612284 0,73324325
1:5 verd. Phospho-
p70 S6 Kinase 
0,840279 2.019.500 0,015844 0,266144  
1:5 verd. Phospho-
p70 S6 Kinase 
0,88962 1.951.758 0,016205 0,274007  
1:5 verd. Phospho-
p70 S6 Kinase 
0,957771 2.061.182 0,023789 0,259108  
1:5 verd. Phospho-
SAPK/JNK 
0,997186 1.627.678 0,063699 0,322445 0,30333625 0,03112836 0,69666375
1:5 verd. Phospho-
SAPK/JNK 
0,987925 1.752.678 0,052897 0,296219  
1:5 verd. Phospho-
SAPK/JNK 
0,99102 1.975.883 0,045339 0,262561  
1:5 verd. Phospho-
SAPK/JNK 
0,999712 1.538.824 0,069984 0,33212  
1:5 verd. Phospho-
Tyrosine 
0,979256 1.608.723 0,03311 0,323354 0,49048175 0,17834084 0,50951825
1:5 verd. Phospho-
Tyrosine 
0,988213 1.406.409 0,060497 0,361506  
1:5 verd. Phospho-
Tyrosine 
0,957483 0,472277 0,059922 0,697742  
1:5 verd. Phospho-
Tyrosine 
0,977711 0,74286 0,043827 0,579325  
1:5 verd. p-Smasd1 0,998173 1.884.289 0,037708 0,285401 0,25531325 0,02942676 0,74468675
1:5 verd. p-Smasd1 0,995325 2.283.454 0,031066 0,23913  
1:5 verd. p-Smasd1 0,965548 2.376.303 0,020248 0,222535  
1:5 verd. p-Smasd1 0,983139 1.958.412 0,029002 0,274187  
1:5 verd. p-
Smasd2/3 
0,978974 1.975.533 0,028085 0,260314 0,25587025 0,00941325 0,74412975
1:5 verd. p-
Smasd2/3 
0,983489 1.983.083 0,033456 0,261985  
1:5 verd. p-
Smasd2/3 
0,995857 2.035.284 0,036276 0,259336  
1:5 verd. p-
Smasd2/3 
0,993996 2.186.207 0,030079 0,241846  
2% Milchpulver 0,892035 0,60821 0,027294 0,624488 0,597176 0,02278158 0,402824
2% Milchpulver 0,885233 0,639897 0,035453 0,605555  
2% Milchpulver 0,855258 0,681071 0,029 0,586539  
2% Milchpulver 0,841476 0,73084 0,028868 0,572122  
c-Myc 0,995835 2.441.020 0,044077 0,204178 0,22181325 0,01959016 0,77818675
c-Myc 0,999712 2.338.907 0,049758 0,218943  
c-Myc 0,99922 1.998.204 0,088317 0,249699  
c-Myc 0,989277 2.280.564 0,049237 0,214433  
p38 (mouse 
monoclonal 10.1) 
0,940887 0,257724 0,03838 0,87831 0,86441575 0,01689283 0,13558425
p38 (mouse 
monoclonal 10.1) 
0,946006 0,253557 0,030557 0,879708  
p38 (mouse 
monoclonal 10.1) 
0,933444 0,280071 0,058625 0,851102  
p38 (mouse 
monoclonal 10.1) 
0,923784 0,283515 0,056582 0,848543  
Phospho Stat3 6E4 0,948288 2.208.675 0,030527 0,237307 0,25564025 0,01445701 0,74435975
Phospho Stat3 6E4 0,96876 1.931.103 0,042722 0,265233  
Phospho Stat3 6E4 0,949352 1.882.470 0,039319 0,268974  
Phospho Stat3 6E4 0,96249 2.010.034 0,036798 0,251047  
Phospho-Akt 4E2 0,948377 1.586.499 0,034364 0,324189 0,3154635 0,00616246 0,6845365
Phospho-Akt 4E2 0,938606 1.657.542 0,046938 0,315045  
Phospho-Akt 4E2 0,90488 1.658.455 0,055112 0,312558  
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0,977689 0,517616 0,059895 0,66799  
Phospho-p44/42 
MAP Kinase 
0,991377 0,588502 0,047094 0,601215 0,62161775 0,03304709 0,37838225
Phospho-p44/42 
MAP Kinase 
0,991087 0,613079 0,044718 0,589061  
Phospho-p44/42 
MAP Kinase 
0,996101 0,542847 0,060759 0,633995  
Phospho-p44/42 
MAP Kinase 
0,996167 0,52182 0,060948 0,6622  
Phospho-p70 S6 
Kinase 
0,951944 1.261.705 0,036758 0,395533 0,4011145 0,00610657 0,5988855
Phospho-p70 S6 
Kinase 
0,946569 1.265.476 0,032618 0,401747  
Phospho-p70 S6 
Kinase 
0,943348 1.270.341 0,047426 0,397755  
Phospho-p70 S6 
Kinase 
0,949729 1.219.100 0,04608 0,409423  
Phospho-
SAPK/JNK 
0,957483 0,026827 0,018664 0,997508 0,9566505 0,0499752 0,0433495
Phospho-
SAPK/JNK 
1.000.000 0,082061 0,006961 0,998788  
Phospho-
SAPK/JNK 
1.000.000 0,212901 0,033213 0,932525  
Phospho-
SAPK/JNK 
1.000.000 0,248385 0,062745 0,897781  
Phospho-Tyrosine 0,969802 2.448.546 0,030465 0,203238 0,20323325 0,04084044 0,79676675
Phospho-Tyrosine 0,991603 2.800.159 0,02925 0,176205  
Phospho-Tyrosine 0,971685 2.884.445 0,029412 0,17254  
Phospho-Tyrosine 0,995968 1.988.042 0,094095 0,26095  
p-Smasd1 0,99844 1.777.349 0,092079 0,28396 0,26628275 0,01613355 0,73371725
p-Smasd1 0,99805 1.789.978 0,080766 0,275773  
p-Smasd1 0,99668 1.961.879 0,064194 0,250544  
p-Smasd1 0,990441 1.937.117 0,067157 0,254854  
p-Smasd2/3 0,987504 2.230.721 0,025368 0,232901 0,2419325 0,008 0,7580675
p-Smasd2/3 0,993605 2.056.766 0,027858 0,252319  
p-Smasd2/3 0,994616 2.140.245 0,024463 0,242159  




























0,943459 0,523054 0,146818 0,653681  
                                                                                                                    





























Spot ID Substance Valid Background QSV Sigma Mean mean-k-cyto-con 
112 1:100 verd. biotin anti rabbit IGG 0 1.000.000 0,132254 0,031706 0,719467 0,72610625
113 1:100 verd. biotin anti rabbit IGG 0 1.000.000 0,136887 0,031602 0,712933 
114 1:100 verd. biotin anti rabbit IGG 0 0,993979 0,122861 0,064943 0,738309 
115 1:100 verd. biotin anti rabbit IGG 0 1.000.000 0,14789 0,036854 0,733716 
106 1:20 verd. biotin anti rabbit IGG 0 1.000.000 0,107473 0,033034 0,775122 0,7641495
107 1:20 verd. biotin anti rabbit IGG 0 1.000.000 0,104288 0,039178 0,772493 
110 1:20 verd. biotin anti rabbit IGG 0 1.000.000 0,16241 0,03619 0,753705 
111 1:20 verd. biotin anti rabbit IGG 0 1.000.000 0,115968 0,036746 0,755278 
78 1:5 verd. c-Myc 0 1.000.000 0,199298 0,040985 0,622969 0,6360385
79 1:5 verd. c-Myc 0 1.000.000 0,204877 0,038356 0,616271 
80 1:5 verd. c-Myc 0 1.000.000 0,186199 0,044133 0,640108 
81 1:5 verd. c-Myc 0 1.000.000 0,166905 0,043968 0,664806 
98 1:5 verd. p38 (mouse monoclonal 10.1) 0 1.000.000 0,161992 0,04371 0,718748 0,717692
99 1:5 verd. p38 (mouse monoclonal 10.1) 0 1.000.000 0,132957 0,04016 0,718726 
100 1:5 verd. p38 (mouse monoclonal 10.1) 0 1.000.000 0,137273 0,046234 0,709175 
101 1:5 verd. p38 (mouse monoclonal 10.1) 0 1.000.000 0,129048 0,042592 0,724119 
20 1:5 verd. Phospho Stat3 6E4 0 1.000.000 0,083647 0,045255 0,809156 0,82517525
21 1:5 verd. Phospho Stat3 6E4 0 1.000.000 0,080377 0,047519 0,818561 
22 1:5 verd. Phospho Stat3 6E4 0 1.000.000 0,073789 0,035442 0,833733 
23 1:5 verd. Phospho Stat3 6E4 0 1.000.000 0,07181 0,040936 0,839251 
10 1:5 verd. Phospho-Akt 4E2 0 0,999931 0,069696 0,050396 0,847746 0,855057
11 1:5 verd. Phospho-Akt 4E2 0 1.000.000 0,064819 0,037479 0,859555 
14 1:5 verd. Phospho-Akt 4E2 0 1.000.000 0,066349 0,038104 0,850004 
15 1:5 verd. Phospho-Akt 4E2 0 0,999931 0,064009 0,037195 0,862923 
88 1:5 verd. phospho-p38 (mouse monoclonal 
9.1) 
0 1.000.000 0,135141 0,032353 0,715108 0,72772925
89 1:5 verd. phospho-p38 (mouse monoclonal 
9.1) 
0 1.000.000 0,134593 0,036922 0,715512 
90 1:5 verd. phospho-p38 (mouse monoclonal 
9.1) 
0 1.000.000 0,132444 0,0335 0,725603 
91 1:5 verd. phospho-p38 (mouse monoclonal 
9.1) 
0 1.000.000 0,11113 0,038052 0,754694 
50 1:5 verd. Phospho-p44/42 MAP Kinase 0 1.000.000 0,106788 0,035996 0,762099 0,7671385
51 1:5 verd. Phospho-p44/42 MAP Kinase 0 1.000.000 0,090257 0,0382 0,792561 
52 1:5 verd. Phospho-p44/42 MAP Kinase 0 1.000.000 0,104888 0,035762 0,761605 
53 1:5 verd. Phospho-p44/42 MAP Kinase 0 1.000.000 0,110804 0,032608 0,752289 
2 1:5 verd. Phospho-p70 S6 Kinase 0 0,988097 0,101948 0,036669 0,771976 0,78226925
3 1:5 verd. Phospho-p70 S6 Kinase 0 0,999014 0,098517 0,033309 0,776329 
4 1:5 verd. Phospho-p70 S6 Kinase 0 0,999792 0,083487 0,038589 0,810956 
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5 1:5 verd. Phospho-p70 S6 Kinase 0 1.000.000 0,105995 0,12524 0,769816 
40 1:5 verd. Phospho-SAPK/JNK 0 1.000.000 0,058644 0,053921 0,869281 0,878055
41 1:5 verd. Phospho-SAPK/JNK 0 1.000.000 0,059985 0,050689 0,865542 
42 1:5 verd. Phospho-SAPK/JNK 0 1.000.000 0,051287 0,040704 0,892855 
43 1:5 verd. Phospho-SAPK/JNK 0 1.000.000 0,053556 0,039155 0,884542 
30 1:5 verd. Phospho-Tyrosine 0 1.000.000 0,080334 0,042583 0,816446 0,8253
31 1:5 verd. Phospho-Tyrosine 0 1.000.000 0,087749 0,043411 0,801094 
32 1:5 verd. Phospho-Tyrosine 0 1.000.000 0,074606 0,043944 0,831038 
33 1:5 verd. Phospho-Tyrosine 0 1.000.000 0,066315 0,042427 0,852622 
58 1:5 verd. p-Smasd1 0 1.000.000 0,09844 0,031776 0,777468 0,77502025
59 1:5 verd. p-Smasd1 0 1.000.000 0,09295 0,031894 0,793695 
62 1:5 verd. p-Smasd1 0 1.000.000 0,105932 0,040119 0,763282 
63 1:5 verd. p-Smasd1 0 1.000.000 0,102999 0,036519 0,765636 
68 1:5 verd. p-Smasd2/3 0 1.000.000 0,17263 0,033315 0,653756 0,6512855
69 1:5 verd. p-Smasd2/3 0 1.000.000 0,183963 0,029749 0,646576 
70 1:5 verd. p-Smasd2/3 0 1.000.000 0,175455 0,031245 0,651104 
71 1:5 verd. p-Smasd2/3 0 1.000.000 0,191911 0,032168 0,653706 
116 2% Milchpulver 0 1.000.000 0,067579 0,033637 0,860137 0,86017675
117 2% Milchpulver 0 1.000.000 0,069382 0,030508 0,855754 
118 2% Milchpulver 0 1.000.000 0,067401 0,023866 0,856481 
119 2% Milchpulver 0 1.000.000 0,06445 0,028776 0,868335 
82 c-Myc 0 1.000.000 0,100911 0,056148 0,775201 0,758987
83 c-Myc 0 1.000.000 0,102703 0,056161 0,772181 
86 c-Myc 0 1.000.000 0,119775 0,059643 0,738513 
87 c-Myc 0 1.000.000 0,113685 0,051879 0,750053 
102 p38 (mouse monoclonal 10.1) 0 1.000.000 0,055817 0,032197 0,880924 0,88527875
103 p38 (mouse monoclonal 10.1) 0 1.000.000 0,055673 0,037855 0,885606 
104 p38 (mouse monoclonal 10.1) 0 1.000.000 0,059678 0,034436 0,875847 
105 p38 (mouse monoclonal 10.1) 0 1.000.000 0,05072 0,031042 0,898738 
26 Phospho Stat3 6E4 0 1.000.000 0,107867 0,083535 0,759998 0,73236525
27 Phospho Stat3 6E4 0 1.000.000 0,126795 0,098682 0,72491 
28 Phospho Stat3 6E4 0 1.000.000 0,137929 0,078782 0,70928 
29 Phospho Stat3 6E4 0 1.000.000 0,119664 0,077743 0,735273 
16 Phospho-Akt 4E2 0 0,99993 0,073018 0,044928 0,830645 0,82156125
17 Phospho-Akt 4E2 0 1.000.000 0,083907 0,03526 0,806323 
18 Phospho-Akt 4E2 0 1.000.000 0,077711 0,049513 0,821507 
19 Phospho-Akt 4E2 0 1.000.000 0,07481 0,036775 0,82777 
92 phospho-p38 (mouse monoclonal 9.1) 0 1.000.000 0,106853 0,043511 0,763773 0,75769275
93 phospho-p38 (mouse monoclonal 9.1) 0 1.000.000 0,114186 0,057452 0,74857 
94 phospho-p38 (mouse monoclonal 9.1) 0 1.000.000 0,106289 0,051199 0,764184 
95 phospho-p38 (mouse monoclonal 9.1) 0 1.000.000 0,112531 0,050836 0,754244 
54 Phospho-p44/42 MAP Kinase 0 1.000.000 0,075079 0,040533 0,825913 0,8419265
55 Phospho-p44/42 MAP Kinase 0 1.000.000 0,077567 0,040518 0,82069 
56 Phospho-p44/42 MAP Kinase 0 1.000.000 0,065921 0,037003 0,851816 
57 Phospho-p44/42 MAP Kinase 0 1.000.000 0,061014 0,041363 0,869287 
6 Phospho-p70 S6 Kinase 0 1.000.000 0,039284 0,04274 0,93233 0,91163925
7 Phospho-p70 S6 Kinase 0 1.000.000 0,048575 0,037189 0,902486 
8 Phospho-p70 S6 Kinase 0 1.000.000 0,050593 0,034886 0,895425 
9 Phospho-p70 S6 Kinase 0 0,999931 0,044527 0,036814 0,916316 
44 Phospho-SAPK/JNK 0 1.000.000 0,058683 0,049661 0,873498 0,865398
45 Phospho-SAPK/JNK 0 1.000.000 0,059368 0,039445 0,871298 
46 Phospho-SAPK/JNK 0 1.000.000 0,066051 0,041312 0,854228 
47 Phospho-SAPK/JNK 0 1.000.000 0,06265 0,042617 0,862568 
34 Phospho-Tyrosine 0 1.000.000 0,068858 0,040795 0,8456 0,83373775
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35 Phospho-Tyrosine 0 1.000.000 0,065515 0,051164 0,854051 
38 Phospho-Tyrosine 0 1.000.000 0,073661 0,046527 0,829397 
39 Phospho-Tyrosine 0 1.000.000 0,08326 0,043709 0,805903 
64 p-Smasd1 0 1.000.000 0,270665 0,037615 0,545155 0,55973425
65 p-Smasd1 0 0,999931 0,260174 0,037256 0,558904 
66 p-Smasd1 0 0,99993 0,247514 0,038147 0,567374 
67 p-Smasd1 0 1.000.000 0,250738 0,033067 0,567504 
74 p-Smasd2/3 0 1.000.000 0,389303 0,044389 0,453497 0,44511475
75 p-Smasd2/3 0 1.000.000 0,399022 0,049981 0,446337 
76 p-Smasd2/3 0 1.000.000 0,40589 0,047047 0,441998 
77 p-Smasd2/3 0 1.000.000 0,412904 0,04029 0,438627 
1 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0 0,988282 0,011125 0,00258 0,999727 750000,25
12 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0 1.000.000 0,000182 0 1.000.000 
36 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0 1.000.000 0,000499 0 1.000.000 
48 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0 1.000.000 0,001278 0 1.000.000 
60 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0 1.000.000 0,000501 0,001431 0,999927 250000,75
72 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0 1.000.000 0,003142 0,001321 0,999934 
73 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0 1.000.000 0,000459 0,00012 0,999996 
84 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0 1.000.000 0,000078 0 1.000.000 
85 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0 1.000.000 0,000684 0 1.000.000 750000,25
96 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0 1.000.000 0,002465 0 1.000.000 
109 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0 1.000.000 0,004421 0 1.000.000 
120 Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 














Substance QSV Sigma Mean mean-k-cyto-bmp sd-k-cyto-bmp 1-k-cyto-bmp 
1:100 verd. biotin anti rabbit IGG 0,075026 0,047302 0,802564 0,80414425 0,0112371 0,19585575
1:100 verd. biotin anti rabbit IGG 0,079171 0,040207 0,797292  
1:100 verd. biotin anti rabbit IGG 0,082319 0,042039 0,79624  
1:100 verd. biotin anti rabbit IGG 0,077494 0,040499 0,820481  
1:20 verd. biotin anti rabbit IGG 0,047121 0,042619 0,915672 0,89849725 0,02463519 0,10150275
1:20 verd. biotin anti rabbit IGG 0,070511 0,056947 0,862678  
1:20 verd. biotin anti rabbit IGG 0,030033 0,034777 0,913688  
1:20 verd. biotin anti rabbit IGG 0,036632 0,035223 0,901951  
1:5 verd. c-Myc 0,197462 0,04117 0,575572 0,57732125 0,02158108 0,42267875
1:5 verd. c-Myc 0,211504 0,033224 0,562669  
1:5 verd. c-Myc 0,215558 0,037233 0,562664  
1:5 verd. c-Myc 0,181772 0,044257 0,60838  
1:5 verd. p38 (mouse monoclonal 
10.1) 
0,044894 0,03614 0,851787 0,85584675 0,00798426 0,14415325
1:5 verd. p38 (mouse monoclonal 
10.1) 
0,049125 0,040559 0,846988  
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1:5 verd. p38 (mouse monoclonal 
10.1) 
0,046084 0,0318 0,859772  
1:5 verd. p38 (mouse monoclonal 
10.1) 
0,046165 0,036514 0,86484  
1:5 verd. Phospho Stat3 6E4 0,03013 0,037982 0,885836 0,87647525 0,00853775 0,12352475
1:5 verd. Phospho Stat3 6E4 0,036161 0,035144 0,865879  
1:5 verd. Phospho Stat3 6E4 0,033289 0,029056 0,874092  
1:5 verd. Phospho Stat3 6E4 0,032505 0,030885 0,880094  
1:5 verd. Phospho-Akt 4E2 0,015369 0,023544 0,950435 0,955746 0,00521716 0,044254
1:5 verd. Phospho-Akt 4E2 0,013086 0,023058 0,962904  
1:5 verd. Phospho-Akt 4E2 0,012559 0,020393 0,955326  
1:5 verd. Phospho-Akt 4E2 0,013409 0,016059 0,954319  
1:5 verd. phospho-p38 (mouse 
monoclonal 9.1) 
0,088723 0,041432 0,748478 0,7481115 0,01241655 0,2518885
1:5 verd. phospho-p38 (mouse 
monoclonal 9.1) 
0,098484 0,040524 0,732895  
1:5 verd. phospho-p38 (mouse 
monoclonal 9.1) 
0,093378 0,042193 0,747772  
1:5 verd. phospho-p38 (mouse 
monoclonal 9.1) 
0,090136 0,04241 0,763301  
1:5 verd. Phospho-p44/42 MAP 
Kinase 
0,032958 0,030938 0,873048 0,8688755 0,0120979 0,1311245
1:5 verd. Phospho-p44/42 MAP 
Kinase 
0,039728 0,034899 0,851603  
1:5 verd. Phospho-p44/42 MAP 
Kinase 
0,033638 0,036698 0,871094  
1:5 verd. Phospho-p44/42 MAP 
Kinase 
0,031437 0,032247 0,879757  
1:5 verd. Phospho-p70 S6 Kinase 0,021159 0,021327 0,916953 0,913698 0,00385296 0,086302
1:5 verd. Phospho-p70 S6 Kinase 0,0221 0,025342 0,911121  
1:5 verd. Phospho-p70 S6 Kinase 0,021326 0,019114 0,917038  
1:5 verd. Phospho-p70 S6 Kinase 0,022718 0,020472 0,90968  
1:5 verd. Phospho-SAPK/JNK 0,017069 0,027985 0,935597 0,921542 0,01881096 0,078458
1:5 verd. Phospho-SAPK/JNK 0,027107 0,010755 0,894966  
1:5 verd. Phospho-SAPK/JNK 0,020847 0,018097 0,921504  
1:5 verd. Phospho-SAPK/JNK 0,018644 0,031622 0,934101  
1:5 verd. Phospho-Tyrosine 0,0182 0,025542 0,932562 0,93702525 0,00766344 0,06297475
1:5 verd. Phospho-Tyrosine 0,016038 0,014687 0,945658  
1:5 verd. Phospho-Tyrosine 0,019873 0,029342 0,928897  
1:5 verd. Phospho-Tyrosine 0,016958 0,019257 0,940984  
1:5 verd. p-Smasd1 0,089257 0,040926 0,754321 0,7534315 0,01164461 0,2465685
1:5 verd. p-Smasd1 0,086184 0,047034 0,768587  
1:5 verd. p-Smasd1 0,081245 0,041589 0,750287  
1:5 verd. p-Smasd1 0,085946 0,040739 0,740531  
1:5 verd. p-Smasd2/3 0,097572 0,040284 0,731962 0,7228305 0,01429447 0,2771695
1:5 verd. p-Smasd2/3 0,1016 0,052273 0,731852  
1:5 verd. p-Smasd2/3 0,121287 0,038149 0,701849  
1:5 verd. p-Smasd2/3 0,112095 0,037854 0,725659  
2% Milchpulver 0,024594 0,027126 0,979906 0,95031825 0,03973564 0,04968175
2% Milchpulver 0,054523 0,04059 0,901587  
2% Milchpulver 0,048115 0,040933 0,934362  
2% Milchpulver 0,03625 0,022086 0,985418  
c-Myc 0,062361 0,051094 0,837725 0,81898225 0,0182114 0,18101775
c-Myc 0,083086 0,055418 0,798124  
c-Myc 0,058188 0,077801 0,809882  
c-Myc 0,051249 0,050828 0,830198  
p38 (mouse monoclonal 10.1) 0,032228 0,041632 0,920025 0,90443 0,01402079 0,09557
p38 (mouse monoclonal 10.1) 0,044989 0,04177 0,88954  
p38 (mouse monoclonal 10.1) 0,045645 0,037553 0,896185  
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p38 (mouse monoclonal 10.1) 0,044938 0,040258 0,91197  
Phospho Stat3 6E4 0,169533 0,031149 0,596734 0,59375625 0,00683154 0,40624375
Phospho Stat3 6E4 0,178717 0,050892 0,584826  
Phospho Stat3 6E4 0,173551 0,038407 0,592629  
Phospho Stat3 6E4 0,169855 0,036978 0,600836  
Phospho-Akt 4E2 0,03007 0,099702 0,889682 0,937451 0,03374369 0,062549
Phospho-Akt 4E2 0,016799 0,019349 0,938739  
Phospho-Akt 4E2 0,011451 0,017207 0,965797  
Phospho-Akt 4E2 0,013081 0,056794 0,955586  
Hospho-p38 (mouse monoclonal 9.1) 0,105468 0,050398 0,738153 0,73888825 0,0177871 0,26111175
Phospho-p38 (mouse monoclonal 
9.1) 
0,097007 0,053256 0,762778  
Phospho-p38 (mouse monoclonal 
9.1) 
0,123072 0,053244 0,719901  
phospho-p38 (mouse monoclonal 
9.1) 
0,118907 0,058185 0,734721  
Phospho-p44/42 MAP Kinase 0,019996 0,036256 0,923541 0,92343825 0,00971648 0,07656175
Phospho-p44/42 MAP Kinase 0,023479 0,031265 0,911893  
Phospho-p44/42 MAP Kinase 0,021612 0,03052 0,922661  
Phospho-p44/42 MAP Kinase 0,01884 0,028785 0,935658  
Phospho-p70 S6 Kinase 0,004942 0,036083 0,984722 0,987013 0,01724115 0,012987
Phospho-p70 S6 Kinase 0,000029 0 1  
Phospho-p70 S6 Kinase 0,000107 0,00235 0,99985  
Phospho-p70 S6 Kinase 0,009271 0,060968 0,96349  
Phospho-SAPK/JNK 0,029855 0,044573 0,89087 0,85879425 0,02236013 0,14120575
Phospho-SAPK/JNK 0,042975 0,042458 0,851802  
Phospho-SAPK/JNK 0,050368 0,046719 0,838918  
Phospho-SAPK/JNK 0,04739 0,057298 0,853587  
Phospho-Tyrosine 0,064429 0,053717 0,794286 0,76183575 0,02204465 0,23816425
Phospho-Tyrosine 0,085373 0,058036 0,753918  
Phospho-Tyrosine 0,08031 0,049828 0,745027  
Phospho-Tyrosine 0,078417 0,057894 0,754112  
p-Smasd1 0,36194 0,042265 0,426577 0,436465 0,00747244 0,563535
p-Smasd1 0,350107 0,039091 0,436096  
p-Smasd1 0,347428 0,036414 0,438678  
p-Smasd1 0,337814 0,03905 0,444509  
p-Smasd2/3 0,387358 0,041287 0,407883 0,425757 0,0190116 0,574243
p-Smasd2/3 0,358008 0,043277 0,426641  
p-Smasd2/3 0,37822 0,035649 0,416649  
p-Smasd2/3 0,327503 0,049132 0,451855  
Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0,085689 0,092183 0,781176 0,93627675 0,10472276 0,06372325
Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0,010376 0,031243 0,964519  
Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0,000267 0,005454 0,999419  
Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0,000159 0,000239 0,999993  
Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0,000189 0 1.000.000 250000,749 499999,5 -249999,749
Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0,000838 0,000779 0,999964  
Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0,00008 0,001448 0,999894  
Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0,005554 0,013867 0,997721  
Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0,019467 0,028646 0,926275 500000,455 577349,744 -499999,455
Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0,007406 0 1.000.000  
Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 
0,037702 0,06869 0,893931  
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Wisp2_129_158r(bio)_1,25 µM, 
htag4(bio)_1,25 µM 









k-nu-con Substance Valid Background QSV Sigma Mean 
1 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,965675 0,095774 0,036426 0,879483
2 1:5 verd. Phospho-p70 S6 Kinase 0 0,989535 0,194866 0,028543 0,770745
3 1:5 verd. Phospho-p70 S6 Kinase 0 0,999574 0,161068 0,033969 0,79251
4 1:5 verd. Phospho-p70 S6 Kinase 0 0,999686 0,131711 0,026282 0,815641
5 1:5 verd. Phospho-p70 S6 Kinase 0 0,999866 0,120469 0,028898 0,824973
6 Phospho-p70 S6 Kinase 0 0,999865 0,091264 0,036831 0,869682
7 Phospho-p70 S6 Kinase 0 0,999821 0,043279 0,036803 0,916118
8 Phospho-p70 S6 Kinase 0 0,995697 0,098169 0,025459 0,866199
9 Phospho-p70 S6 Kinase 0 0,996056 0,051679 0,025688 0,903309
10 1:5 verd. Phospho-Akt 4E2 0 0,996658 0,089786 0,033465 0,861315
11 1:5 verd. Phospho-Akt 4E2 0 0,996101 0,076295 0,037927 0,870837
12 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,984742 0,07885 0,064834 0,877906
14 1:5 verd. Phospho-Akt 4E2 0 0,995833 0,060852 0,030309 0,894854
15 1:5 verd. Phospho-Akt 4E2 0 0,999888 0,060429 0,044171 0,892914
16 Phospho-Akt 4E2 0 1.000.000 0,141198 0,046255 0,810632
17 Phospho-Akt 4E2 0 1.000.000 0,107183 0,03283 0,850632
18 Phospho-Akt 4E2 0 0,999978 0,128865 0,058135 0,820188
19 Phospho-Akt 4E2 0 0,999978 0,107267 0,033757 0,841823
20 1:5 verd. Phospho Stat3 6E4 0 0,995922 0,096514 0,037235 0,85405
21 1:5 verd. Phospho Stat3 6E4 0 0,998476 0,102178 0,035797 0,85114
22 1:5 verd. Phospho Stat3 6E4 0 1.000.000 0,062148 0,041322 0,888954
23 1:5 verd. Phospho Stat3 6E4 0 0,999978 0,071726 0,035334 0,876462
26 Phospho Stat3 6E4 0 1.000.000 0,20321 0,047164 0,762778
27 Phospho Stat3 6E4 0 0,998355 0,184092 0,046063 0,77704
28 Phospho Stat3 6E4 0 0,998529 0,164392 0,033175 0,797208
29 Phospho Stat3 6E4 0 1.000.000 0,186538 0,045313 0,77328
30 1:5 verd. Phospho-Tyrosine 0 1.000.000 0,048276 0,033531 0,903576
31 1:5 verd. Phospho-Tyrosine 0 1.000.000 0,072239 0,036177 0,879635
32 1:5 verd. Phospho-Tyrosine 0 1.000.000 0,063796 0,026406 0,885103
33 1:5 verd. Phospho-Tyrosine 0 1.000.000 0,066905 0,029163 0,887464
34 Phospho-Tyrosine 0 0,999933 0,278951 0,048708 0,70568
35 Phospho-Tyrosine 0 0,999933 0,264672 0,064188 0,722805
36 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,992788 0,262343 0,080964 0,707563
38 Phospho-Tyrosine 0 0,996056 0,296134 0,054147 0,70132
39 Phospho-Tyrosine 0 0,995588 0,276748 0,050055 0,719512
40 1:5 verd. Phospho-SAPK/JNK 0 0,999978 0,085002 0,037387 0,867559
41 1:5 verd. Phospho-SAPK/JNK 0 0,999977 0,087872 0,045955 0,857315
42 1:5 verd. Phospho-SAPK/JNK 0 1.000.000 0,069609 0,033814 0,87852
43 1:5 verd. Phospho-SAPK/JNK 0 1.000.000 0,072281 0,034369 0,876748
44 Phospho-SAPK/JNK 0 0,998185 0,118126 0,037148 0,830651
45 Phospho-SAPK/JNK 0 1.000.000 0,133068 0,04811 0,824042
46 Phospho-SAPK/JNK 0 1.000.000 0,131241 0,049526 0,819203
47 Phospho-SAPK/JNK 0 0,999866 0,120894 0,040024 0,830328
48 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,99888 0,062026 0,038526 0,904293
50 1:5 verd. Phospho-p44/42 MAP Kinase 0 0,9881 0,192776 0,023412 0,777609
51 1:5 verd. Phospho-p44/42 MAP Kinase 0 0,998588 0,165126 0,024042 0,795068
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52 1:5 verd. Phospho-p44/42 MAP Kinase 0 1.000.000 0,184942 0,03342 0,784586
53 1:5 verd. Phospho-p44/42 MAP Kinase 0 1.000.000 0,087114 0,019816 0,860644
54 Phospho-p44/42 MAP Kinase 0 1.000.000 0,078076 0,028977 0,866999
55 Phospho-p44/42 MAP Kinase 0 1.000.000 0,096116 0,048182 0,848422
56 Phospho-p44/42 MAP Kinase 0 0,998185 0,090117 0,028088 0,855856
57 Phospho-p44/42 MAP Kinase 0 0,999617 0,090049 0,040034 0,860931
58 1:5 verd. p-Smasd1 0 0,999597 0,376209 0,035769 0,656995
59 1:5 verd. p-Smasd1 0 0,999532 0,377456 0,050451 0,651446
60 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,998723 0,00222 0,022557 0,995828
62 1:5 verd. p-Smasd1 0 0,996683 0,431257 0,031777 0,629456
63 1:5 verd. p-Smasd1 0 0,999822 0,380165 0,034723 0,65568
64 p-Smasd1 0 1.000.000 1.070.371 0,031798 0,427419
65 p-Smasd1 0 0,99888 0,973937 0,023435 0,450753
66 p-Smasd1 0 0,998873 0,921862 0,02125 0,459726
67 p-Smasd1 0 1.000.000 0,956332 0,024243 0,450116
68 1:5 verd. p-Smasd2/3 0 1.000.000 0,398894 0,031324 0,641533
69 1:5 verd. p-Smasd2/3 0 1.000.000 0,481106 0,03282 0,60097
70 1:5 verd. p-Smasd2/3 0 1.000.000 0,537444 0,055563 0,569726
71 1:5 verd. p-Smasd2/3 0 0,999549 0,545812 0,042663 0,567564
72 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 1.000.000 0,027987 0,037984 0,944038
73 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,985681 0,063284 0,038021 0,890196
74 p-Smasd2/3 0 0,999059 1.662.937 0,035631 0,326019
75 p-Smasd2/3 0 0,999955 1.555.835 0,037369 0,338888
76 p-Smasd2/3 0 0,999978 1.496.536 0,043581 0,348851
77 p-Smasd2/3 0 0,999978 1.366.563 0,034923 0,370413
78 1:5 verd. c-Myc 0 0,999978 0,667168 0,037603 0,529011
79 1:5 verd. c-Myc 0 0,999776 0,627893 0,033269 0,545122
80 1:5 verd. c-Myc 0 0,999865 0,615928 0,058821 0,540388
81 1:5 verd. c-Myc 0 1.000.000 0,67229 0,045122 0,519432
82 c-Myc 0 1.000.000 0,203893 0,057456 0,752884
83 c-Myc 0 0,997602 0,218818 0,059298 0,742287
84 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,998073 0,048099 0,036304 0,905246
85 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,981266 0,052769 0,025672 0,918071
86 c-Myc 0 0,999552 0,244044 0,047083 0,729086
87 c-Myc 0 0,999843 0,248489 0,043759 0,727931
88 1:5 verd. phospho-p38 (mouse monoclonal 9.1) 0 1.000.000 0,202083 0,046031 0,757603
89 1:5 verd. phospho-p38 (mouse monoclonal 9.1) 0 0,999527 0,084951 0,04706 0,859336
90 1:5 verd. phospho-p38 (mouse monoclonal 9.1) 0 0,999527 0,221067 0,027325 0,741699
91 1:5 verd. phospho-p38 (mouse monoclonal 9.1) 0 0,999777 0,259664 0,041676 0,710269
92 phospho-p38 (mouse monoclonal 9.1) 0 0,999866 0,464326 0,040566 0,600627
93 phospho-p38 (mouse monoclonal 9.1) 0 1.000.000 0,487552 0,045276 0,59248
94 phospho-p38 (mouse monoclonal 9.1) 0 1.000.000 0,478859 0,048764 0,598693
95 phospho-p38 (mouse monoclonal 9.1) 0 0,997138 0,460043 0,044246 0,60401
96 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,998953 0,090628 0,072884 0,865509
98 1:5 verd. p38 (mouse monoclonal 10.1) 0 0,959171 0,156632 0,035912 0,798006
99 1:5 verd. p38 (mouse monoclonal 10.1) 0 0,985008 0,233185 0,035064 0,738334
100 1:5 verd. p38 (mouse monoclonal 10.1) 0 0,996326 0,188337 0,037271 0,773318
101 1:5 verd. p38 (mouse monoclonal 10.1) 0 0,999731 0,140491 0,034871 0,809514
102 p38 (mouse monoclonal 10.1) 0 0,999889 0,112506 0,040782 0,833272
103 p38 (mouse monoclonal 10.1) 0 1.000.000 0,122404 0,037507 0,819798
104 p38 (mouse monoclonal 10.1) 0 0,994456 0,15438 0,062156 0,791157
105 p38 (mouse monoclonal 10.1) 0 0,994375 0,181924 0,037152 0,771987
106 1:20 verd. biotin anti rabbit IGG 0 0,999529 0,190669 0,047954 0,767773
107 1:20 verd. biotin anti rabbit IGG 0 0,997894 0,20797 0,051793 0,754508
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109 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,837737 0,211574 0,022305 0,807197
110 1:20 verd. biotin anti rabbit IGG 0 0,882398 0,300576 0,029789 0,706623
111 1:20 verd. biotin anti rabbit IGG 0 0,927585 0,299866 0,026201 0,701375
112 1:100 verd. biotin anti rabbit IGG 0 0,972952 0,376664 0,025672 0,656877
113 1:100 verd. biotin anti rabbit IGG 0 0,998151 0,365525 0,052745 0,649034
114 1:100 verd. biotin anti rabbit IGG 0 0,998648 0,371741 0,045507 0,643631
115 1:100 verd. biotin anti rabbit IGG 0 1.000.000 0,345177 0,047202 0,660827
116 2% Milchpulver 0 0,997928 0,049593 0,036016 0,906703
117 2% Milchpulver 0 0,993681 0,069823 0,042613 0,883587
118 2% Milchpulver 0 0,997356 0,086486 0,039648 0,867566
119 2% Milchpulver 0 0,991216 0,086171 0,034658 0,879115










k-nu-bmp2 Substance Valid Background QSV Sigma Mean 
1 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 1.000.000 0,033192 0,045276 0,918869
2 1:5 verd. Phospho-p70 S6 Kinase 0 0,989945 0,035994 0,0328 0,892598
3 1:5 verd. Phospho-p70 S6 Kinase 0 0,993313 0,039971 0,031828 0,870408
4 1:5 verd. Phospho-p70 S6 Kinase 0 0,996078 0,031928 0,027822 0,897128
5 1:5 verd. Phospho-p70 S6 Kinase 0 0,996808 0,028471 0,035278 0,907029
6 Phospho-p70 S6 Kinase 0 0,997264 0,012178 0,012119 0,994827
7 Phospho-p70 S6 Kinase 0 0,992522 0,014748 0,024078 0,98128
8 Phospho-p70 S6 Kinase 0 0,999772 0,016326 0,028031 0,975933
9 Phospho-p70 S6 Kinase 0 0,999819 0,020701 0,040927 0,950339
10 1:5 verd. Phospho-Akt 4E2 0 1.000.000 0,021489 0,030286 0,947013
11 1:5 verd. Phospho-Akt 4E2 0 1.000.000 0,025543 0,034548 0,927588
12 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 1.000.000 0,025202 0,019435 0,949338
14 1:5 verd. Phospho-Akt 4E2 0 0,99254 0,030045 0,041333 0,912183
15 1:5 verd. Phospho-Akt 4E2 0 0,995873 0,018876 0,03047 0,960946
16 Phospho-Akt 4E2 0 0,999289 0,019538 0,036772 0,952516
17 Phospho-Akt 4E2 0 0,999772 0,020001 0,038586 0,94995
18 Phospho-Akt 4E2 0 0,997053 0,023076 0,022329 0,937053
19 Phospho-Akt 4E2 0 0,992833 0,020728 0,034992 0,945205
20 1:5 verd. Phospho Stat3 6E4 0 1.000.000 0,025352 0,039749 0,924156
21 1:5 verd. Phospho Stat3 6E4 0 0,999818 0,028323 0,043314 0,910572
22 1:5 verd. Phospho Stat3 6E4 0 1.000.000 0,026478 0,029531 0,930586
23 1:5 verd. Phospho Stat3 6E4 0 1.000.000 0,027695 0,037493 0,937787
26 Phospho Stat3 6E4 0 1.000.000 0,049189 0,055305 0,829654
27 Phospho Stat3 6E4 0 1.000.000 0,045965 0,060594 0,837443
28 Phospho Stat3 6E4 0 1.000.000 0,043082 0,045478 0,846176
29 Phospho Stat3 6E4 0 1.000.000 0,041857 0,048712 0,847306
30 1:5 verd. Phospho-Tyrosine 0 1.000.000 0,020154 0,026519 0,9517
31 1:5 verd. Phospho-Tyrosine 0 1.000.000 0,022931 0,032947 0,938026
32 1:5 verd. Phospho-Tyrosine 0 1.000.000 0,020077 0,021234 0,965466
33 1:5 verd. Phospho-Tyrosine 0 1.000.000 0,023733 0,033449 0,952343
34 Phospho-Tyrosine 0 0,999234 0,068854 0,072168 0,771133
35 Phospho-Tyrosine 0 0,999225 0,078495 0,053391 0,746514
36 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,99429 0,031714 0,020577 0,954425
38 Phospho-Tyrosine 0 0,999658 0,075331 0,058223 0,756098
39 Phospho-Tyrosine 0 0,99966 0,078757 0,055781 0,744617
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40 1:5 verd. Phospho-SAPK/JNK 0 1.000.000 0,024393 0,039058 0,926622
41 1:5 verd. Phospho-SAPK/JNK 0 1.000.000 0,029486 0,043288 0,902812
42 1:5 verd. Phospho-SAPK/JNK 0 0,999932 0,02634 0,031367 0,923267
43 1:5 verd. Phospho-SAPK/JNK 0 0,994514 0,026901 0,043579 0,930293
44 Phospho-SAPK/JNK 0 0,994974 0,036697 0,040116 0,87842
45 Phospho-SAPK/JNK 0 0,998141 0,042665 0,057827 0,862464
46 Phospho-SAPK/JNK 0 0,99617 0,048302 0,05493 0,847271
47 Phospho-SAPK/JNK 0 0,998039 0,044979 0,046954 0,870275
48 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,992089 0,035912 0,020165 0,943231
50 1:5 verd. Phospho-p44/42 MAP Kinase 0 0,989107 0,039537 0,034564 0,86305
51 1:5 verd. Phospho-p44/42 MAP Kinase 0 1.000.000 0,040053 0,03213 0,857789
52 1:5 verd. Phospho-p44/42 MAP Kinase 0 1.000.000 0,03952 0,033029 0,861598
53 1:5 verd. Phospho-p44/42 MAP Kinase 0 1.000.000 0,034987 0,028911 0,880824
54 Phospho-p44/42 MAP Kinase 0 0,998427 0,041177 0,040381 0,857751
55 Phospho-p44/42 MAP Kinase 0 0,996694 0,048565 0,038215 0,83373
56 Phospho-p44/42 MAP Kinase 0 0,99316 0,051373 0,046716 0,829825
57 Phospho-p44/42 MAP Kinase 0 0,994922 0,051075 0,045056 0,836785
58 1:5 verd. p-Smasd1 0 0,999887 0,195648 0,045321 0,549156
59 1:5 verd. p-Smasd1 0 0,999184 0,191665 0,05323 0,5523
60 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,99388 0,042822 0,047632 0,927612
62 1:5 verd. p-Smasd1 0 1.000.000 0,211062 0,048489 0,532379
63 1:5 verd. p-Smasd1 0 1.000.000 0,213422 0,047151 0,528441
64 p-Smasd1 0 0,931543 0,592337 0,033878 0,306177
65 p-Smasd1 0 0,880692 0,562753 0,032643 0,316622
66 p-Smasd1 0 0,910328 0,541884 0,033636 0,322916
67 p-Smasd1 0 0,955933 0,54772 0,031649 0,32067
68 1:5 verd. p-Smasd2/3 0 0,958846 0,166756 0,049486 0,585469
69 1:5 verd. p-Smasd2/3 0 0,961924 0,189203 0,039754 0,556406
70 1:5 verd. p-Smasd2/3 0 0,955326 0,192322 0,048073 0,549252
71 1:5 verd. p-Smasd2/3 0 0,95187 0,183307 0,042096 0,559188
72 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,979485 0,049904 0,036634 0,903551
73 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,959923 0,017942 0,010452 0,997947
74 p-Smasd2/3 0 0,959371 0,750033 0,048739 0,259152
75 p-Smasd2/3 0 0,999681 0,811915 0,037367 0,245369
76 p-Smasd2/3 0 0,99984 0,791279 0,038466 0,250451
77 p-Smasd2/3 0 1.000.000 0,769245 0,040147 0,255006
78 1:5 verd. c-Myc 0 0,99991 0,393578 0,038484 0,389855
79 1:5 verd. c-Myc 0 0,999683 0,4453 0,032023 0,363082
80 1:5 verd. c-Myc 0 0,997019 0,461601 0,029911 0,353701
81 1:5 verd. c-Myc 0 0,996147 0,403977 0,043207 0,380326
82 c-Myc 0 0,996532 0,082666 0,041035 0,751261
83 c-Myc 0 0,985486 0,089735 0,041518 0,729583
84 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,955457 0,055883 0,022998 0,898168
85 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 1.000.000 0,020692 0,003246 0,99951
86 c-Myc 0 1.000.000 0,06791 0,053312 0,779746
87 c-Myc 0 0,992134 0,070836 0,040858 0,77192
88 1:5 verd. phospho-p38 (mouse monoclonal 9.1) 0 0,992088 0,091941 0,049162 0,720781
89 1:5 verd. phospho-p38 (mouse monoclonal 9.1) 0 1.000.000 0,098674 0,040951 0,702739
90 1:5 verd. phospho-p38 (mouse monoclonal 9.1) 0 0,999863 0,099816 0,04166 0,704563
91 1:5 verd. phospho-p38 (mouse monoclonal 9.1) 0 0,985288 0,088143 0,04176 0,727174
92 phospho-p38 (mouse monoclonal 9.1) 0 0,978363 0,159678 0,045047 0,588976
93 phospho-p38 (mouse monoclonal 9.1) 0 0,97771 0,270824 0,090716 0,465926
94 phospho-p38 (mouse monoclonal 9.1) 0 0,965726 0,168757 0,052797 0,575882
95 phospho-p38 (mouse monoclonal 9.1) 0 0,949612 0,1562 0,052175 0,59303
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96 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,917349 0,067416 0,022122 0,876374
98 1:5 verd. p38 (mouse monoclonal 10.1) 0 0,997036 0,052082 0,041966 0,833272
99 1:5 verd. p38 (mouse monoclonal 10.1) 0 0,999404 0,054757 0,036756 0,829417
100 1:5 verd. p38 (mouse monoclonal 10.1) 0 0,999818 0,055893 0,04221 0,826473
101 1:5 verd. p38 (mouse monoclonal 10.1) 0 0,999048 0,055233 0,045608 0,832294
102 p38 (mouse monoclonal 10.1) 0 0,999098 0,051762 0,031048 0,852917
103 p38 (mouse monoclonal 10.1) 0 0,996945 0,055494 0,039243 0,841675
104 p38 (mouse monoclonal 10.1) 0 0,984956 0,061661 0,038407 0,828109
105 p38 (mouse monoclonal 10.1) 0 0,970109 0,067175 0,038578 0,816392
106 1:20 verd. biotin anti rabbit IGG 0 0,945121 0,084959 0,043317 0,759397
107 1:20 verd. biotin anti rabbit IGG 0 0,914474 0,090284 0,039037 0,755387
109 Wisp2_129_158r(bio)_1,25 µM, htag4(bio)_1,25 µM 0 0,999339 0,027704 0,006264 0,998936
110 1:20 verd. biotin anti rabbit IGG 0 0,998385 0,056274 0,046865 0,817836
111 1:20 verd. biotin anti rabbit IGG 0 0,997348 0,058916 0,045095 0,807872
112 1:100 verd. biotin anti rabbit IGG 0 0,997724 0,093257 0,054097 0,710381
113 1:100 verd. biotin anti rabbit IGG 0 0,994242 0,087625 0,055573 0,725153
114 1:100 verd. biotin anti rabbit IGG 0 0,99046 0,097779 0,043869 0,701116
115 1:100 verd. biotin anti rabbit IGG 0 0,977388 0,093 0,0487 0,716346
116 2% Milchpulver 0 0,953327 0,057491 0,032666 0,903339
117 2% Milchpulver 0 0,930336 0,066474 0,03147 0,875633
118 2% Milchpulver 0 0,902981 0,076635 0,026875 0,847851
119 2% Milchpulver 0 0,87534 0,088302 0,028278 0,824548



























1:100 verd. biotin 
anti rabbit IGG 
0,356185 0,28564925 0,756150349 0,880326583 1 1,053269232 1,75615035 1,93359581
1:20 verd. biotin 
anti rabbit IGG 
0,37518625 0,2897155 0,796488381 0,892858133 0,98884265 0,991542023 1,78533103 1,88440016
1:5 verd. c-Myc 0,500286 0,365201 1,062064471 1,12549271 1,45150125 1,082945924 2,51356572 2,20843863
1:5 verd. p38 
(mouse 
monoclonal 10.1) 
0,2788945 0,16315875 0,592069216 0,502829904 0,31923109 0,800603385 0,9113003 1,30343329
1:5 verd. Phospho 
Stat3 6E4 
0,363751 0,324481 0,772212321 1 0,88089525 0,936857664 1,65310757 1,93685766
1:5 verd. 
Phospho-Akt 4E2 
















0,4710505 0,26652075 1 0,82137552 1,23438812 1,038302339 2,23438812 1,85967786
1:5 verd. 
Phospho-Tyrosine 
0,33456475 0,11003925 0,710252404 0,339123862 0,83535085 0,759382113 1,54560326 1,09850598
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1:5 verd. p-
Smasd1 
0,61418675 0,50462925 1,30386604 1,555188902 1,22825238 1,109875452 2,53211842 2,66506435
1:5 verd. p-
Smasd2/3 
0,6505125 0,541387 1,380982506 1,668470573 1,60739939 1,109045303 2,98838189 2,77751588
2% Milchpulver 0,21031925 0,12924725 0,446489814 0,398319932 0,47981959 0,600365817 0,9263094 0,99868575
c-Myc 0,290458 0,16601175 0,616617539 0,511622406 1,00617439 1,159803596 1,62279193 1,671426
p38 (mouse 
monoclonal 10.1) 
0,18630125 0,207853 0,39550165 0,640570634 0,42529764 0,202073732 0,82079929 0,84264437
Phospho Stat3 
6E4 
0,67481425 0,71031375 1,432573047 2,189076556 1,12962504 1,109388093 2,56219809 3,29846465




0,36006075 0,398921 0,764378235 1,229412508 0,76107026 0,478427875 1,5254485 1,70784038
Phospho-p44/42 
MAP Kinase 
0,4913715 0,562597 1,043139748 1,733836496 0,68081393 0,563938019 1,72395368 2,29777451
Phospho-p70 S6 
Kinase 
0,4771865 0,45811225 1,013026204 1,411830739 0,85721933 0,892574381 1,87024553 2,30440512
Phospho-
SAPK/JNK 
0,47398725 0,4922575 1,00623447 1,517061091 0,5400922 0,064607764 1,54632667 1,58166886
Phospho-Tyrosine 0,71734825 0,6924385 1,522869098 2,133987814 1,22878669 1,187495086 2,75165579 3,3214829
p-Smasd1 0,48868625 0,3579075 1,037439192 1,103015277 1,22989641 1,093526593 2,2673356 2,19654187
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control1 experiment coaverage 1
0 267200 258400 269600 273600
160 451133,333 446400 483000 424000
285 403066,667 391200 420000 398000
1450 407000 405000 420000 396000
experiment control 2
0 355733,333 355200 349600 362400
30 392800 534400 484000 160000
160 495000 476000 487000 522000
285 521000 539000 513000 511000
1450 412333,333 411000 402000 424000
experiment control 3
0 314133,333 308000 307200 327200
160 1053666,67 1019000 1102000 1040000
285 328666,667 337000 289000 360000
1450 362333,333 378000 350000 359000
50ng/ml-1
0 271333,333 288000 268000 258000
30 820333,333 848000 867000 746000
160 386266,667 409000 364800 385000
285 239333,333 245000 224000 249000
1450 341333,333 332000 344800 347200
#DIV/0!
50ng/ml-2 #DIV/0!
0 365066,667 359200 390400 345600
30 2285000 2310000 2258000 2287000
160 1834000 1802000 1850000 1850000
285 418333,333 436000 414000 405000
1450 307600 320000 312800 290000
#DIV/0!
50ng/ml-3 #DIV/0!
0 419466,667 410400 434400 413600
30 1126333,33 1193000 1100000 1086000
160 495400 496000 483200 507000
285 991000 986000 1007000 980000
1450 377600 396000 364000 372800
100ng/ml-1
0 654400 626400 666400 670400
30 598066,667 598400 603000 592800
160 238866,667 260000 225600 231000
285 1053666,67 1055000 1026000 1080000
1450 393066,667 408800 384800 385600
100ng/ml-2
0 439200 447200 437600 432800
30 1215000 1205000 1238000 1202000
160 720600 620000 897000 644800
285 1028666,67 1026000 1030000 1030000
1450 365533,333 365600 351000 380000
 
 
                                                                                                                    





















0 1007000 1042000 944000 1035000 16
10 979600 967000 996800 975000 16
30 564200 538000 585000 569600 16
160 99333,3333 109000 100000 89000 16
285 189000 182000 188000 197000 16




0 464000 472800 427200 492000 17
10 481666,667 72000 664000 709000 17
30 479933,333 451200 481600 507000
160 477200 455000 491000 485600
285 313600 332800 301600 306400
1450 435000 428000 429000 448000
#DIV/0! 18
1000ng/ml-3 #DIV/0! 18
0 452000 463200 471200 421600 18
10 1059000 1058000 1073000 1046000 18
30 382666,667 368000 372800 407200 18
160 502000 487000 501000 518000 18
285 168400 173600 158000 173600
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160 445666,667 475000 436000 426000 20
285 459333,333 465000 431000 482000
1450 820000 808000 828000 824000
#DIV/0! 21
1500ng/ml-3 #DIV/0! 21
0 841866,667 892800 838400 794400 21
10 471666,667 479000 468000 468000 21
30 1280000 1270000 1290000 1280000 21
160 380666,667 404000 342000 396000
285 356666,667 381000 370000 319000
1450 464666,667 483000 463000 448000
#DIV/0!
2000ng/ml-1 #DIV/0!
0 817866,667 800000 846400 807200 22
10 122866,667 133600 116000 119000 22
30 489600 453000 516800 499000 22
160 334666,667 352000 320000 332000 22
285 1313333,33 1360000 1280000 1300000 22
1450 445600 436800 450000 450000 22
#DIV/0!
2000ng/ml-2 #DIV/0!
0 1312666,67 1298000 1282000 1358000 23
10 792266,667 796000 796000 784800 23
30 812533,333 836800 824800 776000 23
160 360000 384000 348000 348000 23
285 2247666,67 2359000 2250000 2134000 23










average 1  1
 0 267200 258400 269600 273600 1
 160 451133,333 446400 483000 424000 1
 285 403066,667 391200 420000 398000 1
 1450 407000 405000 420000 396000 1
   
experiment control 2  2
 0 355733,333 355200 349600 362400 2
 30 392800 534400 484000 160000 2
 160 495000 476000 487000 522000 2
 285 521000 539000 513000 511000 2
 1450 412333,333 411000 402000 424000 
   
experiment control 3  3
 0 314133,333 308000 307200 327200 3
 160 1053666,67 1019000 1102000 1040000 3
 285 328666,667 337000 289000 360000 3
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 1450 362333,333 378000 350000 359000 
   
50ng/ml-1   4
 0 271333,333 288000 268000 258000 4
 30 820333,333 848000 867000 746000 4
 160 386266,667 409000 364800 385000 4
 285 239333,333 245000 224000 249000 4
 1450 341333,333 332000 344800 347200 
  #DIV/0!  
50ng/ml-2  #DIV/0!  5
 0 365066,667 359200 390400 345600 5
 30 2285000 2310000 2258000 2287000 5
 160 1834000 1802000 1850000 1850000 5
 285 418333,333 436000 414000 405000 5
 1450 307600 320000 312800 290000 
  #DIV/0!  
50ng/ml-3  #DIV/0!  6
 0 419466,667 410400 434400 413600 6
 30 1126333,33 1193000 1100000 1086000 6
 160 495400 496000 483200 507000 6
 285 991000 986000 1007000 980000 6
 1450 377600 396000 364000 372800 
   
   
 100ng/ml-1  
 0 654400 626400 666400 670400 7
 30 598066,667 598400 603000 592800 7
 160 238866,667 260000 225600 231000 7
 285 1053666,67 1055000 1026000 1080000 7
 1450 393066,667 408800 384800 385600 7
   7
   
   
 100ng/ml-2  8
 0 439200 447200 437600 432800 8
 30 1215000 1205000 1238000 1202000 8
 160 720600 620000 897000 644800 8
 285 1028666,67 1026000 1030000 1030000 8
 1450 365533,333 365600 351000 380000 
   
   
 100ng/ml-3  9
 0 368800 324000 398400 384000 9
 30 1019400 1046000 1013000 999200 9
 160 725000 723000 662000 790000 9
 285 1008000 1042000 970000 1012000 9
 1450 488266,667 468800 523200 472800 9
  #DIV/0!  
  #DIV/0!  
 300-1 #DIV/0!  10
 0 100800 116000 174400 12000 10
 10 30133,3333 33600 28800 28000 10
 30 28533,3333 43200 23200 19200 10
 160 422666,667 439000 441000 388000 10
 285 365000 377000 370000 348000 10
 1450 443600 452800 440000 438000 
  #DIV/0!  
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  #DIV/0!  
 300-2 #DIV/0!  11
 0 628266,667 653600 607200 624000 11
 30 709000 723000 696000 708000 11
 160 501866,667 472800 520800 512000 11
 285 678000 657000 670000 707000 11
 1450 412000 409000 420000 407000 
  #DIV/0!  
  #DIV/0!  
 300-3 #DIV/0!  
 0 692533,333 696800 690400 690400 12
 30 1449333,33 1335000 1273000 1740000 12
 160 1294666,67 1242000 1287000 1355000 12
 285 1315333,33 1339000 1289000 1318000 12
 1450 788333,333 762000 800000 803000 12
  #DIV/0!  12
 500ng/ml-1 #DIV/0!  
 0 618933,333 604800 632800 619200 
 10 142400 144000 148000 135200 13
 30 1720000 1717000 1699000 1744000 13
 160 366400 372800 340800 385600 13
 285 604666,667 616000 618000 580000 13
 1450 538666,667 560000 566000 490000 13
  #DIV/0!  
  #DIV/0!  
 500ng/ml-2 #DIV/0!  
 0 654400 644800 683200 635200 14
 10 43466,6667 47200 42400 40800 14
 30 31733,3333 44000 30400 20800 14
 160 665666,667 667000 660000 670000 14
 285 271933,333 275000 276800 264000 14
 1450 436333,333 433000 437000 439000 
  #DIV/0!  
 500ng/ml-3 #DIV/0!  15
 0 1018600 1066000 1005000 984800 15
 10 1286333,33 1294000 1298000 1267000 15
 30 1188000 1193000 1237000 1134000 15
 160 421866,667 436000 421600 408000 15
 285 372666,667 354000 400000 364000 
 1450 387666,667 384000 392000 387000 
  #DIV/0!  
  #DIV/0!  
 1000ng/ml-1 #DIV/0!  
 0 1007000 1042000 944000 1035000 16
 10 979600 967000 996800 975000 16
 30 564200 538000 585000 569600 16
 160 99333,3333 109000 100000 89000 16
 285 189000 182000 188000 197000 16
 1450 459666,667 430000 476000 473000 16
  #DIV/0!  
  #DIV/0!  
 1000ng/ml-2 #DIV/0!  17
 0 464000 472800 427200 492000 17
 10 481666,667 72000 664000 709000 17
 30 479933,333 451200 481600 507000 
 160 477200 455000 491000 485600 
 285 313600 332800 301600 306400 
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 1450 435000 428000 429000 448000 
  #DIV/0!  18
 1000ng/ml-3 #DIV/0!  18
 0 452000 463200 471200 421600 18
 10 1059000 1058000 1073000 1046000 18
 30 382666,667 368000 372800 407200 18
 160 502000 487000 501000 518000 18
 285 168400 173600 158000 173600 
 1450 396333,333 388000 387000 414000 
  #DIV/0!  19
 1500ng/ml-1 #DIV/0!  19
 0 977800 1058000 922400 953000 19
 10 305866,667 446000 50000 421600 19
 30 706866,667 724000 683000 713600 19
 160 1007666,67 1173000 920000 930000 19
 285 1264333,33 1245000 1278000 1270000 
 1450 589333,333 612000 596000 560000 
  #DIV/0!  20
  #DIV/0!  20
 1500ng/ml-2 #DIV/0!  20
 0 915466,667 880000 926400 940000 20
 10 128466,667 127000 121600 136800 20
 30 261333,333 280000 264000 240000 20
 160 445666,667 475000 436000 426000 20
 285 459333,333 465000 431000 482000 
 1450 820000 808000 828000 824000 
  #DIV/0!  21
 1500ng/ml-3 #DIV/0!  21
 0 841866,667 892800 838400 794400 21
 10 471666,667 479000 468000 468000 21
 30 1280000 1270000 1290000 1280000 21
 160 380666,667 404000 342000 396000 
 285 356666,667 381000 370000 319000 
 1450 464666,667 483000 463000 448000 
  #DIV/0!  
 2000ng/ml-1 #DIV/0!  
 0 817866,667 800000 846400 807200 22
 10 122866,667 133600 116000 119000 22
 30 489600 453000 516800 499000 22
 160 334666,667 352000 320000 332000 22
 285 1313333,33 1360000 1280000 1300000 22
 1450 445600 436800 450000 450000 22
  #DIV/0!  
 2000ng/ml-2 #DIV/0!  
 0 1312666,67 1298000 1282000 1358000 23
 10 792266,667 796000 796000 784800 23
 30 812533,333 836800 824800 776000 23
 160 360000 384000 348000 348000 23
 285 2247666,67 2359000 2250000 2134000 23
 1450 341733,333 354400 332800 338000 23
  #DIV/0!  
  #DIV/0!  
 2000ng/ml-3 #DIV/0!  
 0 295400 320800 298400 267000 
 30 1747333,33 1726000 1706000 1810000 24
 160 1081666,67 1057000 1094000 1094000 24
 285 1164666,67 1212000 1141000 1141000 24
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 1450 360133,333 357600 346000 376800 24
   24
   24
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